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Psittacine beak and feather disease, caused by a circovirus known as beak and 
feather disease virus (BFDV), is a threat to both wild and captive psittacine species. 
There is currently no vaccine against BFDV and safe and affordable vaccine 
candidates are needed to alleviate the disease burden caused by this virus. 
Production of the BFDV’s major antigenic determinant, the capsid protein (CP), in 
the inexpensive and highly scalable plant expression system, could satisfy these 
requirements as a potential subunit vaccine. In this work, truncated CP (ΔN40 CP) 
was first expressed in E. coli to successfully generate anti-CP polyclonal antibodies. 
ΔN40 CP and full-length CP transient expression in tobacco (Nicotiana 
benthamiana) was optimised as fusions to elastin-like polypeptide (ELP). Fusion of 
CP or ΔN40 CP to ELPs of different lengths was shown to increase yield relative to 
unfused CP/ΔN40 CP. Free ELP and a GFP-ELP fusion could be purified by inverse 
transition cycling (ITC), using centrifugation and membrane filtration methods. A 
ΔN40 CP-ELP fusion expressed in plants could be partially purified and represents 
low-cost vaccine candidate against BFDV. A candidate DNA vaccine expressing 
ΔN40 CP was also evaluated for expression of the antigen in vitro and may prove 
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Chapter 1: Literature Review 
 
Psittacine beak and feather disease 
Birds belonging to the order Psittaciformes include parrots (Psittacidae) and 
cockatoos (Cacatuidea) and are collectively referred to as psittacines. Infectious 
diseases represent the greatest threat to both wild and captive psitaccine species. Of 
these, psittacine beak and feather disease (PBFD), caused by beak and feather 
disease virus (BFDV), is one of the most common (Shearer et al., 2008). The 
symptoms of PBFD consist of feather loss (Figure 1) and abnormalities in feather 
and beak shape resulting from damage to the epidermis of the feathers and beak 
(Pass & Perry, 1984).  
 
    
Figure 1: BFDV infection in the Cape Parrot 
A healthy Cape parrot (Poicephalus robustus) in the wild is shown in the left panel. Shown in the right 
panel is another Cape parrot infected with BFDV, showing signs of feather loss, a common symptom 
of BFDV infection (courtesy of Dr Steve Boyes, personal communication). 
 
Another symptom is acquired immunodeficiency, which often leads to fatal 
secondary infections (Latimer et al., 1991). BFDV is highly infectious. Viral shedding 
occurs via the feathers and faeces, as is evident from the presence of inclusion 
bodies of the virus in the feathers and the cells of the alimentary tract (Jacobson et 













on the host. The disease may manifest itself in a peracute form in young African 
Grey parrots (Psittacus erithacus erithacus), for example, which is characterised by 
sudden illness, leucopenia (depletion of white blood cells) and death (Schoemaker et 
al., 2000). Other birds may serve as carriers without any detectable symptoms 
(Khalesi et al., 2005). 
 
Circoviridae and beak and feather disease virus 
The family Circoviridae is comprised the genera Gyrovirus, of which chicken 
anaemia virus (CAV) is the only species, and Circovirus, of which beak and feather 
disease virus (BFDV) is a member. The viruses of the genus Circovirus share 
similarities with members of the plant virus family Nanoviridae, and, to a lesser 
extent, with those of the plant virus family Geminiviridae (ICTV, 2005). Several new 
circovirus species, infecting a number of avian species, have recently been 
classified. Among the newest members of genus Circovirus are duck circovirus, gull 
circovirus and finch circovirus (ICTV, 2011). Porcine circovirus (PCV) type 1 and 
PCV-2 are the only viruses in the genus Circovirus which do not infect birds. 
 
 
Figure 2: Negative contrast electron microscopy of CAV and BFDV. 
“Purified virus preparations were mixed and stained with uranyl acetate. The diameters of CAV and 
BFDV were estimated to be 26.5 ± 1.2 and 21.7 ± 1.4 nm, respectively. CAV particles (white arrows) 















The circoviruses are the only known viruses infecting animals with a single-stranded 
DNA genome. These are also the smallest genomes of any virus known to infect 
animals (Todd, 2000). The single-stranded DNA genome of BFDV is approximately 
2000 bases in length, covalently-closed circular and contains two major open 
reading frames in opposite orientation (De Kloet & De Kloet, 2004). These ORFs 
encode the replication-associated protein (Rep) and capsid protein (CP). A third 
ORF has been identified, but its function remains unknown. The Rep gene is located 
on the virion DNA strand and the CP gene is located on the complementary strand, 
once double stranded DNA is formed in the host. The capsid is icosahedral, non-
enveloped and approximately 20 nm in diameter (Todd et al., 1991). The surface of 
the BFDV virion, as viewed by electron microscopy, has a smooth appearance, in 
contrast to the surface structure of CAV (Figure 2) (Todd, 2000).  
 
Circovirus cell entry and replication 
The mechanism of BFDV cell entry has not been studied in detail. The related 
porcine circovirus type 2 (PCV-2) is known to bind to cell surface glycoproteins 
heparin sulphate and chondroitin sulphate B. The entry of the virus into PK-15 cells 
is clathrin-dependent (Nauwynck et al., 2012). Virion disassembly and release of 
PCV-2 components is thought to occur by acidification within endosomes, but serine 
proteases also play an important role (Misinzo et al., 2008). 
 
Once inside the cell, the capsid protein transports BFDV DNA and the replication 
associated protein (Rep) to the nucleus (Heath et al., 2006). The viral single-
stranded DNA is converted to double stranded form by host enzymes, after which 
Rep and CP are transcribed and translated. In circoviruses, Rep protein initiates 
replication of the viral DNA by rolling circle amplification (RCA), the origin of which 
lies within a conserved stem-loop structure (Finsterbusch & Mankertz, 2009). The 

















Detection of BFDV-specific antibodies in sera from infected birds is done by the 
haemagglutination-inhibition assay (HI) (Raidal & Cross, 1994), but a successful 
blocking ELISA has also been developed by Shearer et al. (2009a). Excreted virus in 
feather and faecal samples can be detected by the haemagglutination assay (HA) 
and BFDV genes can be detected by PCR in blood or feather samples using primers 
specific for the Rep or CP genes (Shearer et al., 2009b). Ideally, combining the 
results of HI, HA and PCR tests can provide information on the progress of the 
infection and the immune state of the bird (Khalesi et al., 2005). Rolling circle 
amplification (RCA) of the entire BFDV genome, followed by restriction enzyme 
digestion and sequence analysis of cloned fragments can also identify BFDV 
(Varsani et al., 2010). This is useful for isolating new strains of the virus for which no 
sequence data is available.  
 
Recombinant expression of BFDV CP and potential BFDV vaccines 
The majority of work on circovirus vaccines has focused on PCV-2. A capsid protein 
subunit vaccine has been evaluated for their immunogenicity in mice (Fan et al., 
2008). PCV-2 virus-like particles have been produced in E. coli (Yin et al., 2010), as 
well as a  parvovirus chimaeric virus-like particle displaying the neutralising epitope 
from PCV-2 capsid protein, produced in mammalian cells . The immunogenicity of 
PCV-2 DNA vaccines have also been tested in mouse models (Shen et al., 2008; 
Aravindaram et al., 2009) 
All attempts to propagate BFDV in cell culture have so far been unsuccessful. 
Vaccine development therefore relies on recombinant DNA technology to produce 
the viral antigens in a variety of expression systems. The focus of this approach is 
production of the major antigenic determinant of the virus, the capsid protein. The 
capsid protein may be used as a subunit vaccine, or could self-assemble to produce 
virus-like particles (VLPs). VLP vaccines are typically more immunogenic than their 
subunit vaccine counterparts, as VLPs mimic the surface structure of the native virus 
and preserve conformational epitopes (Liu et al., 2012a).  
BFDV CP has been expressed using the baculovirus-insect cell system, in which the 













2007). This BFDV VLP preparation was used to vaccinate long-billed corellas 
(Cacatua tenuirostris) and was shown to prevent PBFD symptoms upon challenge 
with the virus isolated from infected birds (Bonne et al., 2009). The N-terminal region 
of BFDV CP contains a nuclear localisation signal that is rich in arginine residues. 
Deletion of portions of the N-terminus of BFDV CP resulted in increased expression 
of truncated CP over the full-length CP (Heath et al., 2006). In particular, deletion of 
the first 40 N-terminal amino acids, resulting in the truncated protein ΔN40 CP, was 
beneficial to yield.  
To date, the expression systems used for production of BFDV CP has been limited 
to E. coli and insect cells. There is no published literature describing the expression 
of BFDV proteins in plants or other cell culture expression systems. No subunit 
vaccines consisting of recombinant BFDV CP have yet been tested for the ability to 
protect against lethal challenge. However, the immunogenicity of PCV-2 CP subunit 
vaccines suggests that this is a valid approach to vaccination. The immunogenicity of 
truncated BFDV capsid proteins such as ΔN40 CP relative to the full-length CP has 
not been investigated, even though antibodies h ve been raised in chickens against 
bacterial-expressed ΔN40 CP (Johne et al., 2004). This ΔN40 CP antigen was also 
used successfully in serological tests to screen for the presence of BFDV-specific 
antibodies in psittacine sera. 
 
Plants as a production system for biopharmaceuticals including 
vaccines 
The use of proteins is widespread in research, industry and medicine. The 
production of biopharmaceuticals, which are commercially valuable proteins with 
important medical applications, is the fastest-growing sector of the pharmaceutical 
industry (Karg & Kallio, 2009). The use of plants as a system for the production 
these recombinant proteins is now being recognised as an alternative to traditional 
animal and bacterial cell production systems (Rybicki et al., 2012). The production 
costs for plant systems would be substantially lower, owing to the simple growth 
requirements of whole transgenic plants grown in the field. Up-scaling this process 
simply requires more land. Plants perform all the necessary post-translational 













formation) to produce functional proteins (Karg & Kallio, 2009). The risk of 
contamination with human or animal pathogens is avoided with plant-produced 
proteins. Recombinant proteins produced in plants include hormones, enzymes, 
monoclonal antibodies and vaccine antigens (Sharma & Sharma, 2009). The major 
capsid protein (L1) of human papillomavirus type 16, which was transiently 
expressed in tobacco, is one example of a successfully plant-produced vaccine 
antigen (Varsani et al., 2006; Maclean et al., 2007) 
 
Important considerations when choosing the host plant for expression include the 
total protein content, biomass yield per acre and the ease of transformation. It is 
desirable if the recombinant protein can be expressed in a plant whose native 
proteins differ in their physiochemical properties. For example, the majority of native 
proteins in tobacco leaves are acidic (Balasubramaniam et al., 2003). The extraction 
of a basic recombinant protein under acidic conditions will therefore be contaminated 
with fewer proteins, simplifying the purification. Leafy crops such as tobacco, lettuce 
and alfalfa have been used for recombinant protein production. One drawback of 
using these is that the protein is unstable in the aqueous leaf environment due to 
protease activity (Benchabane et al., 2008). This necessitates immediate processing 
of crops after harvesting. In contrast, seeds are desiccated and the proteins within 
may remain stable for long periods at room temperature (Fischer & Emans, 2000). In 
addition, seeds do not contain the same level of phenolic compounds found in leaves 
(Stoger et al., 2005). Tissue-specific accumulation of the recombinant protein is 
achieved by placing the transgene under the control of tissue-specific promoters. 
Several promoters can be used to target expression of the protein to different parts 
of seeds. For example, the rice glutelin promoter Gt-1 restricts expression to the 
endosperm of monocot seeds (Stoger et al., 2005). Cereal crops such as maize, 
rice, barley and wheat have been investigated for the production of recombinant 
proteins (Fischer & Emans 2000). 
 
Tobacco (Nicotiana benthamiana or N. tabacum species) has been the most widely 
used as a model system for the production of recombinant proteins at the laboratory 
research scale. The genetic transformation of tobacco is relatively efficient and the 













compounds are present in the leaves that can interfere with the purification, although 
there are low-alkaloid cultivars that may be used (Fischer & Emans, 2000). Tobacco 
has a high biomass yield (up to 1000 tonnes of leaf biomass per hectare for close-
cropped tobacco) and a high soluble protein content compared to other leafy crops 
(Tremblay et al., 2010). Because tobacco is a non-food crop, the risk of food or feed 
contamination with any recombinant proteins is avoided. These traits make tobacco 
a suitable candidate for commercial production of recombinant proteins. Tobacco 
leaves must be processed immediately after harvesting, or kept in cold storage, to 
minimise protease activity. 
 
The production of recombinant proteins by rhizosecretion is another alternative that 
shares several advantages with plant cell culture. Plant roots are infected by 
Agrobacterium rhizogenes and tissues at the site of infection become differentiated 
into so-called hairy roots. The plants are cultivated in a hydroponic system and can 
secrete the protein from the roots (Borisjuk et al. 1999). The purification of the 
protein is simplified and does not require harvesting of the plant. 
 
Plant cell cultures have been used for recombinant protein production. The 
production times are shorter than for whole plants. Plant cell culture requires simple 
media, but the operating costs are still significantly greater than for agriculture. The 
potential of scale-up is also reduced. However, if the heterologous protein is 
secreted into the culture medium, the purification of proteins from the culture media 
is far simpler and cheaper than from homogenised biomass (Shih & Doran, 2009). 
Glucocerebrosidase, used in therapy for Gaucher disease, is being produced in 
transgenic carrot cell suspension by Protalix (Israel) and has passed phase 3 clinical 



















Transient and transgenic expression in plants 
Expression of recombinant proteins in whole plants may be achieved by two means: 
generation of transgenic plants with the gene of interest stably integrated into the 
plant genome, or transient expression of the desired protein by means of 
Agrobacterium infiltration. The creation of homozygous transgenic plant lines 
requires several months. Transformation in the case of dicotyledonous plants such 
as tobacco is most often achieved through Agrobacterium gene transfer. 
Monocotyledons such as maize and rice, which are resistant to Agrobacterium gene 
transfer, are typically transformed by biolistic methods (Lowe et al., 2009). However, 
once transgenic lines are established, the production of recombinant protein is highly 
scalable. The production capacity would be limited only by the available acreage. In 
practice, transgenic plants are most often contained within greenhouses to comply 
with regulations. A problem that is often observed in transgenic plants is silencing 
the transgene in later generations, especially if multiple copies of the transgene have 
integrated into the genome. The epigenetic phenomena behind these types of gene 
silencing is an active area of research (Reddy et al., 2003; Lowe et al., 2009). 
Transient expression has a much faster development timescale, because it does not 
require stable transformation of plants. Rather, recombinant Agrobacterium deliver 
DNA into plant cells for expression of the protein of interest over a period of several 
days. In the case of tobacco leaves, the Agrobacterium cell suspension is infiltrated 
into the air spaces surrounding mesophyll cells, using a needleless syringe for small-
scale confirmation of protein expression. This process is termed Agroinfiltration. For 
larger-scale operations, plant leaves may be infiltrated by placing the whole plant in 
an Agrobacterium suspension under a reversible vacuum, or by spraying 
Agrobacterium directly onto leaves (Marillonnet et al., 2005). Although transient 
expression may potentially be less scalable than using field-grown transgenic plants, 
facilities have been established that carry out Agroinfiltration on a large scale, 
capable of processing several tonnes of biomass by vacuum infiltration per hour 
(Yusibov et al., 2011). 
A major factor influencing the yield of plant-produced recombinant proteins is post-













conserved amongst eukaryotes, including plants. The vast majority of viruses 
infecting plants have a single-stranded RNA genome, and they replicate through a 
double-stranded RNA intermediate. The recognition of double stranded RNA by the 
plant’s PTGS response is followed by the subsequent destruction of RNA sharing 
sequence homology to the foreign RNA (Scholthof, 2007). By the same means, 
mRNA transcripts of the recombinant gene of interest are similarly destroyed upon 
induction of PTGS, leading to a lower protein yield. Plant viruses have overcome the 
effects of PTGS by producing silencing suppressor proteins that interfere with 
various stages of the PTGS pathway. The genes encoding silencing suppressors 
can be co-infiltrated with the gene of interest into plants for increased transient 
protein expression (Voinnet et al., 2003). Plants stably transformed with silencing 
suppressor genes typically exhibit negative phenotypic effects (Siddiqui et al., 2008). 
However, Saxena et al. (2011) stably transformed N. benthamiana with a mutant of 
the silencing suppressor p19 (from tomato bushy stunt virus) that had only minor 
developmental effects on the plant. 
 Sub-cellular protein targeting 
The recombinant protein may be targeted to a specific part of the plant cell to 
increase its stability and accumulation (Figure 3). The choice of subcellular 
compartment will influence the protein yield as well as the purification strategy 
employed. Secretion is the default pathway for proteins entering the endomembrane 
system. In the absence of any further targeting information, proteins containing an N-
terminal signal sequence are secreted by the cell, causing the protein to accumulate 
in the apoplastic space (Ma et al., 2003). Non-secretory proteins lacking this 
sequence are retained in the cytosol. Retention of recombinant proteins in the 
cytosol is generally associated with lower yields for most proteins, compared to other 
subcellular compartments such as the endoplasmic reticulum (ER) (Fischer and 
Emans, 2000). Proteins containing the N-terminal signal sequence, in addition to the 
C-terminal tetrapeptides KDEL or HDEL accumulate in the ER. The ER is a 
protease-free environment and contains chaperone proteins to assist in the correct 
folding of proteins. Proteins may accumulate to high levels in the ER of plant cells 






















A: Representation of a typical photosynthetic plant cell with its subcellular compartments, including 
the nucleus, ER and chloroplasts (Lunn, 2007). B: Representation of a chloroplast, showing the 
association of plastoglobules with the thylakoid membrane. 
 
There are as many as 100 chloroplasts in a plant cell and each one contains about 
100 copies of the chloroplast genome (Sharma and Sharma, 2009). Transformation 
of the chloroplast genome therefore will allow thousands of copies of the transgene 
to be present in each cell. This leads to higher levels of expression and production of 
the recombinant protein. Plant chloroplast genomes may be stably transformed, 
generating transplastomic plant lines. Transplastomic plants have an additional 
advantage of biocontainment; because plastids like chloroplasts are maternally 
inherited, there is no spread of the transgene through pollen (Lössl & Waheed, 
2011). The transformation of the chloroplast genome also avoids the problem of 





















gene insertion can be controlled (Dufourmantel et al., 2004). There is one limitation 
to transplastomic expression, in that the translational machinery of the chloroplast is 
similar to that of prokaryotes. Therefore proteins requiring post-translational 
modifications such as glycosylation are not suited for expression in the choloroplast 
(Ma et al., 2003). Recombinant proteins expressed transiently by Agroinfiltration may 
be targeted for accumulation in the chloroplast by a N-terminal chloroplast transit 
peptide (Rybicki, 2010). Such a protein is produced by translation in the cytoplasm 
and is then imported into the chloroplast, where it may accumulate to high levels. 
Using this strategy, Maclean et al. (2007) expressed human papillomavirus protein 
L1 in tobacco plants, with a yield of 11% of the total soluble protein. 
 
Targeting of proteins to the chloroplast has so far mostly been limited to the stroma, 
(Figure 3B). Recently, plastoglobules have been evaluated as sites for protein 
accumulation (Vidi et al., 2007). Plastoglobules are low-density lipid-containing 
stuctures present in all plastids. In chloroplasts they are associated mainly with the 
thylakoid membranes (Figure 3B). A recent study of the proteome of A. thaliana 
plastoglobules identified several proteins of the fibrillin family, specific to 
plastoglobules (Ytterberg et al., 2006). Vidi et al. (2007) targeted the accumulation of 
yellow fluorescent protein to plastoglobules by fusion to one of these fibrillin proteins. 
The plastoglobules were isolated by flotation centrifugation. This system simplifies 
purification from plant leaves and results in efficient enrichment of the target protein 
in a single step. 
 
Protein recovery and purification from plants 
The first phase of downstream processing is protein recovery. This involves 
processing of the plant biomass, solid-liquid separation, protein extraction and 
concentration (Kusnadi et al. 1997). The initial recovery steps are largely dependent 
on the host plant. After harvesting, the tissues of the plant expressing the 
recombinant protein (e.g. seeds or leaves) are separated from the rest of the plant. 
Grinding is required to reduce particle size. This breaks cell walls and releases 
intracellular components, in preparation for protein extraction. For leaves, grinding 













et al., 2004). This process is usually not suitable for seed crops, which must be dry 
ground and subsequently mixed with aqueous extraction buffer.  
 
The ionic strength and especially the pH of extraction buffer are important in 
determining the amount of extracted protein. In one protein extraction study, the 
amount of recombinant lysozyme extracted from tobacco leaves varied from 1.0% to 
1.6% (w/w) for extraction buffers of pH 3 to 9 (Balasubramaniam et al., 2003). High 
concentrations of secondary metabolites can be detrimental to the purification. Of 
these, phenolic compounds (occurring in high concentrations particularly in tobacco) 
are the most problematic. They interact with proteins and can cause aggregation of 
proteins or changes in protein conformation (Farinas et al., 2005). The level of 
phenolic contamination can be minimized by changing the pH or ionic strength of the 
extraction buffer. The degradation of proteins by host proteases is of major concern, 
especially for protein extracted from leaf biosmass. Protease inhibitors such as 
phenylmethanesulphonyl fluoride (PMSF) are usually added to prevent degradation 
of the protein (Kusnadi et al. 1997). Clarification of the protein extract is then 
performed. The residual solids are removed by centrifugation or other methods such 
as rotary vacuum filtration (Evangelista et al., 1998). The clarified protein extract may 
be purified by various methods, including several types of chromatography. 
However, further clarification of the protein extract by dead-end filtration or 
centrifugation steps is often necessary before it may be applied to a chromatography 
column. 
 
As a pre-purification step, the use of aqueous two-phase extraction (ATPE) has been 
applied to the recovery of proteins from tobacco (Platis & Labrou, 2006). When 
polymers such as polyethylene glycol (PEG) are mixed with salt solutions of a 
particular concentration, two immiscible layers are formed. The partitioning of 
proteins between the two phases is based on their charge and hydrophobicity. In one 
study using ATPE, lysozyme in tobacco leaf extracts was concentrated by a factor of 
14 and was partially purified (enrichment factor of 4) (Balasubramaniam et al., 2003). 
In addition, it was found that ATPE can be used to effectively remove phenolic 













2006). ATPE can be applied cost-effectively on a large scale and reduces the load 
on subsequent purification steps. 
 
The final purification steps will depend on the recombinant protein and the host plant. 
Ion-exchange chromatography is often used because of its low cost, high binding 
capacity and reusability of the resin (Platis et al., 2008). Affinity-based purification is 
a powerful purification technique. Fusion proteins can be purified to near 
homogeneity in a single step and at a high yield – often over 90% (Arnau et al., 
2006). It is widely used and invaluable in laboratory-scale research. Affinity 
chromatography is typically not used for protein purification on an industrial scale 
because of the high cost of affinity resins and loss of the bound ligand from the 
column with repeated use (Platis and Labrou, 2006). Therapeutic proteins most often 
require removal of the affinity tag which requires expensive proteases. For the 
purification of lower-value products, the costs of affinity chromatography will 
outweigh the reduction in cost by using plant expression systems. Therefore, more 
cost-effective and technically simple protein purification methods are needed that 
can be easily scaled up.  
 
Non-chromatographic protein purification 
Highly efficient extraction and purification processes are essential for recombinant 
protein production, especially if those proteins have pharmaceutical applications. 
Such proteins would need to be 95-98% pure (Menkhaus et al., 2004). Most of the 
total cost is incurred by downstream processing (Evangelista et al., 1998). In some 
cases, the cost of downstream processing alone may determine if a particular plant 
production system is economically feasible. Factors such as the choice of crop and 
the targeting of recombinant protein accumulation to specific tissues or sub-cellular 
compartments will influence the design of the purification process. Currently, 
chromatography is part of most purification schemes. The use of affinity fusions and 
affinity chromatography, although highly effective as research tools, may be 
unsuitable for large-scale purifications because of the high cost of affinity resins 
(Nilsson et al., 1997). The success of large-scale production will therefore depend on 
robust and inexpensive purification methods. The extraction of protein from plant 













Chromatography is limited in its scalability and the inevitable fouling of 
chromatography resin by volumes of this magnitude would increase the cost of the 
purification process. Non-chromatographic purification methods are therefore very 
attractive for the purification of recombinant proteins from plants. Some of the 
methods described here have been developed in recent years, but not all of them 
may yet be suitable for use at the industrial scale. 
 
Oleosin fusions 
Oil bodies are ER-derived organelles that store oils in plant seeds. They are 
composed of a matrix of triacylglycerols bounded by a phosopholipid monolayer. 
Embedded on the surface are proteins unique to oil bodies, such as oleosins. 
Oleosins have a central hydrophobic domain that associates with the interior of the 
oil body and amphipathic N- and C-termini that are exposed to the cytosol (Bhatla et 
al., 2010). The target protein may be fused to the N- or C-terminus of the oleosin, 
separated by a linker peptide containing an endoprotease recognition sequence. 
This fusion does not affect the targeting of oleosin to oil bodies. The heterologous 
protein is tightly associated to the oil body and is exposed to the cytosol. The oil 
bodies are low-density and are easily separated from other cell components by 
centrifugation methods. The protein may then be cleaved from its oleosin partner by 
digestion with the specific endoprotease. This method has been used to produce and 
purify hirudin, a blood anticoagulant protein, in Brassica carinata seeds (Chaudhary 
et al., 1998) and biologically functional insulin in Arabidopsis thaliana seeds 
(Nykiforuk et al., 2006). 
 
Zein fusions 
Zeins are the major storage proteins of maize endosperm cells. The formation of 
accretions known as protein bodies is dependent on the presence of γ-zein 
(Coleman et al., 1996).  A sequence derived from the proline-rich, N-terminal domain 
of γ-zein, can be fused to the target protein. This results in aggregation of the fusion 
protein to form protein bodies, which are retained in membrane-bound storage 
organelles derived from the ER (Torrent et al., 2009). This sequence, known as the 
Zera® domain (Torrent et al., 2009), has been shown to induce protein body 













cultured cells. Another study using a similar γ-zein sequence fused to bean 
(Phaseolus vulgaris) phaseolin concluded that the presence of this sequence alone 
in the fusion is sufficient for protein body formation (Mainieri et al., 2004). The Zera® 
domain contains a repetitive sequence (PPPVHL)8 which was found to self-assemble 
in vitro (Kogan et al., 2002). Protein bodies are insoluble and can be recovered from 
crude cell or tissue extracts using density gradient centrifugation (Mainieri et al., 
2004). Sequestration of the heterologous protein in protein bodies will isolate it from 
physiological processes of the cell. The benefits of this include the protection of the 
protein from degradation and the prevention of its possible toxic effects on the host. 
The recovery of Zera®-tagged proteins is simplified as the protein storage organelles 
are recovered in a specific fraction following density gradient centrifugation. The 
organelle membrane is dissolved to release the fusion protein. The protein bodies 
are then de-aggregated under mild reducing conditions (Torrent et al., 2009) and the 
Zera® tag is separated from the target protein by protease cleavage. The Zera® 
fusion strategy allows for simultaneous purification and concentration of the 
recombinant protein.  
 
Hydrophobin fusions 
The formation of protein bodies allows for higher accumulation of the recombinant 
protein plant cells. Recently it has been shown that fusion of the protein of interest to 
hydrophobin and expression in plants induces the formation of protein bodies in the 
ER (Joensuu et al., 2010), as with the Zera® tag. Hydrophobins are small (12-17 
kDa) proteins produced by filamentous fungi. These proteins have a conserved 
hydrophobic “patch” that is responsible for their amphipathic nature, and they 
therefore have a propensity to form protein membranes at hydrophobic-hydrophilic 
interfaces (Wang et al., 2005). Hydrophobin fusions can be purified by an aqueous 
two-phase separation process with the addition of a specific surfactant. The 
hydrophobin fusions form micelles that are concentrated in the surfactant phase, but 
absent from the aqueous phase containing the majority of contaminating proteins 
(Mustalahti et al., 2011). This process is simple and highly scalable. The utility of 
hydrophobin fusions has been evaluated for the system of transient expression in 















Elastin-like polypeptide (ELP) fusions 
Elastin is a component of the extracellular matrix of vertebrate connective tissue. It 
imparts elasticity and strength to tissues that are required to deform reversibly, such 
as lung and skin (Floss et al., 2010b). Elastin is deposited in elastic fibres by the 
complex process known as elastogenesis. Tropoelastin is the soluble precursor of 
elastin. It is secreted into the extracellular space, where the action of lysyl oxidase 
forms covalent cross-links between tropoelastin molecules. This forms the mature 
elastin, which is an insoluble polymer (Debelle & Tamburro, 1999). Tropoelastin 
contains large hydrophobic domains that are composed mainly of proline, alanine, 
valine, leucine, isoleucine and glycine residues (Debelle & Tamburro, 1999). These 
residues occur as tetra-, penta- and hexa-peptide repeats. The physical properties of 
these repeat sequences have been studied using synthetic polypeptides such as 
poly-(VPGXG) (X is referred to as the “guest residue”, being any amino acid except 
proline) (Li et al., 2001). 
 
Polypeptides based on the structure of elastin and its precursors, such as poly- 
(VPGXG), are called elastin-like polypeptides (ELPs). These peptides are soluble in 
aqueous solution below a specific temperature, known as the inverse transition 
temperature (Tt). When the temperature is raised above Tt the peptides are 
desolvated and aggregate, making them insoluble (Meyer & Chilkoti, 1999). This is 
termed the inverse phase transition and occurs over a narrow temperature range (2-
3°C) and is reversible. The process can be monitored by measuring the turbidity of 
the solution at 350 nm in real time. At high ELP concentrations, the increase in 
turbidity upon heating is visible to the naked eye, as is the decrease in turbidity when 
the ELP solution is again cooled to below Tt. The Tt is influenced by the length (i.e. 
number of repeat units) of the ELP; longer polypeptides have a lower T t (Urry, 1997). 
The composition of guest residues in the ELP also influences T t, as do factors such 
as the ionic strength and pH of the solution (Urry, 1997). It should be noted that 
ELPs can be designed in regard to length and composition of guest residues to give 
a desired Tt under specific conditions. ELP-tagged proteins are purified in a process 
known as inverse transition cycling (ITC) (Figure 4) (Meyer & Chilkoti, 1999). The 













tissue extract by heating to above the Tt. Typically the Tt is first depressed by the 
addition of salt. This allows the ELP aggregation to occur at temperatures that do not 
denature the target protein; usually 30-40 °C. Once the protein solution is heated to 
above the transition temperature, selective aggregation of the ELP-tagged protein 
occurs. The precipitated ELP fusion is removed by centrifugation or microfiltration 
(Ge et al., 2006). The fusion protein aggregates are then resolubilised by cooling to 
below the Tt.  
 
The concentration of ELP is also an important factor in determining the T t and the 
efficacy of ITC: with more concentrated ELP protein solutions, the recovery of the 
ELP or ELP fusion is more efficient. In order to purify poorly expressed ELP fusions, 
free ELP protein – with a Tt matching that of the fusion protein – may be added in 
order to increase the overall ELP concentration. The free ELP co-aggregates with 
the fusion protein during ITC and improves its recovery. Using this method, 
Christensen et al. (2007) purified picomolar quantities of  a thioredoxin ELP fusion 












Figure 4: Schematic of inverse transition cycling  
1) The ELP fusion aggregates specifically above its transition temperature, allowing it to be 
pelleted by centrifugation at elevated temperature. 
2) The supernatant containing soluble contaminating proteins is discarded. 
3) The purified ELP pellet is resolubilised in cold buffer. Steps 1 to 3 can be repeated several 
times to increase purity. 
4) The ELP can be separated from the target protein by protease digestion. The target protein is 
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At this point the ELP tag may be removed from the target protein by endoprotease 
digestion, which may be necessary for proteins with therapeutic applications. This 
requires the insertion of a specific protease recognition site between the ELP and the 
target protein. The use of ELP-tagged proteases has been recently described by Lan 
et al. (2011) for the removal of proteases by ITC once digestion is complete. 
However, proteases are expensive and may also exhibit non-specific cleavage. As 
an alternative to proteases, an intein sequence may be introduced between the 
target protein and the ELP tag. The intein is a self-cleaving protein element that will 
allow the separation of the ELP tag from the target protein by a mild pH shift, or the 
addition of reducing agents, depending on the specific intein used (Wu et al., 2006). 
The cleaved ELP tag is precipitated by another round of ITC. After centrifugation, the 
pellet containing the precipitated ELPs is discarded and the target protein is 
recovered in the supernatant. Purification using the ELP tag system, as an 
alternative to chromatography, is more economical and can be implemented on a 
large scale.  
 
Apart from cheaper purification, the use of ELP fusions can increase the yield of the 
recombinant protein. The yields of several heterologous proteins, including human 
interleukin-10, expressed in tobacco leaves as ELP fusions were higher than that of 
the un-fused proteins (Patel et al., 2007). The ELP used was a 27-mer of VPGVG. In 
another study, the accumulation of single-chain variable fragments in tobacco seeds 
was increased 40-fold when expressed as an ELP fusion (Scheller et al., 2006). 
Here the ELP was a 100-mer. The yield of a thioredoxin-ELP fusion expressed in 
Escherichia coli was greater when a shorter ELP tag (20-mer) is used as opposed to 
a longer one (90-mer). Shortening the ELP tag did not compromise its ability to be 
purified by ITC, but the phase transition behavior was more complex. The optimal 
length of the ELP may vary for different target proteins (Meyer et al., 2001). The 
presence of the ELP tag can lead to the formation of novel protein bodies, as 
investigated by Conley et al. (2009b). Tobacco leaves (Nicotiana benthamiana) were 
agroinfiltrated, resulting in transient expression of green fluorescent protein (GFP). 
When the expression of a GFP-ELP fusion was targeted to the endoplasmic 













resembling protein bodies were observed by confocal microscopy. The formation of 
these protein bodies allows for higher accumulation of the target protein as well as 
protecting it from proteolytic degradation.  
 
For some proteins expressed in E. coli, fusion to ELP may decrease the yield of the 
target protein, especially for high molecular weight ELPs (Trabbic-Carlson et al., 
2004a). To harness the purification potential of ELP, affinity capture methods have 
been designed that allow protein purification without direct fusion of ELP to the 
protein of interest. The ELP is expressed as a fusion to an affinity capture partner 
that binds to the protein of interest. The target protein binds to its partner and then 
ITC may be used to purify the entire complex. The ELP fusion may then be re-used 
to purify more target protein. The success of this method has been demonstrated for 
the purification of antibodies (Kim et al., 2005). The ELP affinity capture system is 
extremely versatile and can be implemented for any protein with fusion to a small 
affinity tag, as has been done for various dockerin-tagged proteins expressed in E. 
coli (Liu et al., 2012b). 
The applications of ELPs are not limited to recombinant protein purification. By 
modifying the pentapeptide repeat sequence of ELP and by constructing ELP block 
co-polymers, a variety of structures can be formed including membranes, micelles 
and hydrogels (MacEwan & Chilkoti, 2010). Polymers derived from elastin have been 
used in the construction of nanoparticles for drug delivery. Macromolecular drug 
carriers have a longer half-life in plasma, as they are more slowly cleared by the 
kidneys than free drugs, and allow for controlled release of the drug over an 
extended period (Altunbas & Pochan, 2012). Due to the environmental 
responsiveness of ELP, concentrations of the drug-ELP conjugate can be increased 
by ELP aggregation at an area of local hyperthermia, for example at a tumour site 
(McDaniel et al., 2012). Micelles displaying protein on their surface can be formed 
through temperature-dependent aggregation of ELP block copolymers (Hassouneh 
et al., 2012). This could have great potential for vaccine development, as multivalent 
antigen display could potentially increase immunogenicity, which is true in case of 













ELPs have found applications in tissue engineering by acting as scaffolds for cell 
attachment and proliferation. In one study, an ELP membrane was used to allow for 
reversible attachment of intact cell sheets (Mie et al., 2008). ELP has also been used 
for the coating of synthetic cardiovascular devices to improve biocompatibility 
(Woodhouse et al., 2004). 
 
In summary, ELP fusions may be especially useful for the expression and purification 
plant-produced recombinant proteins. Plant systems, which typically exhibit lower 
recombinant protein yields compared to other expression systems, can greatly 
benefit from the increase in protein yield by fusion to ELP. The most expensive step 
in recombinant protein production – purification – may be reduced i  cost by avoiding 
the use of chromatography resins. The highly scalable ELP purification system is 
able to cope with the massive volumes of plant biomass extract that would be 
generated for industrial recombinant protein production in plants such as tobacco. 
 
Project aims and outline 
There is currently no vaccine against beak and feather disease virus and any 
vaccine candidate should be safe and affordable. The aim of this work was to 
produce beak and feather disease virus vaccine candidates using different 
approaches. Firstly, ΔN40 CP was produced in bacteria, using the pPROEX 
expression system. Bacterial over-expression, with its typically high recombinant 
protein yields and short timescale, was used to produce ΔN40 CP as a potential 
subunit vaccine. ELP fusions of ΔN40 CP were also expressed in order to 
characterise the purification conditions of these ELP fusions by ITC. A secondary 
aim for bacterial expression was to generate enough CP antigens for the production 
of CP-specific antibodies. These antibodies are not commercially available and 
would facilitate the detection of BFDV CP produced in a variety of expression 
systems by our laboratory. 
 
As described in Chapter 3, the principal aim of this project was to produce candidate 













transient expression. Plant expression was chosen because of its low cost and 
safety. Fusion of BFDV CP to ELPs of different lengths was done to increase its 
accumulation in plants, and to provide an inexpensive and scalable means of 
purification. GFP-ELP fusions and a free ELP were also produced using this system. 
The ITC purification system was then used to purify ELP fusions.  Due to their high 
expression levels, the GFP-ELP51 fusion and the free ELP51 were first purified in 
order to test the robustness of the ITC system. Two ITC methods, one based on 
centrifugation and the other on membrane filtration, were compared. This was 
followed by purification experiments of a truncated CP-ELP fusion (ΔN40 CP-ELP51) 
which are described in Chapter 4. 
As an alternative to a subunit vaccine candidate, a eukaryotic expression vector 
containing the ΔN40 CP gene was evaluated as a potential DNA vaccine. The 
capacity of this candidate DNA vaccine to express ΔN40 CP in transfected cells was 
tested for two cell types, human embryonic kidney cells and chicken embryonic 
fibroblast primary cells. Proof of truncated CP expression was required in order to 
proceed with future animal trials. This DNA vaccine could potentially be used in a 



















Escherichia coli is the most used organism for the expression of recombinant 
proteins, because of its extensive genetic characterisation and availability of mutant 
strains. Various promoter systems have been developed in order to maximise the 
expression of heterologous proteins (for a review, see Terpe (2006)). Among them, 
the synthetic trc promoter, derived from the E. coli trp and lacUV5 promoters, is 
commonly used for its ability to drive high-level transcription of genes (Tegel et al., 
2011). The expression vector used in this chapter, pPROEX-HT (Life Technologies, 
USA), contains the trc promoter and lacI gene, which is induced by isopropyl-beta-d-
thiogalactopyranoside (IPTG). In order to achieve maximum protein yield and 
solubility, expression must be optimised for individual proteins, using different 
promoters, bacterial strains and culture conditions. 
All attempts to propagate BFDV in cell culture have so far been unsuccessful. BFDV 
proteins must therefore be produced by expression of the recombinant DNA in hosts 
such as bacteria, or eukaryotic systems. As the capsid protein (CP) is the major 
antigenic determinant of the virus, efforts for BFDV vaccine development are 
focused on the production of CP. In addition, CP can be useful for diagnosis of 
BFDV infection when used as an antigen in ELISA-based detection methods. The N-
terminus of circovirus capsid proteins such as BFDV CP and PCV-2 CP is rich in 
basic amino acids that forms part of the nuclear localisation signal (Heath et al., 
2006). The arginine codons AGG and AGA are rare in prokaryotes, but are the most 
commonly used ones in eukaryotes (Alexandrova et al., 1995). Inefficient translation 
of these codons occurs in prokaryotes due to a lack of the corresponding tRNA 
species. Problems arising from codon bias include frameshift events and premature 
termination of translation (Sørensen & Mortensen, 2005). Groups of these codons 













translation (Alexandrova et al., 1995). Codon optimisation of the PCV-2 CP 
sequence by the replacement of rare arginine codons results in a marked increase in 
PCV-2 capsid protein expression in E. coli (Marcekova et al., 2009). Deletion of 
sequence in the BFDV CP gene encoding the first 40 N-terminal amino acids 
resulted in high-level expression of truncated BFDV CP (ΔN40 CP), while full-length 
CP could not be detected when expressed in E. coli (Johne et al., 2004).  
The expression of BFDV ΔN40 CP proteins in E. coli as described in this chapter 
was done primarily to acquire enough protein for anti-BFDV ΔN40 CP antibody 
production. A truncated BFDV CP (ΔN40 CP) gene was previously generated in our 
laboratory and showed higher yields relative to full-length CP when expressed in 
insect cells (Heath et al., 2006). Therefore this ΔN40 CP was used in the bacterial 
expression described here, with the aim of maximising protein yield. Each protein 
was injected into a rabbit and serum was harvested as described in 2.2.7. No 
commercial anti-BFDV CP is available. The serum would facilitate the detection of 
BFDV CP proteins produced by different expression systems, including plants. ELP 
fusions of ΔN40 CP were created with the aim of characterising the purification 
conditions by ITC (see Chapter 4). Expression of recombinant proteins in E. coli is 
rapid and inexpensive. The typically high yield of recombinant protein over-
expressed in microbial systems, compared to eukaryotic systems, makes this option 
attractive for the rapid characterisation of proteins, including its physical properties. 
 
2.2 Materials and Methods 
 
2.2.1 Genes and Plasmids 
Full-length and truncated (40 amino acids from N-terminus) beak and feather 
disease virus coat protein genes (BFDV CP, Genbank accession number 
AY450451.1) were both maintained in pGEM®-T Easy vectors (Promega, USA). The 
full-length capsid protein (UniprotKB accession number Q9YUC8) is designated 
BFDV CP and the truncated version is designated ΔN40 CP. These were obtained 
from the culture collection of the vaccine group at the Department of Molecular and 













previously synthesized by GENEART (Germany), was maintained in the vector pMK-
TEV-ELP (Appendix C). The binary plant expression vector pTRAkc-ERH was 
provided by Rainer Fischer of the Fraunhofer Institute for Molecular Biology and 
Applied Ecology, IME, Germany. The pPROEX-HTb bacterial expression vector was 
obtained from Qiagen (Qiagen, USA) (Appendix B). The antibiotic selection for each 
of the plasmids is summarised in Table 1. 
 
Table 1: Antibiotic selection of plasmids 
Plasmid Antibiotic and concentration 
pGEM®-T Easy Ampicillin, 100 µg/ml 
pMK-TEV-ELP Kanamycin, 50 µg/ml 
pTRAkc-ERH, pTRA-ERH-ELP Ampicillin, 100 µg/ml 
pPROEX-HTb Ampicillin, 100 µg/ml 
 
2.2.2 Construction of pTRA-ERH-ELP28  
The PCR product consisting of the TEV protease recognition site, ELP28 sequence 
comprising 28 VPGVG repeats, His tag and SEKDEL sequences was amplified 
using the primers TEV-ELP For and ELP-HK Rev listed in Table 2, from the template 
pMK-TEV-ELP (Appendix C). This PCR product was digested with NcoI and XhoI 
and cloned into pTRAkc-ERH (Appendix B) to generate the vector termed pTRA-
pTRA-ERH-ELP28, using procedures described in Appendix A. This vector creates 



















Table 2: Oligonucleotide primers used in PCR.  
‘For’ designates a forward primer. ‘Rev’ designates a reverse primer. Restriction enzyme sites are 
underlined. 













5’ NcoI, NotI sites, TEV 






XhoI site, 6X His, SEKDEL 
coding sequence  











NcoI site, interruption of TEV 
recognition sequence  
  
2.2.3 Construction of pTRA-ERH-ELP-51: 
The completed pTRA-ERH-ELP28 vector was transformed into chemically 
competent dam-/dcm- E. coli (Bioline, USA). The plasmid was isolated from an 
overnight culture, digested with PfIMI and the products were separated by gel 
electrophoresis. The digested pTRA-ERH-ELP28 vector and 0.5-1 kb area of the gel 
were excised and digestion products were extracted from the gel. The 0.5-1 kb 













Fermentas Rapid DNA Ligase, with the intention of generating ELP fragments of 
random lengths. The ELP ligation product was then ligated into the digested pTRA-
ERH-ELP28 vector, and transformed into chemically competent E. coli DH5α cells 
(E. cloni®, Lucigen, USA)) (see Appendix A for general cloning procedures). 
Transformants were screened by colony PCR, to determine the size of the ELP 
sequence insert, using pTRA vector-specific sequencing primers forward: 5'-
CATTTCATTTGGAGAGGACACG-3’, reverse: 5'-GAACACTCACACATTATTCT GG-
3'. Clones with inserts larger than those in pTRA-ERH-ELP28 were analysed by 
restriction enzyme digests and were verified by sequencing. The pTRA-ERH-ELP51 
vector contains an ELP sequence encoding 51 repeats of VPGVG.  
 
2.2.4 Generation of pTRA and pPROEX clones 
pTRAkc-ERH and pTRA-ERH-ELP clones 
Both BFDV CP and ΔN40 CP genes each required a NotI restriction site that 
interrupts the stop codon, in order to allow read-through of the C-terminal His-tag (in 
the case of pTRAkc-ERH vector) or ELP (in the case of pTRA-ERH-ELP vectors). 
This was achieved by PCR, using BFDV CP-specific primers AflIII-BFDVN40 For or 
AflIII-BFDV CP For, with the reverse primer, NotI-BFDVN40 Rev, adding the NotI 
site (Table 2).  
CP or ΔN40 CP PCR products were digested with AflIII and XhoI and ligated into 
pTRAkc-ERH vector (Appendix B), digested with NcoI and XhoI, using the 
procedures described in Appendix A. Similarly, to generate CP-ELP or ΔN40 CP-
ELP fusions, CP or ΔN40 CP PCR products were cloned into pTRA-ERH-ELP 
vectors. Transformants were screened for the presence of inserts by colony PCR 































The proteins expressed by pPROEX-HTb are summarised. His: His-tag, ΔN40 CP: truncated BFDV 
CP, ELP: 28 x VPGVG or 51 x VPGVG sequence, TEV: TEV protease recognition sequence at the 
junction of segments. The free ELP51 contains a linker peptide MVYFQG separating the N-terminal 
His tag and the ELP. Note that the N-terminal His tag and TEV recognition sequence are original 
features of the pPROEX-HTb vector.  
 
pPROEX-HTb expression constructs 
The pPROEX CP and pPROEX-ΔN40 CP clones were provided by Guy Regnard 
(Vaccine Group, Department of Molecular and Cell Biology, UCT). These were 
created by subcloning the respective CP genes from the pGEM®-T Easy vectors into 
pPROEX-HTb, using the 5’ AflIII and 3’ XhoI sites flanking the CP genes and the 
compatible 5’ NcoI and 3’ XhoI sites in the multiple cloning site of pPROEX-HTb 
(Appendix D). 
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pPROEX constructs containing ΔN40 CP-ELP fusions were prepared. PCR was 
again used to generate ΔN40 CP-ELP inserts for the pPROEX vector, using the 
respective pTRA-ΔN40 CP-ELP clones as the templates. BFDV ΔN40 CP-specific 
forward primer AflIII-BFDVN40 For and the vector-specific reverse primer, XhoI ERH 
Rev, were used. These PCR products were digested with AflIII and XhoI and ligated 
into the pPROEX vector which had been digested with NcoI and XhoI. The free 
ELP51 PCR product was generated from the pTRA-ERH-ELP51 vector template 
using the primers NcoI-TEV For and XhoI ERH Rev. The free ELP51 PCR product 
was digested with NcoI and XhoI and cloned directly into similarly digested pPROEX. 
The proteins expressed by pPROEX are summarised in Figure 5. 
 
2.2.5 Protein expression with pPROEX-HTb 
Protein expression was performed using E. coli DH5α cells. Ten millilitre LB medium 
starter cultures were inoculated with a single colony, supplemented with 100 µg/ml 
ampicillin and incubated overnight with shaking at 37 °C. Erlenmeyer flasks 
containing 1/5th total volume of LB medium with 100 µg/ml ampicillin was inoculated 
with 1/00th volume of starter culture. These cultures were grown at 37 °C in an orbital 
shaker (120 rpm) until the optical density of the culture at 600 nm reached 0.5-0.8. 
Protein expression was induced by the addition of 0.6 mM IPTG, and the cultures 
were grown at 37 °C in an orbital shaker for a further 3 hours.  
 
2.2.6 Protein extraction from E. coli cells 
Frozen cell pellets were resuspended in 1/10th culture volume of 50 mM Tris-HCl pH 
8.0. The cells were sonicated using a Sonicator 3000 (MISONIX, USA) with microtip 
for 8 x 15 second pulses at an output of 6 W. Triton X-100 was added to the cell 
lysate to 0.1% (v/v) and incubated with gentle shaking at 25 °C for 30 minutes. Cell 
debris was pelleted (insoluble fraction) by centrifugation at 15,000 x g at 4 °C and 
the soluble protein fraction was recovered in the supernatant. The extraction of 
inclusion body protein using Bugbuster® solution (Novagen, USA) and the 
purification of inclusion bodies from E. coli cells was performed using the 
manufacturer’s protocol. To prepare soluble protein to be used as a positive control 
for immunoblots, washed IB proteins were solubilised using 50 mM Tris-HCl buffer 













USA). The soluble protein was collected by recovering the supernatant following 
centrifugation at 15 000 x g for 20 minutes. The NLS was removed by a twofold 
dilution of the sample in PBS, followed by dialysis against PBS overnight at 4 °C, 
with stirring. In cases of TEV protease digestion, ΔN40 CP was digested with AcTEV 
protease (Invitrogen, USA) using the manufacturer’s recommended reaction setup at 
27 °C for 16 hours.  
 
2.2.7 Dialysis and endotoxin testing of antigens 
Dialysis of sample was done using dialysis tubing with a molecular weight cut-off of 
10 kDa (Thermo Fisher Scientific, USA) against 5L sterile Dulbecco’s PBS (Sigma-
Aldrich, USA) for 20h at 4 °C, with constant stirring. Levels of endotoxin were 
measured using a Limulus Amebocyte assay QCL-100  kit (Cambrex, USA) as per 
the manufacturer’s instructions. The absorbance readings were performed using 
Immuno 96-microwell clear solid plates (Thermo Fisher Scientific, USA) and a 
BioTek Powerwave XS plate reader (BioTek, USA). 
 
2.2.8 Polyclonal antibody production in rabbits: inoculation schedule 
The amount of protein was divided equally into 4 tubes for each antigen (for the 
initial and three booster injections; see below) containing a 0.5 mL suspension of the 
inclusion bodies in PBS. The total amount of antigen injected in each dose was 
approximately 40 µg for ΔN40-CP and 17 µg for ΔN40 CP-ELP51. 
Production of rabbit immune sera was done by Deltamune (South Africa) as follows: 
Ten millilitres pre-immune blood was collected from the marginal ear vein, prior to 
administration of the antigen. 
Initial injection: Animals were injected subcutaneously on the back at one site with 
0.5 mL of the antigen in the presence of Freund’s incomplete adjuvant (IFA) made 
according to the protocol in the Difco catalogue (#263910) (Difco, USA). This was 
followed by 3 subsequent booster injections which were also administered 
subcutaneously: 
Booster 1: the first booster followed two weeks after the primary (initial) injection (as 













Booster 2 the second booster followed one week after the first booster (as above) 
with IFA. 
Booster 3: the third and last booster injection followed one week after the second 
booster (as above) with IFA. 
The pre-immune serum and the final serum samples received from Deltamune were 
stored in 1 mL aliquots at -20 °C. All protocols were approved by the Deltamune 
Animal Ethics Committee 
 
2.2.9 SDS PAGE and Immunoblotting: 
5 x SDS sample buffer (25% (v/v) glycerol, 0.5 M DTT, 5% (w/v) SDS, 0.01% (w/v) 
bromothymol blue) was added to protein samples to 1 x concentration. Protein 
samples were then incubated at 85 °C for 5 minutes and loaded onto 12% 
polyacrylamide gels, followed by electrophoresis at 20 mA. Alternatively, gels cast 
and used with the Bio-Rad Tetra Cell system (Bio-Rad Laboratories, USA) were 
electrophoresed at 120 V, as per the manufacturer’s protocol. Gels were stained with 
Coomassie Brilliant Blue stain for 2 hours at 37°C and destained overnight. 
PageRuler™ pre-stained protein ladder #SM6071 (Fermentas, Canada) was used 
for all gels as a molecular weight marker. 
For immunoblots, protein transfer from polyacrylamide gels to nitrocellulose 
membrane was done with a Bio-Rad Trans-Blot® Semi-dry transfer cell at 15 V for 
1.5 hours. Blots were blocked with blocking buffer (PBS pH 7.4, 0.1 % Tween-20,     
5 % skim milk) for 30 minutes and then incubated with a one in 2000 dilution of anti-
His-tag mouse IgG antibody (Serotech, USA), or rabbit serum at the specified 
dilution, in blocking buffer overnight at room temperature, with shaking (50 rpm). 
Blots were washed for 4 x 15 minutes and then incubated with 1/10,000 diluted anti-
mouse (or anti-rabbit) secondary antibody conjugated to alkaline phosphatase 
(Sigma-Aldrich, USA) in blocking buffer for 2 hours at room temperature. After a final 
four 15 minute washes in blocking buffer (without skim milk), blots were developed 
with NBT/BCIP substrate (Roche, USA).  
The amounts of ΔN40 CP and ΔN40 CP-ELP51 antigens on Coomassie gels were 













The quantitation of bands was performed using a Syngene Gene Genius imaging 
system and GeneTools software (Synoptics Inc., UK).  
 
2.2.10 Pre-absorption of rabbit sera 
Where specified, rabbit sera were pre-absorbed against cell lysate from uniduced E. 
coli, or uninfiltrated plant extract, in order to reduce background. Nitrocellulose 
membrane was covered with E. coli cell lysate or plant extract and incubated at room 
temperature on an orbital shaker for 2 hours. The cell lysate or plant extract was 
discarded and the membrane was washed 4 x15 minutes with blocking buffer. The 
membrane was then incubated with rabbit serum, diluted in blocking buffer, for 2 
hours. The membrane was discarded and the pre-absorbed rabbit serum was then 




The pTRAkc-ERH vector was successfully modified to create pTRA-ERH-ELP28, as 
confirmed by restriction enzyme digests (Figure 6) and sequencing.  
 
 
Figure 6: Restriction enzyme digest verification of pTRA-ERH-ELP28 clones 
M: DNA bp marker, 1-4: four putative pTRA-ERH-ELP28 clones digested with NcoI and XhoI to excise 
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CP or ΔN40 CP genes were cloned into pTRA-ERH-ELP28 as described in 2.2.4 to 
create CP-ELP28 or ΔN40 CP-ELP28 fusions, which were confirmed by restriction 
enzyme digests (data not shown) and sequencing. 
A longer ELP (consisting of more than 28 VPGVG repeats) was needed to 
investigate the effect of different ELP lengths on the yield and purification efficiency 
of the ELP fusions. This required a pTRA-ERH-ELP vector with a longer ELP insert. 
A library of pTRA-ERH-ELP constructs with random ELP lengths had been 
generated, as described in 2.2.3. Clones were screened by colony PCR for the size 
of the ELP insert using pTRA-specific primers. As shown in Figure 7, lane 1, a clone 
was identified which contained an insert approximately 300 bp larger than that of the 
original pTRA-ERH-ELP28 vector (approximately 800 bp). This plasmid was later 
screened by restriction enzyme digests and was verified by sequencing. Sequence 
analysis confirmed that the new vector contained the coding sequence for 51 
VPGVG repeats. This confirmed that the pTRA-ERH-ELP51 vector had been 
constructed successfully. CP or ΔN40 CP genes were cloned into pTRA-ERH-
ELP51as described in 2.2.4 to create CP-ELP51or ΔN40 CP-ELP51 fusions, which 






    
Figure 7: Colony PCR identifying the pTRA-ERH-ELP51 vector clone  
M: DNA bp marker, 1: Putative pTRA-ERH-ELP construct with 300 bp larger insert (subsequently 
identified as the coding sequence for 51 VPGVG repeats), 2: original pTRA-ERH-ELP28 positive 
control DNA 
The insertion of ΔN40 CP, ΔN40 CP-ELP28 and ΔN40 CP-ELP51 into pPROEX-HTb 
was confirmed by MluI and XhoI restriction enzyme digests (Figure 8) and 




















                                                                     
Figure 8: MluI-XhoI restriction enzyme digests of pPROEX clones to confirm inserts  
A: M: DNA bp standards, 1: pPROEX-ΔN40 CP-ELP51 2: pPROEX-ΔN40 CP, B: M: DNA bp 
standards, 1: pPROEX-ΔN40 CP-ELP28. The vector backbone is 3670 bp and the inserts are 
indicated by the arrows. MluI is a unique restriction site in the vector and the XhoI site is preserved in 
cloning of the digested PCR product into pPROEX-HT. 
Small-scale protein expression trials were conducted with harvesting of cell samples 
at 1, 2 and 3 hours post-induction with IPTG. The cells were sampled at different 
time points in order to determine the effect of incubation time on protein yield. SDS-
PAGE and immunoblotting of induced whole cells showed that the full-length BFDV 
CP (Figure 9, lanes 2-4) was not expressed in E. coli, in contrast to ΔN40 CP (Figure 
9, lanes 5-7). Lack of IPTG induction produced no ΔN40 CP (Figure 9, lane 4). 
Incubation time of induced cells had no noticeable effect on the yield of ΔN40 CP: 
the minimum incubation tim  of 1 hour yielded as much ΔN40 CP (Figure 9, lane 5) 
as for 3 hours (Figure 9, lane 7). 
         
  
Figure 9: Anti-His immunoblot of E. coli whole cell lysates 
M: molecular weight marker, 1: CP uninduced cells, 2: CP cells 1hour post-induction, 3: CP cells 2 
hours post-induction, 4: ΔN40 CP uninduced cells, 5: ΔN40 CP cells 1 hour post-induction, 6: ΔN40 
CP cells 2 hours post-induction, 7: ΔN40 CP cells 3 hours post-induction (ΔN40 CP band, 25 kDa, 

























The ΔN40 CP and both the ΔN40 CP-ELP28 and ΔN40 CP-ELP28 proteins were 
expressed in E coli, but all of these were almost completely insoluble. The 
recombinant proteins in the insoluble fraction (obtained in the pellet of cell debris 
after cell lysis) were clearly visible by Coomassie Blue staining of polyacrylamide 
gels (Figure 10A, lanes 2, 4 and 6) and their identity was confirmed by immunoblot 
(Figure 10B). ΔN40 CP, ΔN40 CP-ELP28 and ΔN40 CP-ELP51 were the expected 
sizes of 27, 40 and 50 kDa, respectively. The amount of recombinant protein in the 
soluble fraction was too low to be seen by Coomassie Blue staining. However, the 
presence of ΔN40 CP protein could be detected in the soluble fraction by 
immunoblotting (Figure 10 B, lanes 1, 3 and 5).  
Free ELP51 was produced in bacteria to facilitate purification of ΔN40 CP-ELP51 
fusion proteins by inverse transition cycling, by acting as co-aggregate. This free 
ELP was expressed in bacteria as for the ΔN40 CP and ΔN40 CP-ELP proteins. In 
contrast to the ΔN40 CP proteins, ELP51 was more soluble, as the ELP band in the 
soluble fraction could be identified on a Coomassie stained gel (Figure 10A, lane 7). 
Immunoblotting confirmed the identity of the protein, which was the expected size of 
approximately 26 kDa (Figure 10B, lane 7).  A proportion of this ELP protein was 
insoluble (Figure 10B, lane 8). 
 
  
Figure 10: Expression of BFDV, ELP and CP-ELP proteins using pPROEX-HT 
The respective protein bands are indicated by arrows. A: Coomassie-Blue stained gel for which equal 
volumes of all samples were loaded, 1: ΔN40 CP soluble fraction, 2: ΔN40 CP insoluble fraction, 3:  
ΔN40 CP-ELP28 soluble fraction, 4:  ΔN40 CP-ELP28 insoluble fraction, 5: ΔN40 CP-ELP51 soluble 
fraction, 6: ΔN40 CP-ELP51 insoluble fraction, 7: ELP51 soluble fraction, 8: ELP51 insoluble fraction. 
B is the cognate anti-His immunoblot. The volume loaded of insoluble fractions is half that of the 
soluble fractions. Note the presence of dimers for free ELP51 (approximately 55 kDa, lanes 7 and 8). 




















Given the insoluble nature of ΔN40 CP proteins expressed in bacteria, it was most 
likely that most of the the proteins had been sequestered into insoluble inclusion 
bodies (IBs). IBs typically contain the recombinant protein with a high degree of 
purity (Ventura & Villaverde, 2006). It is therefore possible to acquire partially purified 
recombinant protein by successive washes of the insoluble IBs. ΔN40 CP and ΔN40 
CP-ELP51 were produced in 250 mL cultures and the inclusion bodies were 
processed with Bugbuster™ (Novagen, USA), using the manufacturer’s protocol. 
Only one of the ELPylated proteins (ΔN40 CP-ELP51 and not ΔN40 CP-ELP28) was 
used for antibody production, because these two antigens were similar and so they 
would likely evoke the same antibody responses. Bugbuster™ is a mixture of 
detergents that achieves efficient lysis of cells. After ten wash steps, the purity of the 
IB preparation was analysed by SDS-PAGE and Coomassie Blue staining. (Figure 
11, lanes 1-4). Because the expressed ΔN40 CP proteins were insoluble, they could 
not be quantified using a total soluble protein assay, such as the Bradford assay. 
The amount recombinant protein was estimated using serial dilutions of bovine 
serum albumin (BSA) loaded for SDS-PAGE and stained with Coomassie Blue 
(Figure 11, lanes 5-8).  
 
 
Figure 11: Partial purification of E. coli inclusion body samples 
1: ΔN40 CP undiluted, ΔN40 CP diluted 1:2 (indicated  by the arrow), 3: ΔN40 CP-ELP51 undiluted, 
4: ΔN40 CP-ELP51 diluted 1:2 (indicated by the arrow), 5-8: BSA standards of 6.4, 3.2, 1.6 and 0.8 
µg protein, respectively.  
 
 

















The inclusion body suspensions were dialysed against sterile Dulbecco’s PBS 
(Sigma-Aldrich, USA) overnight at 4 °C in order to remove bacterial endotoxins from 
the protein sample. SDS-PAGE and Coomassie Blue staining was done for the 
samples after dialysis (Figure 12, lanes 1 and 2). It was noticed that some of the 
ΔN40 CP-ELP51 (Figure 12, lane 2) protein had been lost during the dialysis 
process, possibly during the transfer from the dialysis tubing. However, the amount 
of background proteins were reduced as well, and most were undetectable on the 
gel. This could have caused fewer non-specific antibodies to be raised in the 
inoculated rabbits. The final antigen doses were 40 µg per 0.5 mL injection for ΔN40 
CP and 17 µg per 0.5 mL injection for ΔN40 CP-ELP51. The protein samples were 
then tested for their levels of bacterial endotoxin using the Limulus Amebocyte assay 
QCL-1000 kit (Cambrex, USA). The endotoxin levels of both antigen samples were 
reduced by the dialysis step (data not shown). The inoculation of rabbits was done 






Figure 12: Inclusion body proteins after dialysis 
Coomassie-stained gel of final inclusion body samples submitted for polyclonal antibody production in 
rabbits. 1: ΔN40 CP, 2: ΔN40 CP-ELP51 (indicated by arrows), 3-6: BSA standards of 6.4, 3.2, 1.6 
and 0.8 µg protein, respectively. 
 
















The use of N-lauroyl sarcosine (NLS) detergent to solubilise insoluble protein 
aggregates produced in E. coli has been previously reported (Frankel et al., 1991). 
Inclusion body proteins were partially purified by washing as before, but these were 
then solubilised in buffer containing 0.2% (w/v) NLS. Centrifugation pelleted the 
remaining insoluble debris. The supernatant was dialysed against PBS to remove 
the detergent and filtered through a 0.2 µm cellulose acetate syringe filter. The result 
was partially purified, soluble ΔN40 CP protein that could be used as standards for 
immunoblots (as used in Figure 13A and B) 
The serum received from Deltamune was used in immunoblots as described in 2.2.9 
to probe for ΔN40 CP or ΔN40 CP-ELP proteins expressed in bacteria. Each serum 
was used at a 1/5000 dilution, after pre-absorbtion against proteins from uninduced 
E. coli as described in 2.2.9. There is no commercially available anti-BFDV ΔN40 CP 
antibody. Therefore all BFDV CP proteins in in our laboratory have been expressed 
as His tag fusions for detection by anti-His immunoblots. The His-tag had to be 
removed from ΔN40 CP in order to determine if the sera recognised ΔN40 CP 
without a His-tag. This was done by TEV protease digestion of ΔN40 CP obtained 
from solubilised inclusion bodies (Figure 13A and B). The TEV digestion was not 
complete, but the lower band corresponding to ΔN40 CP without a His-tag showed 
that the anti-ΔN40 CP serum recognised BFDV ΔN40 CP alone (Figure 13A, lane 2), 
as did the anti-ΔN40 CP-ELP51 serum (Figure 13B, lane 2). Bands of approximately 
50 and 75 kDa were also detected (Figure 13A), corresponding to dimers and 
trimers, respectively, of ΔN40 CP. As shown in Figure 13B, an additional 40 kDa 
protein was detected (lanes 1 and 2) by the anti-ΔN40 CP-ELP51 serum. It was 
suspected that this was a result of an E. coli host protein being recognised by the 
sera. This may correspond to the contaminating E. coli protein of approximately 40 
kDa which can be seen in the ΔN40 CP-ELP51 antigen sample (Figure 12, lane 2). 
The sera were expected to contain antibodies against E. coli host proteins, as the 
antigen used to inoculate rabbits was made in E. coli, although the pre-absorption 

















                                              
Figure 13: Partial TEV digestion of ΔN40 CP produced in bacteria and detection with 
anti-ΔN40 CP serum 
Solubilised ΔN40 CP protein was digested with TEV protease overnight at 27 °C. A: anti-ΔN40 CP 
serum (1/5000 dilution). M: molecular weight marker, 1: undigested control, 2: TEV digested sample. 
B: anti-ΔN40 CP-ELP51 serum (1/5000 dilution). 1: undigested control, 2: TEV digested sample, M: 
molecular weight marker. The ΔN40 CP with the His tag is 26 kDa and ΔN40 CP with the His tag 
removed is indicated by the arrow (approx. 24 kDa). Note that bands of approximately 50 and 75 kDa 
in A (lanes 1 and 2) correspond dimers of ΔN40 CP and the 40 kDa band in B is suspected to be 
recognition of E. coli host protein by non-specific antibodies.  
A final test of the rabbit sera was carried out to determine if they could detect 
proteins expressed by a different host, namely, tobacco plants. The anti-ΔN40 CP-
ELP51 serum was used at a dilution of 1/10,000 to detect plant-expressed ΔN40-
ELP proteins targeted to the ER or cytoplasm (plant expression described in Chapter 
3). ΔN40-ELP51 targeted to the cytoplasm was detected (Figure 14A, lane 2), as 
was the ΔN40-ELP28 targeted to the ER (Figure 14A, lane 3) and ΔN40-ELP51 
targeted to the ER (Figure 14A, lane 4). ΔN40-ELP28 targeted to the cytoplasm was 
loaded in lane 1 (Figure 14A), but the amount of protein was presumably too low to 
be detected. Degradation products of lower molecular weight than the intact proteins 
could be detected for all proteins (Figure 14, ~40kDa band in lanes 2 and 3, and ~45 
kDa band in lane 4,). In another immunoblot, ΔN40-ELP51 targeted to the ER 
(Figure 14B, lane 5) was subjected to one round of cITC purification (see Chapter 4), 
and degradation products ranging from 25-35 kDa in size were detected in the 
purified sample (Figure 14B, lane 6). The anti-ΔN40 CP-ELP51 serum could in fact 
detect any ELPylated protein, including GFP-ELP28 (Figure 14B, lane1), GFP-
ELP51 (Figure 14 B, lane 3) and free ELP51 (Figure 14 B, lane 2), all produced in 
plants.  
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Figure 14: Detection of ELPylated proteins produced in plants using rabbit serum 
 A: Detection of ΔN40 CP-ELP proteins using anti-ΔN40 CP-ELP51 rabbit serum at 1/10,000 dilution. 
1: ΔN40 CP-ELP28 targeted to the cytoplasm, 2: ΔN40 CP-ELP51 targeted to the cytoplasm, 3: ΔN40 
CP-ELP28 targeted to the ER, 4: ΔN40 CP-ELP51 targeted to the ER. B: Detection of other 
ELPylated proteins using anti-ΔN40 CP-ELP51 rabbit serum at 1/8,000 dilution. 1: GFP-ELP28, 2: 
free ELP51, GFP-ELP51, 5: ΔN40 CP-ELP51 crude extract from plants., 6: ΔN40 CP-ELP51 cold spin 




The anti-ΔN40 CP serum was used at a dilution of 1/2000 to detect ΔN40 CP 
proteins produced in plants. It could detect ΔN40 CP produced in plants, which had 
been targeted to the cytoplasm (Figure 15, lane 1). ΔN40 CP produced in bacteria 
was used as a positive control for which a 50 kDa ΔN40 CP dimer was also 
observed (Figure 15, lane 2). The ΔN40 CP-ELP51 produced in plants (Figure 15, 
lane 3) was not detected as strongly as ΔN40 CP, even though the yield of the 
ELPylated protein was significantly higher (see Chapter 3, Figure 23). This suggests 
that the ELP interferes with antibody binding to ΔN40 CP epitopes. The ΔN40 CP-
ELP51 was purified by one round of mITC (see Chapter 4), which concentrated the 
protein, giving rise to a cleaner band (Figure 15, lane 4). Degradation products of 
ΔN40 CP-ELP51, presumably containing ΔN40 CP epitopes, were detected as 25 




























Figure 15: Recognition of BFDV ΔN40 CP expressed in plants by anti-ΔN40 CP serum 
Anti-CP serum used at 1/2,000 dilution to detect plant-expressed ΔN40 CP proteins. M: molecular 
weight marker, 1: ΔN40 CP expressed in plants (25 kDa, indicated by the arrow), 2: ΔN40 CP 
expressed in bacteria, 3: ΔN40 CP ELP-51 crude extract, 4: ΔN40 CP ELP-51(55 kDa, indicated by 




Bacterial expression of BFDV CP proteins was done in order to obtain sufficient 
antigen for antibody production. Truncated BFDV CP, namely ΔN40 CP, was 
successfully expressed in E. coli. Elastin-like polypeptide fusions of ΔN40 CP were 
also expressed (Figure 10). However, the ΔN40 CP proteins expressed in E. coli 
were almost completely insoluble. The insolubility of bacterial-produced ΔN40 CP 
has been described previously (Johne et al., 2004). Strategies that could be tested to 
increase the amount of soluble protein include: lower incubation temperature, lower 
concentration of the inducer (IPTG) or the increased co-expression of molecular 
chaperones (De Marco et al., 2005). In an attempt to produce more soluble ELP 
fusion protein, ΔN40 CP-ELP51 induced cultures were incubated at 22 °C (instead of 
37 °C) for 20 hours. There was no change in the expression level or the solubility of 
the protein (data not shown).  















Expression of full-length CP with pPROEX yielded no detectable protein in induced 
cells, as determined by anti-His immunoblot. The N-terminal nuclear translocation 
signal of the full-length CP is rich in arginine residues, some of them coded for by the 
codons AGA and AGG (Heath et al., 2006). These codons are rarely used in 
prokaryotes and can lead to premature termination of translation (Sørensen & 
Mortensen, 2005). Not even truncated proteins were observed for full-length BFDV 
CP expression, suggesting that translation was inhibited at the early stages.  This 
problem may be rectified by codon optimisation, i.e. replacing rare codons in the 
coding sequence with codons commonly used in E. coli. This strategy worked for the 
translation of full-length PCV-2 CP in E. coli (Marcekova et al., 2009).  Instead of 
codon optimisation or truncation, commercially available bacterial strains such as 
Rosetta (DE3) (Novagen, Germany), that co-express eukaryotic-type tRNAs, could 
be used. This strain has proved useful for the expression of human genes containing 
rare arginine codons (Tegel et al., 2010), and may therefore be useful for the 
expression of BFDV CP genes that have not been codon optimised for bacteria. 
The free ELP51 was expressed in E. coli for use as a co-aggregate during ITC 
purification of plant-produced CP-ELP proteins (see Chapter 4). This free ELP51 
was more soluble than ΔN40 CP or ΔN40 CP-ELP fusion proteins. The band 
corresponding to the ELP protein in the soluble fraction was clearly visible on a 
Coomassie-stained gel (Figure 10). This showed that the ELP was not responsible 
for the insoluble nature of expressed CP-ELP. Fusion to ELP has previously been 
used to increase the solubility of target proteins expressed in E. coli (Solomon et al., 
2004; Trabbic-Carlson et al., 2004). The ΔN40 CP-ELP proteins, like ΔN40 CP, were 
mostly insoluble, i.e. fusion to ELP did not increase the solubility of ΔN40 CP. 
Although a large proportion of free ELP51 protein was trapped in the insoluble 
fraction, the amount of soluble ELP that could be recovered, concentrated and 
purified by ITC was typically up to 1 mg/mL (see Chapter 4). This was sufficient for 
further purification experiments. 
ΔN40 CP and ΔN40 CP-ELP51 inclusion bodies were partially purified from E. coli 
using successive washes in PBS. This protein was injected into rabbits for antibody 
production. Inclusion bodies have long been considered a ‘dead-end’ by-product of 
bacterial protein expression, but the quality and purity of recombinant proteins within 













2012). However, the solubilisation and refolding of proteins from inclusion bodies is 
time-consuming and a large proportion of protein may be lost. Inclusion bodies are 
insoluble and can be separated from the bulk of contaminating host proteins by 
successive washes in PBS. The protein losses using this method are minimal. 
Therefore it was decided to successively wash the IBs and use these in order to 
preserve the antigen dose.  
Bacterial-expressed ΔN40 CP from solubilised inclusion bodies could be recognised 
by anti-ΔN40 CP (Figure 13 A) and anti-ΔN40 CP-ELP (Figure 13B) rabbit sera. It 
has been shown that serum from animals immunised with proteins in the form of 
inclusion bodies is reactive against soluble forms of the protein (Chen et al., 2005). 
Indeed, both sera recognised soluble ΔN40 CP-ELP51 expressed in plants (Figures 
14, 15 and 35B).  
The anti-ΔN40 CP serum had non-detectable anti-His-tag activity, as determined by 
loading a large amount of His-tagged free ELP51 on the same gel for immunoblotting 
(Figure 36B, lanes 2 and 3). Plant-expressed BFDV ΔN40 CP could be detected 
using this serum (Figure 15, lane 1). Interestingly, the recognition of BFDV ΔN40 CP 
as a fusion to ELP reduced the signal when probed with the anti-CP serum, relative 
to unfused CP (compare lane 1 to lanes 3 and 4 in Figure 15). The ELP may 
interfere with antibody binding to the relevant CP epitopes. The anti-ΔN40 CP serum 
could detect 25 kDa degradation products of ΔN40-ELP51, presumably containing 
ΔN40 CP epitopes, as sharp bands on immunoblots (Figure 15).  
The anti-ΔN40 CP-ELP serum recognised ΔN40 CP alone (Figure 13B) as well as 
any ELPylated proteins (Figure 14). This serum could be used to probe for other 
ELPylated proteins expressed in plants, such as GFP-ELP. However, this serum 
exhibited a higher anti-His-tag activity, probably because the ΔN40 CP-ELP51 
antigen used to inoculate rabbits had both N- and C-terminal His tags (data not 
shown). As both antigens used for antibody production were only partially purified, 
antibodies were raised against E. coli host proteins, as seen by the 50 and 70 kDa 
bands on immunoblots (Figure 13A and 13B). The sera were therefore pre-absorbed 
against proteins from untransformed E. coli cell lysate before use, which minimised 













of BFDV CP proteins produced in our laboratory, as no anti-BFDV CP antibodies are 
commercially available.  
To summarise the results, truncated BFDV ΔN40 CP proteins produced in E. coli 
were mostly in the form of insoluble inclusion bodies. In the case of full-length BFDV 
CP, no expression was detected. The free ELP51 exhibited a higher solubility than 
the ΔN40 CP proteins. Due to the insolubility of ΔN40 CP proteins, inclusion bodies 
were partially purified by successive washes in PBS. The inclusion body proteins 
were used to raise antibodies in rabbits. The anti-ΔN40 CP serum could detect ΔN40 
CP protein produced in bacteria as well as ΔN40 CP produced in plants. The anti-
ΔN40 CP-ELP51 serum could be used to detect ΔN40 CP as well as any ELPylated 
proteins. The ΔN40 CP-ELP51 serum did exhibit some anti-His activity as well. 
ΔN40 CP produced in bacteria with a high yield could serve as a vaccine candidate 
after purification and endotoxin removal. Sequence analysis of PCV-2 capsid protein 
(Marcekova et al., 2009) and similarly, BFDV CP, reveals putative sites for N-
glycosylation and phosphorylation. These post-translational modifications would be 
carried out only in eukaryotic expression systems. Whether BFDV CP in native 
virions carries these modifications, and their role in eliciting protective immune 
responses in the case of a CP subunit vaccine, is unclear. ΔN40 CP produced in 
prokaryotic systems could therefore be successful in imitating the epitopes of the 
native virus and provide an effective immune response.  This is true assuming that 
no important epitopes are removed in the N-terminal truncation. None of the 
immunogenic epitopes of PCV-2 identified by Mahé et al. (2000) occurred within the 
first 40 amino acids, but this information is lacking for BFDV CP. The immunogenic 
epitopes of BFDV CP may be difficult to determine as there is no cell culture system 
for the propagation of mutant viruses. The use of truncated BFDV CP to raise 
antibodies that were subsequently used to detect BFDV in psittacine sera (Johne et 
al., 2004) suggests that a truncated CP subunit vaccine could be capable of eliciting 













Chapter 3: Optimisation of BFDV capsid protein 




Proteins naturally produced in eukaryotes requiring post-translational modifications 
such as glycosylation must be produced by eukaryotic expression systems. Yeast 
fermentation and insect- and mammalian cell culture systems have traditionally been 
used to produce the majority of these therapeutic proteins. However, whole plants 
and plant cell cultures are gaining popularity as eukaryotic expression systems 
(Rybicki, 2010). Major advantages of the plant expression system include low cost 
and no risk of contamination with animal pathogens. Transient expression of 
recombinant proteins in plants such as tobacco by infiltration of Agrobacterium 
suspension into the leaves of the plant (agroinfiltration) has the advantages of a 
shorter production timescale and typically higher yields than for transgenic plants 
(Paul & Ma, 2011). Several vaccine antigens have been expressed in plants and 
evaluated in clinical trials (for a review, see Thanavala et al. (2006)).  
Research efforts have been focused on increasing the yield of recombinant proteins 
expressed in plants. Plant viruses are adapted to induce expression of large 
amounts of viral protein in plant cells, as part of their replication. The genetic 
elements of plant viruses, such as promoters, have therefore been incorporated into 
many plant expression vectors. Among these, the cauliflower mosaic virus (CaMV) 
35S promoter is well-studied and often used for its ability to confer high-level 
transcription (Mushegian & Shepherd, 1995). 
Replicating expression vectors give rise to a replicon derived from a particular plant 
virus in order to increase the number of copies of the transgene, which may lead to 
higher protein expression. These replicons may also contain a gene encoding viral 
movement protein, which leads to systemic spread of the transgene via 
plasmodesmata connecting plant cells (Regnard et al., 2010). Non-replicating 













transgene copy number in order to drive high-level expression of recombinant 
protein. 
Cowpea mosaic virus, like the majority of plant viruses, has a positive sense, single-
stranded RNA genome. The virus replicates via a double-stranded RNA intermediate 
and its RNA genome is directly translated by plant ribosomes The genome is 
segmented into two RNA molecules, RNA1 and RNA2 (Verver et al., 1998). The 
genes encoded by RNA2 are flanked by 5’ and 3; untranslated regions (UTR’s), 
which are important for high-level translation of viral polyproteins. Sainsbury and 
Lomonossoff (2008) discovered that the use of these UTR’s flanking a gene of 
interest, in conjunction with the CaMV 35S promoter, could drive high-level 
expression the recombinant proteins in plants. This lead to the construction of pEAQ 
binary expression vectors (Sainsbury et al., 2009). The pEAQ vector has been used 
for the transient expression of enzymes (Vardakou et al., 2012) and monoclonal 
antibodies (Sainsbury et al., 2010) in tobacco plants.  
The aim of the work presented here was to optimise the expression of the BFDV CP 
antigen in plants towards the development of low-cost vaccine candidates. 
Truncated CP (ΔN40 CP) was also expressed with the aim of maximising protein 
yield. In addition, CP and ΔN40 CP were each fused to elastin-like polypeptides 
(ELPs) of 28 or 51 pentapeptide repeats each. The fusion to ELP was done in an 
attempt to increase the yield of the CP-ELP of ΔN40 CP-ELP fusion proteins relative 
to their unfused counterparts. This would produce four new vaccine candidates, 
called CP-ELP28, CP-ELP51, ΔN40 CP-ELP28 and ΔN40 CP-ELP51. Fusion to ELP 
has been shown to increase the yield of several proteins expressed in plants (Patel 
et al., 2007; Floss et al., 2008a; Conley et al., 2009a). Free ELP51 (the ELP51 not 
fused to another protein) was similarly expressed in plants to characterise the 
purification conditions of ELP51. Green fluorescent protein was also expressed in 
plants as ELP28 or ELP51 fusions in order to serve as a model ELP fusion protein. 
The purification of all ELP fusions could then be attempted using the non-
chromatographic method known as inverse transition cycling (ITC) (see Chapter 4).  
This chapter describes the transient expression of BFDV CP and ΔN40 CP their 
respective ELP fusion proteins in tobacco (N. benthamiana) plants by agroinfiltration. 













expression of ΔN40CP-ELP28 fusion protein, which targeted protein accumulation 
the ER. The pEAQ-HT vector was then used to express protein targeted to either the 
endoplasmic reticulum (ER) or the cytoplasm. The pEAQ-HT vector was used for the 
majority of plant expression because of higher protein yields and because it did not 
require co-infiltration with a silencing suppressor plasmid. Expression time trials were 
conducted to optimise the length of transient protein expression. This optimisation 
work is the essential first step towards the goal of a plant-produced BFDV CP 






























3.2 Materials and Methods 
 
3.2.1 Cloning from pTRAkc-ERH and pTRA-ERH-ELP to pEAQ-HT 
CP, free ELP51 and CP-ELP inserts from pTRAkc-ERH or pTRA-ERH-ELP clones 
described in 2.2.4 were prepared for cloning into the pEAQ-HT vector using PCR. 
The primers listed in Table 3 were used to amplify the respective genes. For 
cytoplasmic protein targeting, BFDV CP-specific forward primers BFDV CP-AgeI For 
or BFDVN40-AgeI Rev were used with the XhoI-h Rev reverse primer. For targeting 
to the endoplasmic reticulum, the LPH-AgeI For and XhoI-ERH Rev primer pair was 
used. This added a 5’ AgeI site and preserved the 3’ XhoI site for all genes. 
The pTRA-ERH-ELP28 clone GFP-ELP28 (enhanced green fluorescent protein, 
accession: AY952326.1, with C-terminal ELP28) was provided by Ann Meyers 
(Department of Molecular and Cell Biology, UCT). The GFP-ELP28 insert was 
isolated by PCR using the primers LPH-AgeI For and XhoI-ERH Rev for cloning into 
pEAQ-HT. To generate a GFP-ELP51 clone, the GFP segment was isolated by PCR 
using the LPH-AgeI For primer and the GFP-specific reverse primer GFP-NotI Rev. 
This PCR product was digested with AgeI and NotI. An existing pEAQ-HT clone 
containing CP-ELP-51 was digested with AgeI and NotI and the vector, still 
containing the ELP51 segment, was isolated. This digested vector was ligated with 
the digested GFP PCR product to generate the pTRA-ERH-ELP51 clone, GFP-
ELP51. The GFP-ELP51 and free ELP51 PCR inserts were isolated using the LPH-
AgeI For and XhoI-ERH Rev primer pair, from their respective pTRA-ERH-ELP 
templates, for cloning into pEAQ-HT.  
Cloning into pEAQ-HT was performed as described in Appendix A. All PCR products 
were digested with AgeI and XhoI, and ligated into similarly digested pEAQ-HT 
vector. Colonies were screened by PCR using pEAQ For2 and pEAQ Rev vector-
specific primers (Table 3) and putative positive clones were checked by restriction 
enzyme digest with AgeI and XhoI. pEAQ-HT constructs were then verified by 
sequencing (Macrogen, Netherlands).Targeting protein accumulation to the ER 
required an N-terminal signal peptide, which was already present for all pTRAkc-
ERH constructs (murine IgG heavy chain variable region signal peptide, (Maclean et 













product included the signal peptide upstream of the gene of interest, as well as the 
SEKDEL sequence required for ER retention. Cytoplasmic targeting excluded the 
signal peptide and mutated the S codon of the SEKDEL sequence (TCT) to a stop 
codon (TGA). A schematic of the proteins expressed in pEAQ-HT is shown in Figure 
16.  
 
Table 3: Oligonucleotide primers used for pEAQ-HT subcloning 
‘For’ designates a forward primer and ‘Rev’ designates a reverse primer. Restriction enzyme sites are 
underlined. 
Primer name Sequence Features 
BFDV CP-AgeI For 5’-GAACCGGTATGTGGGGC 
ACCTCTAAC-3' 
AgeI site 
BFDVN40-AgeI Rev 5'-GAACCGGTATGGAGTGGAGC 
TGGATC-3' 
AgeI site 
LPH-AgeI For 5'-GAACCGGTATGGAGTGG 
AGCTGGATC-3’ 
AgeI site, anneals to 
start of 5’ LPH signal 
sequence 
XhoI-h Rev 5'-GACTCGAGCTAGAGCTCA 
TCTTTCTCCTAGTGATGGTG-3' 
XhoI site, mutation of 
S codon of SEKDEL 
sequence into stop 
codon 
XhoI-ERH Rev 5'-GACTCGAGCTAGAG 
CTCATCTTTCTCAG-3' 
XhoI site 








GFP-NotI Rev 5’-ATGCGGCCGCCTTGTACAGC 
TCGTCCATGCC-3’ 


























Representation of proteins expressed in pEAQ-HT using different subcellular protein targeting. sp: 
signal peptide, BFDV CP: full-length or truncated capsid protein (replaced by GFP at this position for 
GFP-ELP proteins), ELP: 28 x VPGVG or 51 x VPGVG (absent in the case of non-ELPylated BFDV 
CP), TEV: protease recognition site at the junction of segments, His: His tag, SEKDEL: ER retention 
signal, (*) indicates a stop codon. The free ELP51 includes a linker peptide MVYFQG between the 
signal peptide and the ELP. Note that the free ELP51 has no TEV protease recognition site. 
 
3.2.2 Transformation of A. tumefaciens 
Electrocompetent Agrobacterium tumefaciens GV3101::pMP90RK or LBA4044 cells 
were prepared (Shen & Forde, 1989). A 100µl aliquot of competent cells was mixed 
with 400ng of recombinant plasmid DNA in a 1 mm gap electroporation cuvette and 
electroporated using a Bio-Rad GenePulser (1.8kV, 25F, 200Ω) (Bio-Rad 
Laboratories, USA). The cells were incubated in LB broth for 2 hours at 27°C and 
were then plated on LB agar plates containing the relevant antibiotics (see Table 4). 
The plates were incubated at 27°C for 2-3 days. The LBA4044 strain containing the 
sp BFDV CP ELP His 
BFDV CP ELP His i  
ER-targeted CP-ELP 
Cytoplasm-targeted CP-ELP 






















silencing-suppressor gene NSs (of tomato spotted wilt virus) in pBIN (see Table 4) 
was obtained from culture collection. 
 
Table 4: Antibiotic selection of Agrobacterium strains containing different plasmids 
A. tumefaciens 
strain 
Plasmids Antibiotics  
GV3101::pMP90RK pTRAkc-ERH 30 µg/ml kanamycin, 50 µg/ml 
carbenicillin and 50 µg/ml 
rifampicin 
LBA4044 pBIN-NSs 30 µg/ml kanamycin and 50 
µg/ml rifampicin 
LBA4044 pEAQ-HT 30 µg/ml kanamycin and 50 
µg/ml rifampicin 
 
Colonies were picked from transformed Agrobacterium plates with a sterile toothpick 
and transferred to LB broth containing the relevant antbiotics. For the LBA4044 
strain, 2 mM MgSO4 was added to prevent cell clumping.  Ten millilitre cultures were 
grown overnight at 27°C. Plasmid DNA was isolated and ‘back-transformed’ into 
chemically competent E. coli DH5α cells (E. cloni®, Lucigen) and was plated with 
antibiotic selection to confirm transformation of Agrobacterium with the relevant 
expression construct. Agrobacterium cultures were also tested directly by PCR for 
the presence of the respective constructs using pEAQ-HT-specific primers listed in 
Table 3. 
 
3.3.3 Transient protein expression in N. benthamiana leaves by agroinfiltration 
One millilitre of Agrobacterium culture was used to inoculate 50 ml of induction 
media (LB broth with 10 mM MES, 2 mM MgCl2, 1 mM acetosyringone antibiotics, 
pH 5.6) and was allowed to grow for 16-24 hours in an orbital shaker at 27°C, 120 
rpm. Agrobacterium cells were pelleted by centrifugation at 4000 x g for 10 min and 
resuspended in infiltration media (3% (w/v) sucrose, 10 mM acetosyringone, 10 mM 
MES, 2 mM MgCl2, pH 5.6). For expression with pTRAkc-ERH vector,, the optical 













media and equal volumes of the two Agrobacterium strains harbouring the pTRA and 
pBIN-NSs constructs (see Table 4) were mixed together. For expression with pEAQ-
HT, the OD600 of the culture was adjusted to 1.0 with infiltration medium. The cultures 
were left at room temperature for 1 hour to allow induction of vir genes. Leaves from 
6-8-week-old Nicotiana benthamiana plants were infiltrated with Agrobacterium 
suspensions by injecting the bacterial suspension into the abaxial air spaces from 
the underside of the leaf, using a 1 ml syringe. The plants were grown at 22 °C under 
conditions of 16 h light and 8 h dark. 
 
3.2.4 Protein extraction 
Three 7mm leaf disks (fresh weight approximately 20mg in total) was homogenised 
in liquid nitrogen in a 1.5 ml microcentrifuge tube and resuspended in 200 µl 
extraction buffer (see Table 5 for a list of buffers used. All extraction buffers were 
supplemented with Roche EDTA-free Complete protease inhibitor cocktail (Roche, 
USA) before use). Tubes were then centrifuged at 10,000 rpm for 5 minutes in a 
benchtop Eppendorf 5424 microcentrifuge (Eppendorf, Germany) and the 
supernatant was recovered. Samples were prepared immediately for SDS-PAGE or 
stored at – 20 °C.  
Expression time trials were carried out to monitor the levels of protein expression 
over time. Two plants per construct were infiltrated on the same day for each 
expression time trial. Protein was extracted from plants at 2, 4 and 7 days post-
infiltration (dpi), using 200 µL Tris-HCl pH 8.0, 0.1 % (v/v) TritonX-100 (Tris-Triton), 
per 3 leaf disks. These samples were stored at -20 °C until used for SDS-PAGE.  
 
3.2.5 Total soluble protein assay of plant crude extracts 
The TSP assay was performed on crude plant extracts using the Bio-Rad DC protein 
assay kit according to the manufacturer’s instructions, using a BioTek Powerwave 
XS microplate reader. The standard curve was created by serial dilutions of a 1.43 
mg/mL bovine IgH standard solution (Bio-Rad) in 50 mM Tris-HCl pH 8.0, 0.1% (v/v) 
TritonX-100, which is the same buffer used for protein extraction from plants. The 
densitometry analysis of immunoblots was done by manual band selection and 
quantitation using Sygene GeneTools software (Synoptics, UK). The raw volume of 














Table 5: Extraction buffers used 
Buffer abbreviation Buffer composition 
PBS 10 mM phosphate buffered saline pH 7.4, 0.14 M 
NaCl 
PBST  10 mM phosphate-buffered saline pH 7.4, 0.14 M 
NaCl, 0.1% Tween-20  
Tris-Triton 50 mM Tris-HCl pH 8.0, 0.1% Triton X-100  
Urea 8 M urea 
 
3.2.6 SDS-PAGE and immunoblotting 
SDS-PAGE and immunoblotting were done are described in section 2.2.9. Note that 
all of the immunoblots shown in this chapter are anti-His-tag immunoblots, done 
using commercial anti-His-tag primary antibody (Serotech, USA) (at a dilution of 1in 
2000) and anti-mouse secondary antibody (at a dilution of 1 in 10,000), conjugated 




The expression of ΔN40 CP-ELP28 in plants was initially performed using pTRAkc-
ERH expression vector. This vector targets accumulation of the expressed protein to 
the endoplasmic reticulum (ER) through the N-terminal signal sequence and C-
terminal SEKDEL ER retention signal. ΔN40 CP-ELP28 was expressed in initial 
experiments with the pTRA vector because the pTRA clone expressing ΔN40 CP-
ELP28 was among the first plant expression constructs created. Plants were co-
infiltrated with Agrobacterium cultures containing the pTRA and pBIN-NSs constucts 
and protein was extracted at 3 and 5 days post-infiltration (dpi). Expressed ΔN40 
CP-ELP28 protein was detected by anti-His immunoblotting, but the soluble protein 
levels were low. The maximum protein was extracted using 8 M urea (Figure 17, 













(Figure 17, lanes 1, 2, 4 and 5). Protein extracted with 8 M urea cannot be used in 
inverse transition cycling experiments (see Chapter 4), because heating of urea 
solutions causes carbamylation of proteins (Schokker et al., 1998). The pEAQ-HT 
vector had been reported to give high yields of recombinant protein (Sainsbury & 
Lomonossoff, 2008). The pEAQ-HT construct targeting ΔN40 CP-ELP28 to the ER 
(Figure 19 panel 2 dpi, lane 4 and panel 4 dpi, lane 4)  gave higher yields of ΔN40 
CP-ELP28, in a shorter time, than the pTRA construct (Figure 17, lane 5), using mild 
extraction buffers such as Tris-Triton. Using pEAQ-HT is also more convenient 
because it contains the p19 silencing suppressor gene on the same T-DNA, which 
means that it does not need to be co-infiltrated with a silencing suppressor plasmid 
as for pTRA vectors. Therefore, the majority of plant expression work was carried out 




Figure 17: pTRA-ΔN40CP-ELP28 expression time trial 
Anti-His-tag immunoblot of pTRA-ΔN40CP-ELP28 expression time trial, which targets ΔN40CP-
ELP28 protein to the ER. M: molecular weight marker, lanes 1 and 4: extraction with PBS, lanes 2 
and 5: extraction with Tris-Triton buffer, lanes 3 and 6: extraction with 8 M urea. Proteins were 
extracted at 3 dpi and 5 dpi, as shown. See Table 5 for buffer compositions.  
 
All pEAQ-HT constructs were verified by restriction enzyme digests and sequencing. 
Agrobacterium tumefaciens LBA4044 was transformed with pEAQ-HT constructs by 
electroporation. The back-transformation as described in 3.2.2 confirmed the 
presence of pEAQ-HT constructs. N. benthamiana leaves were infiltrated with 
recombinant A. tumefaciens containing pEAQ-HT constructs. Initial extractions were 
done for ΔN40 CP and ΔN40-CP-ELP51 at 2 dpi to optimise the extraction buffer 
(Figure 18). This showed that extaction with 50 mM TrisHCl buffer with 0.1% (v/v) 
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TritonX-100 (Tris-Triton) maximised the amount of recombinant protein in crude 




Figure 18: Optimisation of BFDV ΔN40CP protein extraction 
ΔN40 CP and ΔN40 CP-ELP51 (indicated by arrows) were extracted at 2dpi as described using 
different extraction buffers shown in Table 5. Equal volumes of crude extract were analysed by SDS-
PAGE and anti-His immunoblot. M: molecular weight marker, Lanes 1 and 2: ΔN40 CP extracted with 
PBST or Tris-Triton, respectively, Lanes 3-6: ΔN40 CP-ELP51 extracted with PBS, PBST, Tris and 
Tris-Triton buffers, respectively.  
 
Thereafter, expression time trials were performed for all pEAQ-HT constructs. An 
expression time trial involves extracting the expressed protein at different time 
points, over a one-week period, in order to monitor the levels of recombinant protein 
in the plant leaf over time. Protein was extracted for SDS-PAGE, followed by 
immunoblots using anti-His-tag antibody. The ΔN40 CP protein time trial is shown in 
Figure 19 and the full-length CP protein time trial is shown in Figure 20. In both time 
trials, rapid expression resulted in detection of proteins by two days post-infiltration 
(dpi).  The sizes of unfused BFDV CP proteins were as expected, but the ELPylated 
proteins exhibited a higher molecular weight (by approximately 5 kDa) than the 
calculated theoretical weight. Full-length and truncated BFDV CP, each fused to 
ELP, exhibited the same sizes, being approximately 45 kDa for ELP28 fusions and 
55 kDa for ELP51 fusions. This suggests that the ELP has a major influence on the 
electrophoretic mobility of the fusion protein. The ER-targeted fusions appeared to 
be slightly larger than their cytoplasmic-targeted counterparts. This may be due to 



















the signal peptide not being removed correctly, or glycosylation of the protein in the 
ER. As the time trial progressed, degradation products, of lower molecular weight 
than the intact proteins indicated by arrows, were evident for all of the expressed 









Figure 19: Expression time trial of ΔN40 CP proteins produced in plants 
Expression time trial of ΔN40 CP proteins expressed in plants. Protein was harvested at 2 , 4 and 7 
dpi as described in 3.2.4 and equal volumes of crude extract were subjected to SDS-PAGE and anti-
His-tag immunoblot. For the 4 dpi blot, an equal amount of total soluble protein (70 µg) was loaded for 
all samples. 1: ΔN40 CP targeted to the cytoplasm, 2: ΔN40 CP targeted to the ER, 3: ΔN40 CP-
ELP28 targeted to the cytoplasm, 4: ΔN40 CP-ELP28 targeted to the ER, 5: ΔN40 CP-ELP51 
targeted to cytoplasm, 6: ΔN40 CP-ELP51 targeted to the ER. The relevant protein bands are 














M     1     2    3    4      5    6 
M     1     2     3    4     5     6 



















Figure 20: Expression time trial of full-length BFDV CP proteins produced in plants 
Expression time trial of full-length BFDV CP proteins expressed in plants. Protein was harvested at 2, 
4 and 7 dpi as described in 3.2.4 and equal volumes of crude extract were subjected to SDS-PAGE 
and anti-His-tag immunoblot. 1: CP targeted to the cytoplasm, 2: CP targeted to the ER, 3: CP-ELP28 
targeted to the cytoplasm, 4: CP-ELP51 targeted to the cytoplasm, 5: CP-ELP28 targeted to the ER, 
6: CP-ELP51 targeted to the ER. The relevant protein bands are indicated by arrows, where 
applicable. 
 
The highest yields of ELPylated BFDV CP proteins were compared to that of their 
unfused counterparts by analysing equal amounts of total soluble protein (70 µg) by 
anti-His immunoblot, followed by analysis with densitometry software. Expression 
time trials provided evidence that targeting to the ER decreased the expression of 
ΔN40 CP and CP but increased that of ΔN40 CP-ELP fusions only. Therefore ΔN40 
CP-ELP targeted to the ER and CP-ELP fusions targeted to the cytoplasm were then 
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biological repeats were used for each comparison by harvesting leaf discs from three 
different infiltrated (upper) leaves of the plant. The results showed that fusion to ELP 
significantly increased the yield of both full-length and truncated BFDV CP (Figures 
21 and 22). Fusion to ELP28 increased the yield of ΔN40 CP approximately three-
fold, while fusion to ELP51 increased the yield of ΔN40 CP 4.5-fold (Figure 23). 
Fusion of full-length CP to either ELP28 or ELP51 increased the yield of CP by 
approximately three-fold. There was a significant difference in yield between ELP28 
and ELP51 fusions for truncated BFDV CP (Figure 21), but this difference was not 
significant for full-length BFDV CP (Figure 22).  
 
 
Figure 21: Comparison of ΔN40 CP proteins expressed in plants 
Anti-His immunoblot of selected ΔN40 CP proteins extracted 4 dpi. M: molecular weight marker, 1-3: 
ΔN40 CP targeted to the cytoplasm, 4-6: ΔN40 CP-ELP28 targeted to the ER, 7-9: ΔN40 CP-ELP51 
targeted to the ER. Seventy micrograms of total soluble protein was loaded for each lane. Each 
protein is represented by three different biological repeats. The arrows indicate the bands 
corresponding to each (undegraded) protein. 
 
 
Figure 22: Comparison of BFDV CP proteins expressed in plants 
Anti-His immunoblot of selected full-length CP proteins extracted 4 dpi. M: molecular weight marker, 
1-3: BFDV CP targeted to the cytoplasm, 4-6: BFDV CP-ELP28 targeted to the cytoplasm, BFDV CP-
ELP51 targeted to the cytoplasm. Seventy micrograms of total soluble protein was loaded for each 
lane. Each protein is represented by three different biological repeats. The arrows indicate the bands 
corresponding to each (undegraded) protein. 
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Figure 23: Densitometry analysis of BFDV CP and ΔN40 CP proteins expressed in 
plants 
The bands indicated by the arrows on the immunoblots in Figure 21 and 22 were quantitated using 
densitometry software. The top graph shows the average relative intensities of the bands for the 
ΔN40 CP proteins and the bottom graph shows the same for the full-length BFDV CP proteins. The 
error bars indicate standard deviation. 
 
GFP is a favourite reporter protein because of its high yield when expressed in most 
systems. pEAQ-HT constructs expressing GFP as a fusion to ELP28 or ELP51 were 
created (described in 3.2.1), which targeted protein accumulation to the ER.  These 
GFP proteins were expressed because of their anticipated high yield relative to CP-
ELP. With greater yield, the total ELP concentration increases, and therefore GFP-
ELP51 could possibly be used as a model for purification using the ELP51 fusions by 











































































detected by immunoblot using anti-ΔN40 CP-ELP51 serum (Figure 14B, lanes 1 and 
3). GFP-ELP51 was later purified by ITC (see Chapter 4, Figure 27) and used as a 
standard His-tagged protein in order to quantify the yield of ΔN40 CP-ELP51 
targeted to the ER (Figure 24). Using this method, the yield of ΔN40 CP-ELP51 
targeted to the ER and extracted 4dpi was calculated at 0.74 ± 0.19 % of the total 
soluble protein. 
 





Figure 24: Quantitation of ΔN40 CP-ELP51 by immunoblot and densitometry analysis 
A: ΔN40 CP-ELP51 targeted to the ER was extracted 4 dpi and the crude extracts were analysed by 
SDS-PAGE and anti-His immunoblot. Serial dilutions of purified GFP-ELP51 were analysed 
concurrently. B: Bands were quantified by densitometry software to to create a GFP-ELP51 standard 
curve and calculate the yield of ΔN40 CP-ELP51. 
 
Based on the successful results of free ELP51 expression in bacteria (Chapter 2), 
free ELP51 was produced in plants and was intended to assist in the purification of 
CP-ELP (Chapter 4). In this way, the production and purification of CP-ELP could be 
exclusively plant-based. The pEAQ-HT construct expressing ELP51 targeted protein 
accumulation to the ER in order to increase its yield and stability. The protein was 
y = 2E+06x + 827834 
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detected by Coomassie staining of a SDS-PAGE gel (approximate size of 26 kDa, 
Figure 25), and its identity was confirmed by anti-His immunoblot (data not shown). 
 
   
Figure 25: Free ELP51 expressed in plants 
Free ELP51 (26 kDa, indicated by the arrow) was extracted from plants at different time points. 1: 
crude extract from 2 dpi, 2: crude extract from 4 dpi. The crude extracts were analysed by SDS-PAGE 




Transient expression by agroinfiltration is the fastest way for evaluating the 
expression of new proteins in plants. Recombinant protein yields using this method 
are typically higher than those achieved with transgenic plants (Rybicki et al., 2012; 
Paul & Ma, 2011). The use of this method allowed for the rapid expression of CP-
ELP proteins and may also have contributed to increased yield, as transient 
expression typically gives higher protein yields than transgenic plants (Rybicki, 
2010). 
The expression of BFDV CP proteins in plants was optimised first by testing two 
different vector systems, the pTRA system and the pEAQ-HT system. Expression of 
ΔN40 CP-ELP28 using pTRA targeted protein accumulation to the ER. The amount 
of protein that could be extracted with Tris-HCl buffer was very low (Figure 17, lanes 
2 and 5). The pEAQ-HT vector was then tested to express the same ΔN40 CP-
ELP28 protein targeted to the ER. As shown in Figure 19 (panels 2dpi and 4dpi, lane 
















2), a greater amount of ΔN40 CP-ELP28 was obtained using the same extraction 
protocol. Therefore the pEAQ-HT vector was used for all further plant expression 
work. 
The plant expression vector pEAQ developed by Sainsbury et al. (2009) has been 
used for rapid and high-level expression of several proteins in tobacco, including the 
human papillomavirus coat protein L1 (Matić et al., 2012).  The use of the pEAQ-HT 
vector gave higher yields of L1 protein than produced by a replicating vector based 
on tobacco mosaic virus (TMV). The situation was reversed when GFP was 
expressed, suggesting that the particular protein being produced, in conjunction with 
its expression vector, has a major influence on yield. In this work, ΔN40 CP-ELP and 
CP-ELP proteins were expressed rapidly using pEAQ-HT, reaching a high level at 
only 2 days post-infiltration (Figures 19 and 20). The pEAQ-HT vector includes the 
silencing suppressor gene p19 from tomato bushy stunt virus on the same T-DNA. 
This system is more efficient than the pTRAkc-ERH system, for which silencing 
suppressor T-DNA must be provided by co-infiltration with another Agrobacterium 
strain. The p19 protein acts as a potent inhibitor of the plant’s post-transcriptional 
gene silencing (PTGS) defence by sequestering small RNA molecules in a sequence 
non-specific manner (Lakatos et al., 2004). The suppression of PTGS in this manner 
has been shown to greatly increase the yield of recombinant proteins (Gelvin, 2003).  
The choice of Agrobacterium strain also influences the efficacy of DNA transfer and 
ultimately, all other factors being equal, the protein yield. The pEAQ constructs for 
expression of CP-ELP proteins were initially transformed into Agrobacterium strain 
GV3101, resulting in successful expression.  In previous studies that have made use 
of the pEAQ vector, the Agrobacterium strain LBA4044 was chosen to mediate the 
transient protein expression in tobacco leaves (Sainsbury et al., 2009; Vardakou et 
al., 2012). The use of the LBA4044 strain increased the yield of all CP-ELP proteins 
tested (data not shown) and was adopted for all further work with pEAQ constructs.  
The choice of extraction buffer is another important factor influencing the yield of 
protein. The calculated isoelectric point of CP-ELP proteins is approximately 9.5, 
therefore buffers with pH range of 7.5 – 8.5 were used in extraction of these proteins 
to promote solubility, given their slightly negative charge in this pH range. When 













a concentration of 0.1% (v/v) increased the extraction efficiency. It was determined in 
initial extraction experiments that 50 mM Tris HCl pH 8.0 with 0.1% (v/v) TritonX-100 
gave the highest amount of CP-ELP protein (Figure 18). 
Recombinant expression of a CP-His-tag fusion and targeting to the ER did not yield 
any detectable protein when expressed in plants (Figure 19). The expression levels 
of unfused CP proteins, when targeted to the cytoplasm, were low. For truncated 
BFDV CP targeted to the ER, some His-tagged proteins were detected, of which the 
~26 kDa band may have been ΔN40 CP, but nevertheless the yield was very low 
and these proteins were not detectable at 7 dpi (Figure 20). 
Fusion of ΔN40 CP to ELP, and targeting to the ER, led to a significant increase in 
the yield of the respective fusion proteins (Figures 21). This could be a result of the 
formation of ELP protein bodies observed previously in ER-targeted GFP-ELP 
fusions (Conley et al., 2009b). For both ΔN40 CP-ELP and CP-ELP fusions, 
cytoplasmic accumulation resulted in more degradation products observed than for 
ER-targeted proteins (Figures 19 and 20). This could be because proteins in the 
cytoplasm are more exposed to proteases than in the ER. This was especially true 
for ΔN40 CP fusions, and may be explained by the observation that truncated CP 
alone was unstable in the cytoplasm, as it could not be detected at 7 dpi (Figure 19, 
panel 7 dpi, lane 1). The expression of ΔN40 CP in the cytoplasm reached its peak 
at 4 dpi, although evidence of degradation was already apparent. Thereafter it was 
degraded and was undetectable at 7 dpi. The degradation of ΔN40 CP-ELP fusions 
targeted to the cytoplasm resulted in several degradation products being observed 
which were smaller than the expected protein sizes. Furthermore, recombinant 
proteins in the cytoplasm are more likely to have a toxic effect on the host, as 
opposed to ER accumulation, which segregates the protein from the rest of the cell 
and renders it physiologically inert (Conley et al., 2011). In contrast to ΔN40 CP 
proteins, different subcellular targeting seemed to have no effect on the yield of full-
length CP fusions. Full-length CP in the cytoplasm continued to accumulate 
gradually up to 7 dpi, which suggests that it is less susceptible to degradation in the 
cytoplasm. This would explain the relatively high yield of full-length CP-ELP fusions 













Based on the results of CP-ELP expression and subcellular localisation, the free 
ELP51 expressed in plants was targeted to the ER to maximise yield. This protein 
was to be used in assisting purification of CP-ELP fusions (see Chapter 4). The yield 
of ELP51 was high at 4 dpi and could be detected on a Coomassie-stained gel 
(Figure 25, lane 2). There is some evidence that the expression profile of a free ELP 
is different to respective ELP fusion proteins, and is influenced by ELP length 
(Conley et al., 2009a). However, expression free ELP51 seemed to follow a similar 
trend as the CP-ELP51 fusions.  
GFP-ELP fusion proteins were expressed in order to demonstrate that the ELP 
fusion strategy could be used to purify proteins other than BFDV CP-ELP (see 
Chapter 4 for purification data). GFP was chosen as it is a widely used model 
protein, known to express at a high level in most systems, and it is highly stable and 
an easily detectable fluorophore (Grebenok et al., 1997; Harper et al., 1999).  GFP-
ELP28 and GFP-ELP51 fusion proteins were targeted to the ER to increase yield, as 
GFP fused to an ELP of 28 VPGVG repeats, and targeting to the ER, has been 
shown to form novel protein bodies in the ER (Conley et al., 2009b). These proteins 
were rapidly expressed, reaching a maximum at 4 dpi (Figure 14B, lanes 1 and 3), 
but remaining stable in the plant leaf up to 7 dpi (data not shown). GFP-ELP51 could 
be purified by ITC (see Chapter 4) and used as a standard His-tagged protein for 
immunoblots (Figure 24). 
There are no published reports on BFDV or PCV-2 capsid protein expression in 
plants. Although the ELP fusion strategy has been used for many plant-expressed 
proteins, ranging from full-size antibodies to spider silk proteins (for a review, see 
Floss et al., 2010b), there are not many reports on the production of antigen-ELP 
fusions (for the purpose of creating a vaccine) in any expression system. In one 
study, Mycobacterium tuberculosis antigens were each fused to ELP and expressed 
in transgenic tobacco (Floss et al., 2010a). Interestingly, the ELP was not removed 
from the antigen, and it was found that the ELP had no effect on the immune 
response against the antigens in mice. However, more work needs to be done in 
order to assess the immunogenicity, or potential adjuvant effect, of ELP when fused 
to an antigen. The CP-ELP fusions produced in plants could serve as vaccine 
candidates against BFDV, following purification. The removal of ELP may not be 


















By exploiting the temperature-dependent phase transition of elastin-based polymers, 
McPherson et al (1996) successfully purified an ELP produced in E. coli consisting of 
251 repeats of VPGVG. The use of elastin-like polypeptide fusions for purification of 
recombinant proteins was first described for proteins produced in E. coli (Meyer & 
Chilkoti, 1999), when it was noted that the fusion protein retained the phase 
transition behaviour of the ELP. Later, this strategy was applied to the plant 
expression system, to increase the yield and stability of recombinant proteins (Patel 
et al., 2007; Floss et al., 2008b) while providing a means for simple and scalable 
purification (Conley et al., 2009a; Phan & Conrad, 2011). 
The factors influencing the inverse transition temperature (T t) of ELPs include: ionic 
strength of the solution, the length of the ELP and hydrophobicity of the guest 
residues (Meyer & Chilkoti, 1999). The total ELP concentration is also a critical factor 
influencing Tt and the overall successful recovery of the fusion protein. This of 
considerable importance to plant expressed ELP fusions, for which yields may be 
lower than those produced by microbial systems. Fusion to longer ELPs increases 
the purification efficiency by ITC, but decreases the yield of the fusion protein (Meyer 
et al., 2001). Therefore, choosing the length of the ELP fusion partner requires a 
compromise between yield of the target protein and the purification efficiency.  
This chapter describes the purification of elastin-like polypeptide fusions expressed 
in E. coli and plants, using ITC. These include ELP fusions of GFP or BFDV CP 
proteins and free ELP51 expressed in both E. coli and plants. Free ELP51 was 
expressed in order optimise the conditions required for the phase transition of this 
ELP51 and its fusions. Free ELP51 was also used as a co-aggregate during 
purification of CP-ELP fusions, increasing the total ELP concentration and improving 













4.2 Materials and Methods 
 
4.2.1 Proteins 
The proteins that were used in ITC experiments are: ΔN40 CP-ELP51 and free 
ELP51 produced in bacteria (Figure 5) using the relevant pPROEX-HT constructs 
(bacterial protein production and extraction described in 2.2.5 and 2.2.6)  and GFP-
ELP51, free ELP51 and ΔN40 CP-ELP51 (ER-targeted) expressed in plants (Figure 
16), using the relevant pEAQ-HT constructs (agroinfiltration described in 3.3.3). Only 
ELP51 and its fusions were purified by ITC, because ELP51 (which is longer than 
ELP28) has a lower transition temperature than ELP28, which means that a lower 
temperature is required for ELP51 purification. This is an important factor in 
preventing thermal denaturation of ELP fusion proteins during purification. 
 
4.2.2 Bulk extraction of ELP fusion proteins from plants 
For large-scale extractions, leaves from infiltrated plants were pooled, weighed and 
homogenised in liquid nitrogen using a mortar and pestle. Two volumes of extraction 
buffer (w/v) were added. Samples were then centrifuged at 20,000 x g in a Beckman-
Coulter Avanti® J25-I centrifuge (Beckman-Coulter, USA) for 20 minutes. The 
supernatant was filtered through two layers of Miracloth™ (EMD Chemicals, USA). 
The sample was centrifuged again at 20,000 x g for 20 minutes to remove any 
remaining insoluble matter. Protein samples were stored at – 20 °C. Total soluble 
protein concentrations were determined using a Bio-Rad Protein Assay Kit (Bio-Rad 
Laboratories, USA) as per the manufacturer’s instructions, using a IgG standard 
curve and a BioTek microplate reader (BioTek, USA). 
 
4.2.3 Inverse transition cycling (ITC) by centrifugation (cITC) 
Stock salt solution (3 M ammonium sulphate or 5 M sodium chloride) was added to 
the protein sample in 1 mL increments, with constant mixing, until the desired salt 
concentration was achieved (the optimised salt concentration of 0.4 M ammonium 
sulphate was most often used, unless specified otherwise). For ‘spiked’ ITC, in which 













in excess of 5 µM was used. In these cases, the free ELP51 was added to the 
sample prior to the addition of salt solution. The sample was then pre-incubated in a 
water bath at the specified temperature (the optimised temperature of 37 °C was 
most often used, unless specified otherwise) for 10 minutes to trigger the phase 
transition of the ELP. Samples were then centrifuged in a Beckman Coulter Optima 
L-100 XP ultracentrifuge pre-heated to the specified temperature for 40 minutes at 
20,000 x g. This step is termed ‘hot spin’. The supernatant was removed and the 
pellet resuspended in 1/10th sample volume of ice-cold 50 mM Tris-HCl-pH 8.0, 0.1% 
TritonX-100. In some cases, mechanical grinding of the pellet with a pestle in a 1.5 
mL plastic tube was required for complete resuspension. To further break up protein 
aggregates, the resuspended pellet was sonicated on ice using a Misonix 3000 
sonicator (Misonix, USA) for four 15 second pulses at 12 W. The sample was then 
incubated at 4 °C on an orbital shaker for approximately 30 minutes to allow for 
solubilisation of ELP proteins. The resuspended pellet sample was centrifuged at 
15,000 x g at 4 °C for 10 minutes to remove insoluble debris. This step is termed 
‘cold spin’ (CS). The supernatant resulting from the cold spin step was recovered. 
The pellet was resuspended in 1/10th sample volume of 50 mM Tris-HCl-pH 8.0, 
0.1% TritonX-100 and kept for further analysis. Where specified, ELP fusions were 
digested using AcTEV protease (Invitrogen, USA), with the manufacturer’s 
recommended reaction setup at 27 °C for 16 hours. 
 
4.2.4 Membrane filtration-based ITC (mITC) 
Five millilitres of crude extract clarified by centrifugation was pre-filtered through 0.2 
µm Acrodisc® syringe filters (with Supor® membrane (hydrophilic polyethersulfone)) 
(Pall Corporation, USA). Free ELP51 was added in the case of spiked ITC as 
described previously. Ammonium sulphate was added to a final concentration of 0.4 
M. Samples were incubated in a 37 °C water bath for 15 minutes to induce ELP 
aggregation. Samples were then filtered through 0.2 µm syringe filters, using a sterile 
syringe, and the filtrate was kept for further analysis. An equal volume of pre-warmed 
0.5 M ammonium sulphate solution was passed through the membrane in a washing 
step. Ice-cold 50 mM Tris-HCl pH 8, 0.1 % (v/v) TritonX-100 was added to the 
syringe, without a plunger, fixed to the filter. This was allowed to pass through the 













extract volume; if this volume had not passed through the filter by gravity flow after 
the specified time, a plunger was used to force the solution through the filter until the 










The crude extract is first pre-incubated at 37 °C in the presence of ammonium sulphate (0.4 M) to 
cause ELP aggregation. Filtration through the membrane captures ELP aggregates on the membrane 
while contaminating proteins pass through in the filtrate. The membrane is washed by passing a salt 
solution through the membrane. The ELP-tagged proteins are then eluted from the membrane by 
passing cold buffer through it. The purified ELP fusion protein is now located in the elution fraction. 
 
4.2.5 SDS-PAGE and immunoblotting 




4.3.1 Purification of GFP-ELP51  
GFP-ELP51 could be purified using cITC, which was recovered to a high degree in 
the cold spin supernatant. However, it is likely that some Rubisco large subunit 
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purified protein was digested with TEV protease, to separate GFP from its ELP51 
fusion partner. The digestion was partial, with the the 55 kDa band being reduced in 
volume, and the unfused GFP could be seen on a Coomassie stained gel (Figure 
27B, lane 2). The size of ELP51 (26 kDa) is similar to that of GFP (30 kDa), but 
ELP51 probably is not contributing to the intensity of the band indicated by the arrow 
in Figure 27B, as it was later found that free ELP51 it is poorly visualised on 
Coomassie-stained gels (Figure 30, lane 2). Preliminary experiments done at 37 °C, 
0.4 M ammonium sulphate, showed that a substantial amount of GFP-ELP51 was 
left in the hot spin supernatant, indicating that not all of the protein was precipitated 
efficiently, leading to a low recovery of GFP-ELP51 (data not shown). The 
centrifugation temperature and the salt concentration were increased in order to 
cause more of the GFP-ELP51 to aggregate and pellet during centrifugation. The 
use of a high salt concentration (1 M ammonium sulphate) and 40 °C resulted in 
higher recovery of GFP-ELP51 after purification (Figure 27 A, lane 2). However, 
these conditions may have increased the amount of contaminating proteins, 
especially Rubisco large subunit protein, that co-precipitated with GFP-ELP51 during 
purification. 
           
 
              
Figure 27: Plant-produced GFP-ELP51 purification by cITC 
GFP-ELP51 was purified by centrifugation ITC, using 1 M ammonium sulphate and 40 °C 
centrifugation temperature. A: M: molecular weight marker, 1: GFP-ELP51 crude extract, 2: 
supernatant from the cold spin step. GFP-51 band is indicated by the arrow. B: The supernatant from 
the cold spin step was partially digested by overnight incubation with TEV protease. 1: undigested 
control, 2: TEV digest. Note the GFP band of approximately 30 kDa (indicated by the arrow). 
 



















ELP fusions may also be purified by membrane filtration, instead of centrifugation, to 
capture ELP aggregates.  ITC by membrane filtration is referred to here as ‘mITC’. 
This method was used to purify GFP-ELP51 to homogeneity in only one purification 
cycle (Figure 28). This was done as described in 4.2.4, except that the pre-
incubation temperature used was 42 °C. The pre-incubation temperature was 
increased from 37 °C to 42 °C based on the results of cITC experiments of GFP-
ELP51. Contaminating proteins passed though the membrane in the filtrate (Figure 
28A, lane 3), while GFP-ELP51 was successfully captured on the membrane and 
subsequently eluted with cold buffer (Figure 28A, lane 2). The identity of GFP-ELP51 
was confirmed by anti-His immunoblot (Figure 28B). The immunoblot showed that 
much of the GFP-ELP51 protein was lost in the filtrate. The purification of GFP-
ELP51 was not optimised further (to reduce this loss), because it could not be used 
as a model for ΔN40 CP-ELP51 purification as originally intended. Nevertheless, 
purification of GFP-ELP51 demonstrated the proof of concept for the purification of 
ELP51 fusions by ITC. The results suggest that GFP-ELP51 aggregates more 
effectively at higher temperatures (42 °C) and higher salt concentrations. These 
conditions are different to those required for effective ΔN40 CP-ELP51 aggregation, 
as determined by later empirical experiments. 
 
 
                   
Figure 28: Purification of GFP-ELP51 by mITC 
GFP-ELP51 expressed in plants was purified by one cycle of the membrane ITC protocol as 
described, with the addition of 0.5 M ammonium sulphate and pre-incubation at 42 °C. A: Coomassie-
stained gel showing: lane 1: the crude extract, lane 2: the elution fraction, lane 3: the filtrate. B is the 
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4.3.2 Purification of free ELP51 
The free ELP51 produced in bacteria (Figure 29) or plants (Figure 30) could both be 
purified by ITC. The purification of free ELP51 was done in order to determine the 
purification conditions later used for ΔN40 CP-ELP51. These ITC conditions were 
determined as 0.4 M ammonium sulphate and 37 °C centrifugation temperature. 
ELP51 extracted from E. coli was subjected to one round of ITC, in triplicate 
experiments (Figure 29). In the case of bacterial-expressed ELP51, there was a loss 
of protein – due to irreversible aggregation – during ITC (Figure 29, lanes 4-6). This 
could be ELP51 that was improperly folded or processed. All soluble ELP recovered 
after the first ITC cycle (Figure 29, lanes 1-3) exhibited high recovery in subsequent 
ITC cycles. The ELP51 purified from plants could be visualised on a Coomassie-
stained gel (Figure 30), although it was poorly stained in comparison to other 
proteins. This phenomenon has been described previously (McPherson et al., 1996). 
The ELP51 produced in bacteria had more extraneous sequences on the N-terminus 
(an additional His tag), which may be responsible for its superior staining on a 
Coomassie gel (Figure 29, lanes 1-3). The purification of plant-produced free ELP51 
confirmed that ammonium sulphate was the more effective salt to use during 
purification, compared to NaCl. A reduced amount of ELP51 was recovered when 
NaCl was used (Figure 30, lane 7), compared to when ammonium sulphate was 
used (Figure 30, lanes 2, 4 or 6).   
 
 
Figure 29: Free ELP51 purification from E. coli cell lysate 
Free ELP51 purified from E. coli cell lysate by one round of cITC: M: molecular weight marker, lanes 
1-3: soluble proteins after purification, lanes 4-6: insoluble proteins after purification, lanes 7 and 8: 
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Figure 30: Plant-produced ELP51 expression and purification 
Optimisation of free ELP51 cITC purification produced in plants at 37 °C, using three different salt 
conditions. M: molecular weight marker, 1: crude extract (ELP band indicated by the arrow), 2: (0.3 M 
ammonium sulphate) soluble proteins, 3: (0.3 M ammonium sulphate) insoluble proteins, 4 and 6: (0.4 
M ammonium sulphate) soluble proteins, 5: (0.4 M ammonium sulphate) insoluble proteins, 7:  (2.5 M 
NaCl) soluble proteins. The ELP51 band is indicated by arrows. Equal volumes of all samples were 
loaded. 
 
4.3.3 Purification of ΔN40 CP-ELP51 
In order to establish purification conditions for ΔN40 CP-ELP51, this protein was 
expressed in bacteria. The ΔN40 CP-ELP51 protein expressed in bacteria was 
mostly insoluble (Figure 10A, lane 6). The protein band for ΔN40 CP-ELP51 in the 
crude lysate is not clearly visible on a Coomassie-stained gel, in contrast to the 
insoluble fraction (the pellet of cell debris obtained after centrifugation of the cell 
lysate) (Figure 31, la e 2). ITC purification requires soluble protein. However, an 
attempt at ITC was made using the soluble fraction of expressed ΔN40 CP-ELP51, 
using the ITC conditions previously determined for free ELP51. The ΔN40 CP-ELP51 
could be concentrated and purified by ITC, and the protein was recovered in the 
pellet of the cold spin step (Figure 31, lanes 3 and 4). The pellet from the cold spin 
step was resuspended in 1/40th of the soluble fraction volume.  However, the 
aggregation was irreversible, as none of the ΔN40 CP-ELP51 remained soluble after 
ITC. The identity of the bands indicated by the arrow in Figure 31 was confirmed to 






















Figure 31: Purification of ΔN40 CP-ELP51 from E. coli cell lysate 
Purification of ΔN40 CP-ELP51 from E. coli cell lysate by cITC: M: molecular weight marker, 1: 
soluble cell lysate, 2: insoluble proteins from cell lysate, 3 and 4: resuspended pellets from the cold 
spin step of purification, 5: supernatant from the hot spin step. Equal volumes of all samples were 
loaded. 
 
The majority of purification experiments of CP-ELP from plants were performed 
using the ER-targeted ΔN40 CP-ELP51. The yield of this protein in crude extracts 
was consistently one of the highest of the CP-ELP proteins. Also, the longer ELP of 
this fusion  protein (51 x VPGVG) reduces the temperature necessary for the ELP 
aggregation (Meyer & Chilkoti, 1999), which could be important in preventing 
temperature-induced denaturation of BFDV ΔN40 CP. Under ITC conditions of 0.8 M 
ammonium sulphate and 40 °C, the fusion protein was shown to be pelleted 
effectively, as a large amount of the protein as detected in the pellet (Figure 32, lane 
2). However, the resolubilisation of the pellet was poor, as there was a reduced 
amount of the protein in the cold spin supernatant (Figure 32, lane 3). The protein 
level in the cold spin supernatant was very low and while it could be detected by 
immunoblot, it was not detectable by Coomassie staining. Some of the ΔN40 CP-
ELP51 had not been pelleted during the hot spin step and remained in the 
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Figure 32: Plant-produced ΔN40 CP-ELP51 ITC 
ΔN40 CP-ELP51 produced in plants was subjected to cITC followed by SDS-PAGE and anti-His 
immunoblot. M: molecular weight marker, 1: crude extract, 2: resuspended pellet after heated 
centrifugation, 3: supernatant after cold spin step, 4: supernatant after hot spin step. The ΔN40 CP-
ELP51 band (55 kDa) is indicated by the arrow. Equal volumes of all samples were loaded. 
 
The combination of elevated temperatures and high salt concentrations may cause 
the denaturation of CP. This would lead to irreversible aggregation, should the CP 
target proteins come into contact with each other. Therefore, milder ITC conditions 
were tested. The salt concentration was lowered to 0.4 M and the centrifugation 
temperature was set to 37 °C. The resuspended pellet was also sonicated at 4 °C to 
disrupt any persistent ELP aggregates. The first round of purification was performed 
with four technical repeats. The cold spin supernatants resulting from the first round 
of purification were pooled for the second round of purification. This revised protocol 
led to a greater recovery of purified soluble ΔN40 CP-ELP51, as is evident from the 
greater amount of ΔN40 CP-ELP51 in the cold spin supernatants (Figure 33B, lanes 
2 and 3). The greater proportion of ΔN40 CP-ELP51 that was recovered using the 
new purification conditions (Figure 33B, from lane 1 to lane 2) can be compared with 
the low recovery of previous conditions (Figure 32, from lane 1 to lane 3). The 
majority of contaminants were removed during the first ITC cycle, and remained in 
the hot spin supernatant (Figure 33A, lane 5). Some ΔN40 CP-ELP51 was not 
pelleted and remained in the hot spin supernatant (Figure 33B, lane 5). However, 
irreversible aggregation remained the major cause of ΔN40 CP-ELP51 protein loss. 
This is evident from the amount of ΔN40 CP-ELP51 remaining in the insoluble debris 



















               
Figure 33: Purification of ΔN40-CP-ELP51 using optimised ITC protocol 
ΔN40-CP-ELP51 extracted from plants was purified by two rounds of cITC using the optimised 
protocol, which involved centrifugation at 37 °C and sonication of the ELP pellet. A: Coomassie-
stained gel; M: molecular weight marker, 1: crude extract, 2: supernatant from first cold spin, 3: 
supernatant from the second cold spin, 4: resuspended pellet of insoluble matter from the second cold 
spin, 5: supernatant from the first hot spin. B is the cognate anti-His immunoblot, which was loaded 
with half the volume of all samples in A. The position of the ΔN40-CP-ELP51 band is indicated by the 
arrow. Equal volumes of all samples were loaded. 
 
‘Spiked’ ITC of ΔN40 CP-ELP51 
The purification conditions of free ELP51 and ΔN40 CP-ELP51 were matched (37 
°C, 0.4 M ammonium sulphate) so that co-aggregation could occur if the two proteins 
were mixed. Free ELP51expressed in bacteria was purified by two ITC cycles and 
was added to crude plant extracts containing ΔN40 CP-ELP51 protein. However, the 
free ELP51 (Figure 34A, lane 2 (26 kDa)) expressed in bacteria exhibited a band of 
approximately 55 kDa when analysed by anti-His immunoblot (Figure 34B, lane 2), 
which is similar in size to the ΔN40 CP-ELP51 fusion (Figure 34B, lane 1). It is 
suspected that this is an ELP dimer that failed to dissociate under the conditions of 
denaturing SDS-PAGE. Higher bands indicate the presence of higher molecular 
weight ELP multimers as well (Figure 34B, lane 2 and 3). Therefore it was not 
possible to distinguish between the ELP dimer band and the band corresponding to 
ΔN40 CP-ELP51 protein on an anti-His immunoblot, when the two proteins were 
mixed. The ELP51 expressed in plants exhibited similar multimers on SDS-PAGE 
gels. It should be noted that the addition of free ELP51 increased the pelleting 
efficiency of ΔN40 CP-ELP51, as the amount of ΔN40 CP-ELP51 present in the hot 
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spin supernatant (Figure 33B, lane 5) was reduced relative to that of unspiked 
purification experiments. 
 
     
 
 
Figure 34: ΔN40 CP-ELP51 ITC spiked with bacterial ELP51 
cITC of ΔN40 CP-ELP51 produced in plants with added free ELP51 produced in E. coli. A: 
Coomassie-stained gel; M: molecular weight marker, 1: ΔN40 CP-ELP51 crude extract (protein 
indicated by the arrow), 2: free ELP51 added, purified by two rounds of ITC from E. coli cell lysate, 3: 
supernatant from the cold spin step, 4: pellet from the cold spin step, 5: supernatant from the hot spin 
step. B: cognate anti-His immunoblot. Note that the 55 kDa band for the ELP51 is a dimer. 
 
The spiked ITC was repeated to determine the effect of free ELP51 in the purification 
of ΔN40 CP-ELP51. Purification of ΔN40 CP-ELP51 was performed without the 
addition of free ELP51 (‘unspiked’), or free ELP purified by two ITC cycles (Figure 
35A, lane 9) was added (‘spiked’). Samples of the pellets resulting from the hot spin 
step were analysed, as well as the cold spin supernatants. The results showed that 
the ΔN40 CP-ELP51 was pelleted in unspiked purification (Figure 35B, lanes 2 and 
4), but was lost in the cold spin step, as there is reduced amounts of the protein in 
the cold spin supernatants (Figure 35B, lanes 3 and 5). The ΔN40 CP-ELP51 band 
could be seen on a Coomassie-stained gel (Figure 35A, lane 2, indicated by the red 
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(Figure 35A, lane 7). This was thought to be ΔN40 CP-ELP51, but this could not be 
confirmed as there is an ELP51 dimer of similar size (Figure 35B, lane 8 and 9). In 
conclusion, the effect of free ELP51 on the purification of ΔN40 CP-ELP51 could 
only be determined by immunoblot, using an antibody that could detect ΔN40 CP but 
not the free ELP51 dimer. The anti-ΔN40 CP serum was used for this purpose 





Figure 35: Plant produced ΔN40-ELP51: spiked or unspiked ITC and free ELP51 
purification 
cITC of ΔN40 CP-ELP51 produced in plants without added free ELP51 (”unspiked”) or with added 
free ELP51 produced in E. coli (“spiked”). The unspiked purification was performed in duplicate. A: 
Coomassie-stained gel; M: molecular weight marker, 1: ΔN40 CP-ELP51 crude extract, 2 and 4: 
(unspiked) resuspended pellet after hot spin step, 3 and 5: (unspiked) supernatant from cold spin 
step, 6: (spiked) resuspended pellet from cold spin step, 7: (spiked) supernatant from cold spin step. 
The red arrow indicates the ΔN40 CP-ELP51 band and the black arrow indicates the Rubisco large 
subunit band. 8 and 9 represent one and two cycles, respectively, of cITC purification of free ELP51 
(25 kDa) from E. coli cell lysate. B is the cognate anti-His immunoblot. Equal volumes were loaded for 
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Spiked purification of ΔN40 CP-ELP51 was performed by adding free ELP51 
(expressed in plants) to ΔN40 CP-ELP51 crude extract. The cold spin supernatant 
and the insoluble proteins from the cold spin step were analysed by Coomassie 
staining and immunoblot using the anti-ΔN40 CP serum. The anti-ΔN40 CP serum 
could be used to detect exclusively ΔN40 CP-ELP51 in a mixture of free ELP51 and 
ΔN40 CP-ELP51 (Figure 36B). There was no detection of ELP51 (circled in Figure 
36A) by the serum (Figure 36B, lane 2). The results showed that the majority of the 
ΔN40 CP-ELP51 was insoluble after purification, as most of it was located in the cold 
spin pellet (Figure 36B, lane 4). Only a small amount of ΔN40 CP-ELP51 was 
detected in the cold spin supernatant after purification, (Figure 36B, lane 3). 
Therefore the addition of free ELP51, which itself exhibited high recovery, could not 




        
Figure 36: cITC of ΔN40 CP-ELP51 spiked with plant-produced free ELP51 
cITC of ΔN40 CP-ELP51 produced in plants with added plant-produced free ELP51. A: Coomassie-
stained gel; M: molecular weight marker, 1: crude ΔN40 CP-ELP51, 2: purified ELP51 (the free 
ELP51 band is circled), 3: supernatant from the cold spin step, 4: resuspended pellet from the cold 
spin step. B is the cognate anti-ΔN40 CP immunoblot. The ΔN40 CP-ELP51 band is indicated by the 
arrow. Note the absence of free ELP51 detection by anti-ΔN40 CP serum. Equal volumes of all 
samples were loaded. 
 
The mITC method was employed for the purification of ΔN40-CP-ELP51 produced in 



















the filtrates (Figure 37A, lanes 4 and 5) and ΔN40-CP-ELP51 was concentrated by 
eluting in 1/5th of the sample volume (Figure 37B, lanes 2 and 3). Using this method, 
the amount of soluble ΔN40-CP-ELP51 recovered was increased, because the 
concentration of the protein was evident (compare Figure 37B lane 1 to lanes 2 and 
3), in contrast to the cITC method. However, a substantial amount of ΔN40-CP-
ELP51 was lost in in the filtrates (Figure 37B, lanes 4 and 5). In two separate 
experiments, free ELP51 was added to the ΔN40-CP-ELP51 prior to mITC (i.e. 
spiked mITC) In these cases, no His-tagged protein was detected in the filtrate 
(Figure 37B, lanes 6 and 7) suggesting that more stable particles were formed, and 
prevented detectable loss of protein in the filtrate. The presence of ΔN40 CP-ELP51 
in the elution fraction of the spiked mITC experiment was confirmed by anti-ΔN40 CP 




                
Figure 37: Purification of ΔN40 CP-ELP51 by mITC 
Plant-produced ΔN40 CP-ELP51 was subjected to mITC. The experiment was performed in duplicate. 
A: Coomassie-stained gel: M: molecular weight marker, 1: crude extract, 2 and 3: elution fractions 
from the two experiments, 4 and 5: filtrates from the two expermiments. B: anti-His immunoblot 
analysis. Lanes 6 and 7 are filtrates from two separate mITC experiments in which free ELP51 was 
added as a co-aggregate. The elution fraction resulting from one of these spiked mITC experiments 
was analysed by anti-ΔN40 CP immunoblot as shown in Figure 15, lane 4.  Equal volumes of all 
























GFP-ELP51 was expressed in order to serve as a model ELP51 fusion protein. This 
protein was expressed at a high level and was highly stable, and therefore a large 
amount of this protein could be generated in order to test the purification conditions 
of a typical ELP51 fusion protein. GFP-ELP51 could be efficiently purified by ITC. 
Similar plant-expressed GFP-ELP51 fusions described in the literature also exhibit a 
relatively high recovery after ITC (Conley et al., 2009a). This is probably because of 
the high stability and solubility of GFP and the high yield of the fusion protein. One 
cycle of cITC produced a single band on a Coomassie-stained gel, but it is likely that 
some Rubisco large subunit protein is also present, which is approximately the same 
size of GFP-ELP51 (Figure 26). The conditions used for purification of GFP-ELP51 
were a high salt concentration of 1 M ammonium sulphate and 40 °C centrifugation 
temperature. The salt concentration and temperature are greater than those used to 
later purify free ELP51 or ΔN40 CP-ELP51. It is known that GFP increases the 
transition temperature (T)t of an ELP fusion partner due to the prevalence of 
hydrophilic residues on the surface of GFP (Trabbic-Carlson et al., 2004b). 
Therefore, GFP-ELP51 could not be used as a model for the purification of ΔN40 
CP-ELP51 because GFP-ELP51 required a higher temperature for its purification. 
Nevertheless, the successful purification of GFP-ELP51 verified the utility of the 
ELP51 fusion in protei  purification. ITC by membrane filtration was more successful 
than cITC, as GFP-ELP51 was purified to homogeneity in only one cycle (Figure 28) 
and this protein was used as a standard ELP- and His-tagged protein for 
immunoblots, and also for the optimisation of TEV cleavage reactions. Although the 
purification of GFP-ELP51 by membrane ITC was not optimised, the degree of purity 
after one cycle of mITC is much greater than that of other plant-expressed GFP-ELP 
proteins described by Conley et al. (2009a). The authors used cITC to purify GFP 
fused to ELPs of varying lengths, but the majority of contaminants still remained after 
one round of purification. 
The pioneering work on the environmentally-responsive nature of protein polymers 













ELP expressed in bacteria could be purified to a high degree after only one ITC cycle 
(McPherson et al., 1996). When this was later applied to the purification of ELP 
fusions, it was noted that purification efficiency of the fusion was typically less than 
that of the free ELP (Meyer & Chilkoti, 2002b). This suggests that the target protein 
fused to the ELP can have an effect of the purification efficiency, and the degree of 
this effect may vary for different target proteins. The bacterial-expressed free ELP51 
described in this chapter exhibited irreversible aggregation during the first cycle of 
ITC (Figure 29), but in later cycles exhibited high recovery (Figure 35A, lanes 8 and 
9). This suggests that a proportion of the ELP expressed in bacteria was not properly 
folded, as irreversible aggregation is not among the expected physical 
characteristics of an ELP. Free ELP expressed in plants was observed by Conley et 
al. (2009a) to have a higher purification efficiency than ELP fusion proteins. The 
purification of free ELP51 produced in plants (Figure 30) was very efficient and 
exhibited a higher recovery during the first ITC cycle than the bacterial-produced 
ELP (Figure 29,). Also shown in Figure 30 is that the use of ammonium sulphate to 
depress Tt leads to much greater recovery than when of sodium chloride is used 
(Figure 30, lane 7). Fong et al. (2009) described the use of low concentrations of 
ammonium sulphate during ITC, instead of high NaCl concentrations, to increase 
ELP recovery and minimise co-precipitation of impurities. 
The purification of ΔN40 CP-ELP51 produced in plants presented the same problem 
as in the attempt to purify bacterial-expressed ΔN40 CP-ELP51. The fusion protein 
aggregated during ITC and was pelleted effectively, but the protein in the pellet 
remained largely insoluble. The protein was not recovered in the cold spin 
supernatant and therefore additional rounds of purification were not possible. The 
efficient purification of free ELP suggests that BFDV CP is the cause of this problem. 
BFDV capsid proteins naturally interact to form the capsid of the virion. The strong 
interaction between ΔN40 CP proteins to form a virus-like particle (VLP) could be a 
factor that leads to irreversible aggregation of ΔN40 CP-ELP51, when at high 
concentrations in the pellet. Modification of the purification conditions and the 
addition of a sonication step led to increased recovery of ΔN40 CP-ELP51 (Figure 
33). When over-expressed in bacteria, the ΔN40 CP protein alone was mostly 
insoluble, in contrast to free ELP51 protein. This suggests that ΔN40 CP in higher 













expressed in the baculovirus insect cell system was also found to be largely 
insoluble (Stewart et al., 2007).  
The addition of a free ELP to successfully assist in the purification of poorly-
expressed ELP fusions was described for protein expressed in bacteria (Christensen 
et al., 2007). An ELP with matched Tt is added to the crude extract containing the 
target ELP fusion before commencing with ITC. The rationale behind this strategy is 
to increase the total ELP concentration and thus promote the aggregation of all ELP 
proteins, including the target ELP fusion. The target ELP fusion can then be 
concentrated and purified effectively. Once protease digestion (or intein cleavage) 
has separated the ELP from the target protein, all ELP can be separated from it by 
one additional ITC cycle. The spiked experiments of plant-produced ΔN40 CP-
ELP51 described in this chapter showed that addition of free ELP51 reduced the 
amount of ΔN40 CP-ELP51 left behind in the hot spin supernatant (in the case of 
cITC) or filtrate (in the case of mITC). This is evidence that an increased 
concentration of total ELP leads to more efficient purification. In this case, the ΔN40 
CP-ELP51 co-aggregated with the free ELP51 and formed hybrid aggregates more 
efficiently than could be achieved with ΔN40 CP-ELP51 alone. 
This strategy was used to recover as little as 10 pM of thioredoxin-ELP fusion from 
crude extracts, which, without the addition of free ELP, would have been impossible 
by ITC (Ge & Filipe, 2006). In addition, The free ELP protein may increase the 
efficiency of purification by preventing contact between target proteins, which may 
result in irreversible aggregation (Meyer & Chilkoti, 2002b). It is possible that contact 
between BFDV CP proteins is responsible for the irreversible aggregation of CP-ELP 
fusions. Free ELP51 was added in an attempt to mitigate this problem – the more 
free ELP51 in the aggregates, the less chance of contact between BFDV CP 
proteins. However, the addition of free ELP did not reduce the amount of irreversible 
aggregation of ΔN40 CP-ELP51, as most of the protein was located in the cold spin 
pellet after purification (Figure 36B, lane 4).  
Spiked ITC was done with the assumption that the free ELP51 and ΔN40 CP-ELP51 
had the same transition temperature (Tt). Trabbic-Carlson et al. (2004b) showed that 
the mean surface hydrophobicity of the target protein fused to an ELP can have an 













residues tend to depress Tt, meaning that a lower temperature is required for 
aggregation of the ELP fusion relative to the free ELP. Conversely, more charged 
proteins elevate Tt. It is not clear whether BFDV CP could modulate the Tt of the 
fused ELP51, as the 3D structure of BFDV CP has not been solved. Studies have 
shown that mixtures of ELPs with different transition temperatures aggregate 
independently of each other as a function of temperature (Meyer & Chilkoti, 2002a). 
However, the use of the same conditions to pellet both free ELP51 and CP-ELP51 
suggests that the use of ELP51 to act as a coaggregate is valid.  
The sizes of the aggregates formed by ELP molecules above Tt are greater than one 
micron in diameter (Meyer et al., 2001). This presents another method in which to 
purify ELP-tagged proteins. Filtration by 0.2 µm membrane may be used to capture 
ELP aggregates, while contaminating proteins are passed through in the filtrate (Ge 
et al., 2006). When cold buffer is passed over the membrane, the aggregation of 
ELP is reversed and the protein may be eluted from the membrane. This method has 
been used for plant-expressed ELP fusions and was found to reduce the irreversible 
aggregation of ELP fusions that was observed for ITC by centrifugation (Phan & 
Conrad, 2011; Tian & Sun, 2011). Phan & Conrad purified influenza antigens 
haemagglutinin (H5) and neuraminidase (N1), each fused to an ELP of 100 repeats 
and expressed transiently in tobacco leaves. Tian & Sun purified a lectin protein, 
fused to an ELP of 60 repeats, produced in transgenic rice. This method, termed 
‘mITC’ (for membrane ITC), was used in the purification of ΔN40 CP-ELP proteins, in 
an attempt to mitigate the irreversible aggregation that was observed for ITC by 
centrifugation.  
GFP-ELP51 was first used to test the mITC purification method and could be purified 
efficiently (Figure 28). ΔN40 CP-ELP51 purification was then attempted under similar 
conditions (Figure 37). The recovery of soluble ΔN40 CP-ELP51 was greater than for 
centrifugation ITC. However, there were significant protein losses in the filtrate, 
which suggests that a proportion of the ΔN40 CP-ELP did not aggregate completely 
to form micron-sized particles, or that the aggregation was partially reversed upon 
filtration. Filtration was carried out at room temperature immediately after removing 
the sample from the 37 °C water bath, but some cooling may have occurred, which 
could have caused some of the ΔN40 CP-ELP aggregation to be reversed. When 













observed in the filtrate (Figure 37, lanes 6 and 7), suggesting that the co-aggregation 
increased the proportion of stable micron-sized particles. Membrane ITC with added 
free ELP has been used to concentrate and purify ELP fusions expressed at very low 
levels in E. coli (Christensen et al., 2007). This was shown by diluting 14C-labelled 
bacterial-expressed proteins to 15-20 pmol per liter and tracking their purification by 
scintillation counting. The labelled proteins were recovered after purification by mITC 
only when free ELP51 was added. 
Based on these results, future production of the ΔN40 CP-ELP51 vaccine candidate 
should be performed by transient expression in tobacco and the purification should 
be done by several cycles of mITC ‘spiked’ with free ELP51. The amount of crude 
extract processed should be scaled up by using membranes with larger surface 
areas and by using vacuum pumps to increase the filtration pressure. Fortunately, 
membrane filtration is already well-established in industry and this process is easily 
scalable (Ge et al., 2006). The purification of ELP fusions of full-length BFDV CP 
could also be optimised in future work, based on the results presented here for ΔN40 
CP-ELP51. The removal of ELP from the ΔN40 CP-ELP51 vaccine candidate may 
not be necessary, as ELPs are biocompatible (Rincón et al., 2006), which would 





















Chapter 5: Towards the development of a candidate 
BFDV DNA vaccine 
 
5.1 Introduction 
With the advent of recombinant DNA technology, the evolution of vaccines has 
progressed from inactivated and attenuated virus to subunit vaccines and virus-like 
particles. The latter have several advantages including safety and rapid response 
(El-Attar et al., 2009; Toussaint et al., 2011). Delivery of recombinant DNA encoding 
an antigen directly to the host is another strategy that can be used for vaccination. 
DNA vaccines consist of a bacterial plasmid DNA backbone containing an antigen-
encoding gene under the control of a strong eukaryotic promoter (Doria-Rose, 2003; 
Hitzeroth et al., 2009). 
There are several modes of delivery of DNA vaccines including injection or 
electroporation. Intramuscular electroporation has become the preferred route of 
administration for animals, as it has proven to be more immunogenic than other 
methods (Van Drunen Littel-van den Hurk & Hannaman, 2010). The plasmid is taken 
up by muscle cells and monocytes and the antigen is expressed. Antigens are 
processed and displayed on the cell surface by MHC class I molecules, which 
initiates the adaptive immune response. DNA vaccines offer several advantages, 
including flexibility in design and rapid preparation of plasmid DNA, which allows for 
a rapid response agai st emerging viral strains (Saade & Petrovsky, 2012).  
DNA immunisation of mice against PCV-2 has proven to be effective in providing 
protection (Fu et al., 2011). This suggests that a DNA vaccine against BFDV could 
be a good vaccine candidate. The expression of HIV and Plasmodium falciparum 
antigens using pTH eukaryotic expression vector has shown to induce CTL 
responses in mice (Hanke et al., 1998). A pTH clone containing the BFDV ΔN40 CP 
gene (pTH-ΔN40 CP) had been previously constructed in our laboratory by Guy 














This chapter describes the expression of truncated BFDV CP (ΔN40 CP) in the 
human embryonic kidney cell line HEK293T and in chicken embryonic fibroblast 
primary cells, by transfection with pTH-ΔN40 CP. ΔN40 CP was expressed instead 
of full-length CP, as it was expected that ΔN40 CP would be expressed at a higher 
level. The expression of BFDV ΔN40 CP by the pTH vector in vitro is a requirement 
for further challenge experiments of the DNA vaccine in animals. 
 
5.2 Materials and Methods 
  
5.2.2 Plasmid 
The truncated BFDV CP, including the N-terminal His-tag, was isolated from 
pPROEX-ΔN40 CP, with the addition of 5’ HindIII and 3’ EcoRI sites, by PCR. The 
PCR product was digested with HindIII and EcoRI and ligated into the similarly 
digested pTH expression vector (Appendix B) (Hanke et al., 1998). The ligation 
product was transformed into E. coli DH5α cells (E. cloni®, Lucigen). This pTH-ΔN40 
CP clone was provided by Guy Regnard. The insertion of ΔN40 CP gene into the 
pTH mammalian expression vector was confirmed by restriction digests, after which 
the sequence was verified (Macrogen, Netherlands) using vector specific primers. 
Endotoxin-free plasmid DNA was prepared using the NucleoBond® Xtra Midi EF kit 
(Macherey-Nagel, USA) according to the manufacturer’s protocol.  
 
5.2.3 Cell culture 
HEK293T human embryonic kidney cells were obtained from the ATCC (ATCC® 
number CRL-11268™). These cells were grown in Dulbecco’s modified Eagle 
medium (DMEM) with GlutaMAX™, 5% glucose (Invitrogen, USA), supplemented 
with 10% foetal calf serum (FCS) (Gibco, USA). Penicillin-streptomycin 100x (Sigma-
Aldrich, USA) was added to media to a final concentration of 10 mL/L to control 
bacterial contamination. HEK293T cells were grown in a 37°C incubator with CO2 













Chicken embryonic fibroblast (CEF) primary cells were isolated from 11-day old 
embryonated chicken eggs. Foetuses were removed from the eggs and the head 
limbs were amputated using sterilised scissors and forceps. The foetus body was 
washed in sterile PBS twice and was then incubated in 0.125% Trypsin-EDTA 
(Sigma-Aldrich, USA) at 37 °C for 20 minutes. The foetus was removed and the cell 
suspension was filtered through sterile cheesecloth. The cells were pelleted by 
centrifugation at 1000 x g. The supernatant was discarded and the cell pellet was 
resuspended in DMEM containing 5% FCS. The cells were counted and 2x106 were 
seeded in 75 cm2 tissue culture flask (Corning, USA), with 10 ml of DMEM, 5% FCS. 
The cells were grown for 3 days in a CO2-controlled incubator at 37°C, before 
passaging. The preparation of primary cells of from embryonated eggs complied with 
animal ethics regulations (animal ethics number 010/012).  
 
5.2.4 Transfection and cell harvesting 
Cells were seeded in 6-well plates in a total volume of 2 ml DMEM, 10% FCS in 
order to obtain 70-90% confluency in 24 hours. Fugene® 6 transfection reagent 
(Roche, USA) was used in initial transfection experiments, using the manufacturer’s 
protocol. Thereafter, cells were transfected with ExtremeGene HP transfection 
reagent (Roche, USA), using the manufacturer’s quick protocol, with a ratio of 3 µl 
reagent to 1µg pTH plasmid DNA. For negative controls, the DNA was replaced with 
sterile water. All transfections were performed in duplicate. As a positive control, the 
reporter construct pLuc-SV40 (luciferase gene under the control of SV40 promoter) 
was transfected separately, using 3 µl of transfection reagent and 50 ng plasmid 
DNA per well. Cells were incubated for 72 hours before harvesting. Cells were 
dislodged from the wells by washing with PBS, and pelleted by centrifugation. The 
cells were resuspended in 1 x Glo Lysis buffer (Promega, USA) supplemented with 
EDTA-free protease inhibitor (Roche). These samples were then prepared directly 
for SDS-PAGE by the addition of SDS loading buffer. 
 
5.2.5 SDS-PAGE and immunoblotting 
SDS-PAGE and immunoblots were done as described in 2.2.9. Note that all the 















The insertion of ΔN40 CP into expression vector pTH was confirmed by restriction 




Figure 38: Restriction enzyme digests of pTH-ΔN40 CP to confirm insert and plasmid 
integrity  
1: undigested pTH DNA, 2: NcoI digest, excising insert of approximately 1.3 kbp (indicated by the 
arrow), 3: XhoI digest, generating linearised vector of approximately 6 kbp. 
 
HEK293T cells were transf cted with pTH-ΔN40 CP and whole cell lysates were 
subjected to anti-6xHis immunoblot analysis (Figure 39). Optimisation of transfection 
was performed by varying the transfection reagent (Fugene™ 6, Roche, USA) to 
DNA ratio. Ratios of Fugene® (µl) to DNA (µg) of 3:1 and 3:2 did not yield detectable 
expression of CP. There was no detectable expression of CP after 24 or 48 hours 
(data not shown).  Only with a 6:1 ratio and 72 hours incubation was CP expression 
detected (Figure 39, lane 3). For negative controls, the cells were transfected with a 
mixture that had sterile water added instead of DNA. The transfection was repeated 
with X-tremeGene HP tranfection reagent (Roche) using a 3:1 reagent to DNA ratio, 
as recommended by the manufacturer. In this case, expression was detected after 5 
days incubation (Figure 40, lanes 3 and 4). 
 



















Figure 39: Optimisation of transfection in HEK293T cells 
Anti-His immunoblot analysis of 72 hours after transfection of HEK293T cells with Fugene® 6 
transfection reagent using different ratios of transfection reagent (µl) to DNA (µg). 1: 3:1 ratio, 2: 3.2 
ratio, 3: 6:1 ratio, 4: negative control. The ΔN40 CP band is indicated by the arrow (25 kDa). 
 
 
Figure 40: HEK293T cells 5 days post-transfection 
Anti-His Immunoblot analysis of HEK293T cells transfected with with X-tremeGENE HP transfection 
reagent. The transfections were performed in duplicate. Whole cell lysates were analysed five days 
post-transfection, 1 and 2: negative controls, 3 and 4: transfected cells. The ΔN40 CP band is 
indicated by the arrow (25 kDa). 
 
The prepared CEF cells were seeded for transfection after no more than two 
passages. Based on the previous work in HEK293T cells, the CEF cells were 
transfected with a 3:1 ratio of X-tremeGENE HP reagent to pTH-ΔN40 CP plasmid 
DNA. Additional cells were transfected separately with the reporter construct pLuc-
SV40 using 3 µl of transfection reagent and 50 ng plasmid DNA per well. This was 
done in order to measure the efficiency of the transfection procedure and the 
capacity of the prepared CEF cells for protein expression. High luciferase readings 
were obtained at 3 days post-transfection (data not shown). 
The expression of ΔN40 CP in transfected CEF cells was detected by anti-His 
immunoblot of whole cell lysates after 4 days incubation (Figure 41, lanes 3 and 4). 
Soluble proteins in cell lysates taken three days post transfection did not contain any 
detectable ΔN40 CP (Figure 41, lanes 1 and 2), suggesting that the expressed ΔN40 
CP was insoluble. The transfection was repeated and only whole cell lysates were 
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Expression of ΔN40 CP was detected in CEF whole cell lysate at two days post 
transfection (Figure 42, lanes 1 and 2). After five days post transfection, the cell layer 
had begun to detach from the culture plate. Cells harvested five days after 




Figure 41: Transfection of CEF cells 
Anti-His immunoblot analysis of transfection of CEF cells. M: molecular weight marker, 1 and 2: 
soluble proteins in cell lysate 3 days post-transection, 3 and 4: whole cells 4 days post-transfection, 5: 
negative control, 6: positive control (ΔN40 CP expressed in E. coli). The ΔN40 CP band is indicated 
by the arrow (25 kDa). 
 
 
Figure 42: Repeat transfection of CEF cells 
Anti-His immunoblot analysis of transfection of CEF cells. M: molecular weight marker, 1 and 2: whole 
cells 2 days post-transfection, 3 and 4: whole cells 5 days post transfection, 5: negative control, 6: 
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DNA vaccines expressing the coat protein of PCV-2 have been shown to be 
immunogenic in mice (Shen et al., 2008; Fu et al., 2011). The capsid protein is the 
major antigenic determinant of PCV-2 and BFDV. Therefore DNA vaccines 
expressing CP should be promising vaccine candidates for BFDV as well. In one 
study of PCV-2 vaccination, DNA vaccination yielded comparable humoral 
responses to recombinant subunit CP vaccination, but the DNA vaccine generated a 
superior CD8 T+ cell response (Shen et al., 2008). There are currently no published 
reports of DNA vaccination for BFDV. The success of PCV-2 DNA vaccines 
suggests that this may be a viable vaccination strategy for BFDV. 
Transfection of cells in vitro with candidate DNA vaccines is done to confirm the 
expression of the antigen. Truncated BFDV CP is expressed as an N-terminal His-
tag fusion. The human embryonic kidney cell line HEK293T was transfected with the 
candidate BFDV DNA vaccine pTH-ΔN40 CP, and ΔN40 CP was detected by anti-
His immunoblot after 72 hours. As there is no cell culture system for psitaccine 
species, chicken embryonic fibroblasts (CEF) were also used for confirmation of CP 
expression, as these are more closely related to cells naturally infected by BFDV. 
The CEF cells were prepared from chicken embryos by trypsin treatment of the 
embryo surface. Therefore a mixture of dermal cells and fibroblasts may have been 
isolated, as there was no selection applied for either cell type. The fibroblasts have a 
typical elongated and branching morphology. After successive passages, cells with  
this type of morphology predominated, suggesting that the culture conditions 
favoured the proliferation of the fibroblasts. 
Resuspended whole cells were loaded directly (with the addition of SDS sample 
buffer) for SDS-PAGE followed by anti-His immunoblots, because no protein was 
detected in the soluble part of the lysate at three days post-transfection when the 
lysate was cleared by centrifugation (Figure 41). This suggests that the majority of 
the expressed ΔN40 CP was insoluble. The expression of full-length BFDV CP in 
insect cells also yielded protein that was mostly insoluble, with most of the CP 
detected in the cell pellet after lysis (Stewart et al., 2007). ΔN40 CP was detected 













protein was detected after 5 days, but this is probably due to most of the cells having 
died and detached from the wells. ΔN40 CP was detected in HEK cells after 5 days 
when the viable cell monolayer was still present. Anti-ΔN40 CP serum was used to 
probe for the expressed protein, but due to high background and the low level of 
ΔN40 CP as determined by anti-His immunoblots, the ΔN40 CP band could not be 
identified (data not shown).  
DNA vaccines can be manufactured on a large scale, and the simplicity of plasmid 
purification reduces the cost of downstream processing.  Immune responses elicited 
by DNA vaccines may be ‘boosted’ by subsequent inoculation with a subunit or virus-
like particle vaccines (Doria-Rose, 2003). This has been shown to elicit broader 
neutralising antibody responses in the case of H5N1 influenza (Lin et al., 2012). The 
BFDV ΔN40 CP DNA vaccine described here could be used in such a ‘prime-boost’ 
regimen in conjunction with a BFDV CP subunit vaccine r VLP vaccine. Plant-
produced BFDV CP, or one of the CP-ELP vaccine candidates described in Chapter 
3, could be used as a subunit vaccine. The cost of a DNA vaccine with a plant-













Chapter 6: Conclusions 
 
The aim of the project was to produce potential vaccine candidates against BFDV. 
Three strategies were employed: Expression truncated CP (ΔN40 CP) in E. coli, 
expression of CP and ΔN40 CP in plants as ELP fusions, and a DNA vaccine 
expressing ΔN40 CP. The  truncated CP (ΔN40 CP), formed by removal of the first 
40 N-terminal amino acids, was used in all of these strategies because of its 
expected high yield relative to the full-length CP, based on previous work done in our 
laboratory.  
ΔN40 CP was produced in bacteria with or without an ELP tag, but these proteins 
were mostly insoluble. ΔN40 CP and ΔN40 CP-ELP51 inclusion body proteins were 
partially purified by successive washes and injected into rabbits for polyclonal 
antibody production. The ΔN40 CP-ELP51 antigen sample in particular contained 
relatively few impurities, as assessed by SDS-PAGE and Coomassie staining 
(Figure 12). Additional ΔN40 CP-ELP51 prepared in this way could potentially be 
used in animal trials to evaluate whether it could produce an immune response 
against BFDV. The rabbit sera could recognise BFDV CP proteins produced in 
bacteria and plants, indicating a targeted immune response against ΔN40 CP.  
The expression of BFDV CP was optimised in tobacco by using different expression 
vectors, pTRAkc-ERH and pEAQ-HT. The pEAQ-HT expression vector was mainly 
used to transiently express BFDV CP or ΔN40 CP, and their respective ELP fusions, 
in tobacco plants because of the convenience of single-culture infiltration and the 
large increase in yield using this vector system. Next, fusion to ELP of 28 or 51 
repeats was investigated to increase the yield of BFDV CP and ΔN40 CP. Fusion to 
either ELP increased the yield of BFDV CP and ΔN40 CP proteins by a minimum of 
threefold, and non-fused BFDV CP/ ΔN40 CP had a characteristically lower yield. 
Targeting accumulation of CP-ELP fusions to the ER also increased the stability of 
the fusion proteins, especially the truncated BFDV CP fusions. Expression was rapid 
and high levels of protein were observed 2 days post-infiltration. The yield of ΔN40 














Purification of GFP-ELP51 expressed in plants showed that the ELP fusion strategy 
could be used to successfully purify ELP51 fusion proteins. ΔN40 CP-ELP51 
produced in bacteria was first used to characterise the conditions necessary for 
ΔN40 CP-ELP51 purification from plants. However, ITC of ΔN40 CP-ELP51 
produced in bacteria resulted in irreversible aggregation. Nevertheless, the resulting 
insoluble ΔN40 CP-ELP51 was purified to a high degree with one cycle and was 
concentrated despite low levels in the soluble cell lysate. The resulting insoluble and 
purified ΔN40 CP-ELP51 antigen could be used as a vaccine candidate, following 
endotoxin removal. Future work involving the vaccination of animals with this antigen 
in its insoluble form could evaluate its immunogenicity. 
Inverse transition cycling was used in attempts to purify the ΔN40 CP-ELP51 
produced in plants. This protein had the highest yield of all the BFDV CP fusions and 
therefore was the best candidate for ITC, as purification efficiency increases with 
increasing ELP concentration. As with the bacterial-expressed protein, irreversible 
aggregation was observed. An alternate method of ITC using membrane filtration 
was used to mitigate the irreversible aggregation. This method allowed concentration 
and partial purification of ΔN40 CP-ELP51, but with significant protein losses in the 
filtrate, probably due to incomplete aggregation. Free ELP51 was produced in 
bacteria and plants and both of these proteins could be purified by ITC. These were 
added to ΔN40 CP-ELP51 crude extract to act as a co-aggregate during purification. 
The results showed that the free ELP51 could be recovered, but the ΔN40 CP-
ELP51 still aggregated irreversibly. However, the free ELP51 was able to increase 
the aggregation efficie cy of ΔN40 CP-ELP51, which was especially useful for mITC 
purification. 
Future work could involve the optimisation of ELP length and guest residue 
composition (any amino acid ‘X’ in the VPGXG repeating sequence of the ELP) in 
order to prevent the irreversible of aggregation of ΔN40 CP-ELP during purification. 
Designing an ELP fusion with a lower transition temperature reduces the 
temperature required for purification. This could be useful if ΔN40 CP-ELP is 
thermally unstable. It has been reported that longer ELP tags increase the recovery 
of ELP fusion after purification, although this may compromise the yield of the fusion 













A candidate DNA vaccine, pTH-ΔN40 CP, was evaluated for its capacity to induce 
BFDV ΔN40 CP expression in transfected cells. A human CMV promoter is used to 
drive expression of the protein. HEK293T cells were transfected with pTH-ΔN40 CP 
and protein expression was detected by anti-His immunoblot after 72 hours. Chicken 
embryonic fibroblast cells were prepared to serve as model avian cells, which are 
more closely related to psittacine cells than HEK293T. These cells were transfected 
and protein expression was similarly detected after 2-4 days. The expression of 
BFDV CP in vitro by this DNA vaccine approves it for future vaccination studies. This 
DNA vaccine may be used in a ‘prime-boost’ regimen together with a BFDV CP 
subunit or VLP vaccine. If the subunit vaccine could be produced in plants, such as 
ΔN40 CP-ELP51 expressed in tobacco, the combination of this DNA vaccine and 
subunit vaccine boost would be highly affordable. 
Production of BFDV CP in bacteria can give higher yields f the protein, but rare 
codons in the coding DNA sequence requires truncation of the gene or the use of 
special strains that co-express eukaryotic-type tRNAs. The BFDV Δ40 CP expressed 
in bacteria were mostly insoluble, the purification of which would require time-
consuming denaturation and refolding steps. Recombinant expression of BFDV CP 
has yielded lower levels of protein in eukaryotic systems such as insect cells (Heath 
et al., 2006; Stewart et al., 2007). However, these are most likely to produce proteins 
with the correct post-translational modifications. BFDV CP was transiently expressed 
in plants, although the yields were low. The yield was significantly increased by 
fusion to elastin-like polypeptide. The production of BFDV CP fused to ELP in plants 
is a viable method of antigen production, due to the large increase in yield. The use 
of ITC is an economical and scalable first step in the purification of CP-ELP. Based 
on the results, mITC with added free ELP51 as a co-aggregate is the purification 
method giving the highest recovery of ΔN40 CP-ELP51. Future work on purification 
of CP-ELP fusions should focus on up-scaling this membrane filtration protocol. For 
animal studies, the protein may need to be purified further by immobilized metal 
affinity chromatography (IMAC), by making use of the His tag on the ELP. Removal 
of the ELP from BFDV CP may not be necessary, as there is evidence of ELP having 
no immune-modulating effects (Floss et al., 2010a). The production of BFDV CP in 
plants as an ELP fusion therefore has great promise for the development of an 















Alexandrova, R., Eweida, M., Georges, F., Dragulev, B., Abouhaidar, M.G. & Ivanov, 
I. (1995). Domains in human interferon alpha-1 gene containing tandems of 
arginine codons AGG play the role of translational initiators in E. coli. The 
International Journal of Biochemistry & Cell Biology. 27 (5), 469–473. 
Altunbas, A. & Pochan, D.J. (2012). Peptide-based and polypeptide-based hydrogels 
for drug delivery and tissue engineering. In: T. Deming (ed.). Topics in Current 
Chemistry. Springer, 135–167. 
Aravindaram, K., Kuo, T.-Y., Lan, C., Yu, H., Wang, P., Chen, Y.-S., Chen, G.H. & 
Yang, N.-S. (2009). Protective immunity against porcine circovirus 2 in mice 
induced by a gene-based combination vaccination. The Journal of Gene 
Medicine. 11 (4), 288–301. 
Arnau, J., Lauritzen, C., Petersen, G.E. & Pedersen, J. (2006). Current strategies for 
the use of affinity tags and tag removal for the purification of recombinant 
proteins. Protein Expression and Purification. 48 (1), 1–13. 
Balasubramaniam, D., Wilkinson, C., Van Cott, K. & Zhang, C. (2003). Tobacco 
protein separation by aqueous two-phase extraction. Journal of 
Chromatography A. 989 (1), 119–129. 
Benchabane, M., Goulet, C., Rivard, D., Faye, L., Gomord, V. & Michaud, D. (2008). 
Preventing unintended proteolysis in plant protein biofactories. Plant 
Biotechnology Journal. 6 (7), 633–648. 
Bhatla, S.C., Kaushik, V. & Yadav, M.K. (2010). Use of oil bodies and oleosins in 
recombinant protein production and other biotechnological applications. 
Biotechnology Advances. 28 (3), 293–300. 
Bonne, N., Shearer, P., Sharp, M., Clark, P. & Raidal, S. (2009). Assessment of 
recombinant beak and feather disease virus capsid protein as a vaccine for 
psittacine beak and feather disease. Journal of General Virology. 90 (3), 640–
647. 
Borisjuk, N. V, Borisjuk, L.G., Logendra, S., Petersen, F., Gleba, Y. & Raskin, I. 
(1999). Production of recombinant proteins in plant root exudates. Nature 
Biotechnology. 17 (5), 466–469. 
Chaudhary, S., Parmenter, D.L. & Moloney, M.M. (1998). Transgenic Brassica 
carinata as a vehicle for the production of recombinant proteins in seeds. Plant 













Chen, D., Duggan, C., Texada, D.E., Reden, T.B., Kooragayala, L.M. & Langford, 
M.P. (2005). Immunogenicity of enterovirus 70 capsid protein VP1 and its non-
overlapping N- and C-terminal fragments. Antiviral Research. 66 (2-3), 111–117. 
Christensen, T., Trabbic-Carlson, K., Liu, W. & Chilkoti, A. (2007). Purification of 
recombinant proteins from Escherichia coli at low expression levels by inverse 
transition cycling. Analytical Biochemistry. 360 (1), 166–168. 
Coleman, C.E., Herman, E.M., Takasaki, K. & Larkins, B.A. (1996). The maize 
gamma-zein sequesters alpha-zein and stabilizes its accumulation in protein 
bodies of transgenic tobacco endosperm. The Plant Cell. 8 (12), 2335–2345. 
Conley, A.J., Joensuu, J.J., Jevnikar, A.M., Menassa, R. & Brandle, J.E. (2009a). 
Optimization of elastin-like polypeptide fusions for expression and purification of 
recombinant proteins in plants. Biotechnology and Bioengineering. 103 (3), 562–
573. 
Conley, A.J., Joensuu, J.J., Menassa, R. & Brandle, J.E. (2009b). Induction of 
protein body formation in plant leaves by elastin-like polypeptide fusions. BMC 
Biology. 7 (48). 
Conley, A.J., Joensuu, J.J., Richman, A. & Menassa, R. (2011). Protein body-
inducing fusions for high-level production and purification of recombinant 
proteins in plants. Plant Biotechnology Journ l. 9 (4), 1–11. 
Debelle, L. & Tamburro, A.M. (1999). Elastin: molecular description and function. 
The International Journal of Biochemistry & Cell Biology. 31 (2), 261–272. 
Doria-Rose, N. (2003). DNA vaccine strategies: candidates for immune modulation 
and immunization regimens. Methods. 31 (3), 207–216. 
Van Drunen Littel-van den Hurk, S. & Hannaman, D. (2010). Electroporation for DNA 
immunization: clinical application. Expert Review of Vaccines. 9 (5), 503–517. 
Dufourmantel, N., Pelissier, B., Garçon, F., Peltier, G., Ferullo, J.-M. & Tissot, G. 
(2004). Generation of fertile transplastomic soybean. Plant Molecular Biology. 
55 (4), 479–489. 
El-Attar, L., Oliver, S.L., Mackie, A., Charpilienne, A., Poncet, D., Cohen, J. & 
Bridger, J.C. (2009). Comparison of the efficacy of rotavirus VLP vaccines to a 
live homologous rotavirus vaccine in a pig model of rotavirus disease. Vaccine. 
27 (24), 3201–3208. 
Evangelista, R., Kusnadi, A., Howard, J. & Nikolov, Z. (1998). Process and economic 
evaluation of the extraction and purification of recombinant beta-glucuronidase 
from transgenic corn. Biotechnology Progress. 14 (4), 607–614. 
Fan, H., Xiao, S., Tong, T., Wang, S., Xie, L., Jiang, Y., Chen, H. & Fang, L. (2008). 
Immunogenicity of porcine circovirus type 2 capsid protein targeting to different 













Farinas, C.S., Leite, A. & Miranda, E.A. (2005). Aqueous extraction of maize 
endosperm: Insights for recombinant protein hosts based on downstream 
processing. Process Biochemistry. 40 (10), 3327–3336. 
Finsterbusch, T. & Mankertz, A. (2009). Porcine circoviruses--small but powerful. 
Virus Research. 143 (2), 177–183. 
Fischer, R. & Emans, N. (2000). Molecular farming of pharmaceutical proteins. 
Transgenic Research. 9 (4-5), 279–299. 
Floss, D.M., Mockey, M., Zanello, G., Brosson, D., Diogon, M., Frutos, R., Bruel, T., 
Rodrigues, V., Garzon, E., Chevaleyre, C., Berri, M., Salmon, H., Conrad, U. & 
Dedieu, L. (2010a). Expression and immunogenicity of the mycobacterial 
Ag85B/ESAT-6 antigens produced in transgenic plants by elastin-like peptide 
fusion strategy. Journal of Biomedicine & Biotechnology, doi: 
10.1155/2010/274346. 
Floss, D.M., Sack, M., Stadlmann, J., Rademacher, T., Scheller, J., Stöger, E., 
Fischer, R. & Conrad, U. (2008a). Biochemical and functional characterization of 
anti-HIV antibody-ELP fusion proteins from transgenic plants. Plant 
biotechnology journal. 6 (4), 379–391. 
Floss, D.M., Sack, M., Stadlmann, J., Rademacher, T., Scheller, J., Stöger, E., 
Fischer, R. & Conrad, U. (2008b). Biochemic l and functional characterization of 
anti-HIV antibody-ELP fusion proteins from transgenic plants. Plant 
Biotechnology Journal. 6 (4), 379–391. 
Floss, D.M., Schallau, K., Rose-John, S., Conrad, U. & Scheller, J. (2010b). Elastin-
like polypeptides revolutionize recombinant protein expression and their 
biomedical application. Trends in Biotechnology. 28 (1), 37–45. 
Fong, B.A., Wu, W. & Wood, D.W. (2009). Optimization of ELP-intein mediated 
protein purification by salt substitution. Protein Expression and Purification. 66 
(2), 198–202. 
Frankel, S., Sohn, R. & Leinwand, L. (1991). The use of sarkosyl in generating 
soluble protein after bacterial expression. Proceedings of the National Academy 
of Sciences of the United States of America. 88 (4), 1192–1196. 
Fu, F., Li, X., Lang, Y., Yang, Y., Tong, G., Li, G., Zhou, Y. & Li, X. (2011). Co-
expression of ubiquitin gene and capsid protein gene enhances the potency of 
DNA immunization of PCV2 in mice. Virology Journal. 8 (264). 
García-Fruitós, E., Vázquez, E., Díez-Gil, C., Corchero, J.L., Seras-Franzoso, J., 
Ratera, I., Veciana, J. & Villaverde, A. (2012). Bacterial inclusion bodies: making 
gold from waste. Trends in Biotechnology. 30 (2), 1–6. 
Ge, X. & Filipe, C.D.M. (2006). Simultaneous phase transition of ELP tagged 
molecules and free ELP: an efficient and reversible capture system. 













Ge, X., Trabbic-Carlson, K., Chilkoti, A. & Filipe, C.D.M. (2006). Purification of an 
elastin-like fusion protein by microfiltration. Biotechnology and Bioengineering. 
95 (3), 424–432. 
Gelvin, S.B. (2003). Agrobacterium-mediated plant transformation: the biology 
behind the “gene-jockeying” tool. Microbiology and Molecular Biology Reviews. 
67 (1), 16–37. 
Grebenok, R.J., Pierson, E., Lambert, G.M., Gong, F.C., Afonso, C.L., Haldeman-
Cahill, R., Carrington, J.C. & Galbraith, D.W. (1997). Green-fluorescent protein 
fusions for efficient characterization of nuclear targeting. The Plant Journal. 11 
(3), 573–586. 
Hanke, T., Schneider, J., Gilbert, S.C., Hill, A. V & McMichael, A. (1998). DNA multi-
CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in 
mice. Vaccine. 16 (4), 426–435. 
Harper, B.K., Mabon, S.A., Leffel, S.M., Halfhill, M.D., Richards, H.A., Moyer, K.A. & 
Stewart, C.N. (1999). Green fluorescent protein as a marker for expression of a 
second gene in transgenic plants. Nature Biotechnology. 17 (11), 1125–1129. 
Hassouneh, W., Fischer, K., MacEwan, S.R., Branscheid, R., Fu, C.L., Liu, R., 
Schmidt, M. & Chilkoti, A. (2012). Unexpected multivalent display of proteins by 
temperature triggered self-assembly of elastin-like polypeptide block 
copolymers. Biomacromolecules. 13 (5), 1598–1605. 
Heath, L., Williamson, A.-L. & Rybicki, E.P. (2006). The capsid protein of beak and 
feather disease virus binds to the viral DNA and is responsible for transporting 
the replication-associated protein into the nucleus. Journal of Virology. 80 (14), 
7219–7225. 
Hitzeroth, I.I., Passmore, J.S., Shephard, E., Stewart, D., Müller, M., Williamson, A., 
Rybicki, E.P. & Kast, W.M. (2009). Immunogenicity of an HPV-16 L2 DNA 
vaccine. Vaccine. 27 (46), 6432–6434. 
ICTV (2005). Circoviridae. In: C. M. Fauquet, M. A. Mayo, J. Maniloff, U. 
Desselberger, & L. A. Ball (eds.). Virus Taxonomy: Eighth Report of the 
International Committee on Taxonomy of Viruses. Elsevier Inc., 327–334. 
ICTV (2011). Virus Taxonomy: 2011 Release (current). [Online]. 2011. International 
Committee on Taxonomy of Viruses. Available from: 
http://www.ictvonline.org/virusTaxonomy.asp. [Accessed: 30 August 2012]. 
Jacobson, E.R., Clubb, S., Simpson, C., Walsh, M., Lothrop, C.D., Gaskin, J., Bauer, 
J., Hines, S., Kollias, G. V & Poulos, P. (1986). Feather and beak dystrophy and 
necrosis in cockatoos: clinicopathologic evaluations. Journal of the American 













Joensuu, J.J., Conley, A.J., Lienemann, M., Brandle, J.E., Linder, M.B. & Menassa, 
R. (2010). Hydrophobin fusions for high-level transient protein expression and 
purification in Nicotiana benthamiana. Plant Physiology. 152 (2), 622–633. 
Johne, R., Raue, R., Grund, C., Kaleta, E.F. & Müller, H. (2004). Recombinant 
expression of a truncated capsid protein of beak and feather disease virus and 
its application in serological tests. Avian Pathology. 33 (3), 328–336. 
Karg, S.R. & Kallio, P.T. (2009). The production of biopharmaceuticals in plant 
systems. Biotechnology Advances. 27 (6), 894–897. 
Khalesi, B., Bonne, N., Stewart, M., Sharp, M. & Raidal, S. (2005). A comparison of 
haemagglutination, haemagglutination inhibition and PCR for the detection of 
psittacine beak and feather disease virus infection and a comparison of isolates 
obtained from loriids. The Journal of General Virology. 86 (11), 3039–3046. 
Kim, J.-Y., Mulchandani, A. & Chen, W. (2005). Temperature-triggered purification of 
antibodies. Biotechnology and Bioengineering. 90 (3), 373–379. 
De Kloet, E. & De Kloet, S.R. (2004). Analysis of the beak and feather disease viral 
genome indicates the existence of several genotypes which have a complex 
psittacine host specificity. Archives of Virology. 149 (12), 2393–2412. 
Kogan, M.J., Dalcol, I., Gorostiza, P., Lopez-Iglesias, C., Pons, R., Pons, M., Sanz, 
F. & Giralt, E. (2002). Supramolecular properties of the proline-rich gamma-Zein 
N-terminal domain. Biophysical Journal. 83 (2), 1194–1204. 
Kusnadi, A.R., Nikolov, Z.L. & Howard, J.A. (1997). Production of recombinant 
proteins in transgenic plants: Practical considerations. Biotechnology and 
Bioengineering. 56 (5), 473–484. 
Lakatos, L., Szittya, G., Silhavy, D. & Burgyán, J. (2004). Molecular mechanism of 
RNA silencing suppression mediated by p19 protein of tombusviruses. The 
EMBO Journal. 23 (4), 876–884. 
Lan, D., Huang, G., Shao, H., Zhang, L., Ma, L., Chen, S. & Xu, A. (2011). An 
improved nonchromatographic method for the purification of recombinant 
proteins using elastin-like polypeptide-tagged proteases. Analytical 
Biochemistry. 415 (2), 200–202. 
Latimer, K.S., Rakich, P.M., Kircher, I.M., Ritchie, B.W., Niagro, F.D., Steffens, W.L. 
& Lukert, P.D. (1990). Extracutaneous Viral Inclusions in Psittacine Beak and 
Feather Disease. Journal of Veterinary Diagnostic Investigation. 2 (3), 204–207. 
Latimer, K.S., Rakich, P.M., Steffens, W.L., Kircher, I.M., Ritchie, B.W., Niagro, F.D. 
& Lukert, P.D. (1991). A Novel DNA Virus Associated with Feather Inclusions in 
Psittacine Beak and Feather Disease. Veterinary Pathology. 28 (4), 300–304. 
Li, B., Alonso, D.O. & Daggett, V. (2001). The molecular basis for the inverse 













Lin, S.-C., Lin, Y.-F., Chong, P. & Wu, S.-C. (2012). Broader Neutralizing Antibodies 
against H5N1 Viruses Using Prime-Boost Immunization of Hyperglycosylated 
Hemagglutinin DNA and Virus-Like Particles. PloS One. 7 (6), e39075. 
Liu, F., Ge, S., Li, L., Wu, X., Liu, Z. & Wang, Z. (2012a). Virus-like particles: 
potential veterinary vaccine immunogens. Research in Veterinary Science. 93 
(2), 553–559. 
Liu, F., Tsai, S.-L., Madan, B. & Chen, W. (2012b). Engineering a high-affinity 
scaffold for non-chromatographic protein purification via intein-mediated 
cleavage. Biotechnology and bioengineering, doi: 10.1002/bit.24545. 
Lowe, B.A., Shiva Prakash, N., Way, M., Mann, M.T., Spencer, T.M. & Boddupalli, 
R.S. (2009). Enhanced single copy integration events in corn via particle 
bombardment using low quantities of DNA. Transgenic Research. 18 (6), 831–
840. 
Lunn, J.E. (2007). Compartmentation in plant metabolism. Journal of Experimental 
Botany. 58 (1), 35–47. 
Lössl, A.G. & Waheed, M.T. (2011). Chloroplast-derived vaccines against human 
diseases: achievements, challenges and scopes. Plant Biotechnology Journal. 9 
(5), 527–539. 
Ma, J.K.-C., Drake, P.M.W. & Christou, P. (2003). The production of recombinant 
pharmaceutical proteins in plants. Nature Reviews Genetics. 4 (10), 794–805. 
MacEwan, S.R. & Chilkoti, A. (2010). Elastin-like polypeptides: biomedical 
applications of tunable biopolymers. Biopolymers. 94 (1), 60–77. 
Maclean, J., Koekemoer, M., Olivier, a J., Stewart, D., Hitzeroth, I.I., Rademacher, 
T., Fischer, R., Williamson, A.-L. & Rybicki, E.P. (2007). Optimization of human 
papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the 
suitability of different HPV-16 L1 gene variants and different cell-compartment 
localization. The Journal of General Virology. 88 (5), 1460–1469. 
Mahé, D., Blanchard, P., Truong, C., Arnauld, C., Le Cann, P., Cariolet, R., Madec, 
F., Albina, E. & Jestin, A. (2000). Differential recognition of ORF2 protein from 
type 1 and type 2 porcine circoviruses and identification of immunorelevant 
epitopes. The Journal of General Virology. 81 (Pt 7), 1815–1824. 
Mainieri, D., Rossi, M., Archinti, M., Bellucci, M., De Marchis, F., Vavassori, S., 
Pompa, A., Arcioni, S. & Vitale, A. (2004). Zeolin. A new recombinant storage 
protein constructed using maize gamma-zein and bean phaseolin. Plant 
Physiology. 136 (3), 3447–3456. 
Marcekova, Z., Psikal, I., Kosinova, E., Benada, O., Sebo, P. & Bumba, L. (2009). 
Heterologous expression of full-length capsid protein of porcine circovirus 2 in 
Escherichia coli and its potential use for detection of antibodies. Journal of 













De Marco, A., Vigh, L., Diamant, S. & Goloubinoff, P. (2005). Native folding of 
aggregation-prone recombinant proteins in Escherichia coli by osmolytes, 
plasmid- or benzyl alcohol-overexpressed molecular chaperones. Cell stress & 
Chaperones. 10 (4), 329–339. 
Marillonnet, S., Thoeringer, C., Kandzia, R., Klimyuk, V. & Gleba, Y. (2005). 
Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for 
efficient transient expression in plants. Nature Biotechnology. 23 (6), 718–723. 
Matić, S., Masenga, V., Poli, A., Rinaldi, R., Milne, R.G., Vecchiati, M. & Noris, E. 
(2012). Comparative analysis of recombinant Human Papillomavirus 8 L1 
production in plants by a variety of expression systems and purification 
methods. Plant Biotechnology Journal. 10 (4), 410–412. 
McDaniel, J.R., Macewan, S.R., Dewhirst, M. & Chilkoti, A. (2012). Doxorubicin-
conjugated chimeric polypeptide nanoparticles that respond to mild 
hyperthermia. Journal of Controlled Release. 159 (3), 362–367. 
McPherson, D.T., Xu, J. & Urry, D.W. (1996). Product purification by reversible 
phase transition following Escherichia coli expression of genes encoding up to 
251 repeats of the elastomeric pentapeptide GVGVP. Protein Expression and 
Purification. 7 (1), 51–57. 
Menkhaus, T.J., Bai, Y., Zhang, C., Nikolov, Z.L. & Glatz, C.E. (2004). 
Considerations for the recovery of recombinant proteins from plants. 
Biotechnology Progress. 20 (4), 1001–1014. 
Meyer, D.E. & Chilkoti, A. (2002a). Genetically encoded synthesis of protein-based 
polymers with precisely specified molecular weight and sequence by recursive 
directional ligation: examples from the elastin-like polypeptide system. 
Biomacromolecules. 3 (2), 357–367. 
Meyer, D.E. & Chilkoti, A. (2002b). Protein Purification by Inverse Transition Cycling. 
In: E. A. Golemis (ed.). Protein-Protein Interactions: A Molecular Cloning 
Manual. New York: Cold Spring Harbor Laboratory Press, 329–344. 
Meyer, D.E. & Chilkoti, A. (1999). Purification of recombinant proteins by fusion with 
thermally-responsive polypeptides. Nature Biotechnology. 17 (11), 1112–1115. 
Meyer, D.E., Trabbic-Carlson, K. & Chilkoti, A. (2001). Protein purification by fusion 
with an environmentally responsive elastin-like polypeptide: effect of polypeptide 
length on the purification of thioredoxin. Biotechnology Progress. 17 (4), 720–
728. 
Mie, M., Mizushima, Y. & Kobatake, E. (2008). Novel extracellular matrix for cell 
sheet recovery using genetically engineered elastin-like protein. Journal of 













Misinzo, G., Delputte, P.L. & Nauwynck, H.J. (2008). Inhibition of endosome-
lysosome system acidification enhances porcine circovirus 2 infection of porcine 
epithelial cells. Journal of Virology. 82 (3), 1128–1135. 
Mushegian, A.R. & Shepherd, R.J. (1995). Genetic elements of plant viruses as tools 
for genetic engineering. Microbiological Reviews. 59 (4), 548–578. 
Mustalahti, E., Saloheimo, M. & Joensuu, J.J. (2011). Intracellular protein production 
in Trichoderma reesei (Hypocrea jecorina) with hydrophobin fusion technology. 
New Biotechnology, doi: 10.1016/j.nbt.2011.09.006. 
Nauwynck, H.J., Sanchez, R., Meerts, P., Lefebvre, D.J., Saha, D., Huang, L. & 
Misinzo, G. (2012). Cell tropism and entry of porcine circovirus 2. Virus 
Research. 164 (1-2), 43–45. 
Nilsson, J., Ståhl, S., Lundeberg, J., Uhlén, M. & Nygren, P.A. (1997). Affinity fusion 
strategies for detection, purification, and immobilization of recombinant proteins. 
Protein Expression and Purification. 11 (1), 1–16. 
Nykiforuk, C.L., Boothe, J.G., Murray, E.W., Keon, R.G., Goren, H.J., Markley, N.A. 
& Moloney, M.M. (2006). Transgenic expression and recovery of biologically 
active recombinant human insulin from Arabidopsis thaliana seeds. Plant 
Biotechnology Journal. 4 (1), 77–85. 
Pass, D.A. & Perry, R.A. (1984). The pathology of psittacine beak and feather 
disease. Australian veterinary journal. 61 (3), 69–74. 
Patel, J., Zhu, H., Menassa, R., Gyenis, L., Richman, A. & Brandle, J. (2007). 
Elastin-like polypeptide fusions enhance the accumulation of recombinant 
proteins in tobacco leaves. Transgenic Research. 16 (2), 239–249. 
Paul, M. & Ma, J.K.-C. (2011). Plant-made pharmaceuticals: leading products and 
production platforms. Biotechnology and Applied Biochemistry. 58 (1), 58–67. 
Phan, H.T. & Conrad, U. (2011). Membrane-based inverse transition cycling: an 
improved means for purifying plant-derived recombinant protein-elastin-like 
polypeptide fusions. International Journal of Molecular Sciences. 12 (5), 2808–
2821. 
Platis, D., Drossard, J., Fischer, R., Ma, J.K.-C. & Labrou, N.E. (2008). New 
downstream processing strategy for the purification of monoclonal antibodies 
from transgenic tobacco plants. Journal of Chromatography A. 1211 (1-2), 80–
89. 
Platis, D. & Labrou, N.E. (2006). Development of an aqueous two-phase partitioning 
system for fractionating therapeutic proteins from tobacco extract. Journal of 
Chromatography A. 1128 (1-2), 114–124. 
Raidal, S.R. & Cross, G.M. (1994). The haemagglutination spectrum of psittacine 













Reddy, M.S.S., Dinkins, R.D. & Collins, G.B. (2003). Gene silencing in transgenic 
soybean plants transformed via particle bombardment. Plant Cell Reports. 21 
(7), 676–683. 
Regnard, G.L., Halley-Stott, R.P., Tanzer, F.L., Hitzeroth, I.I. & Rybicki, E.P. (2010). 
High level protein expression in plants through the use of a novel autonomously 
replicating geminivirus shuttle vector. Plant Biotechnology Journal. 8 (1), 38–46. 
Rincón, A.C., Molina-Martinez, I.T., De Las Heras, B., Alonso, M., Baílez, C., 
Rodríguez-Cabello, J.C. & Herrero-Vanrell, R. (2006). Biocompatibility of elastin-
like polymer poly(VPAVG) microparticles: in vitro and in vivo studies. Journal of 
Biomedical Materials Research Part A. 78 (2), 343–351. 
Rybicki, E.P. (2010). Plant-made vaccines for humans and animals. Plant 
Biotechnology Journal. 8 (5), 620–637. 
Rybicki, E.P., Chikwamba, R., Koch, M., Rhodes, J.I. & Groenewald, J.-H. (2012). 
Plant-made therapeutics: an emerging platform in South Africa. Biotechnology 
Advances. 30 (2), 449–459. 
Saade, F. & Petrovsky, N. (2012). Technologies for enhanced efficacy of DNA 
vaccines. Expert Review of Vaccines. 11 (2), 189–209. 
Sainsbury, F. & Lomonossoff, G.P. (2008). Extremely high-level and rapid transient 
protein production in plants without the use of viral replication. Plant Physiology. 
148 (3), 1212–1218. 
Sainsbury, F., Sack, M., Stadlmann, J., Quendler, H., Fischer, R. & Lomonossoff, 
G.P. (2010). Rapid transient production in plants by replicating and non-
replicating vectors yields high quality functional anti-HIV antibody. PloS ONE. 5 
(11), e13976. 
Sainsbury, F., Thuenemann, E.C. & Lomonossoff, G.P. (2009). pEAQ: versatile 
expression vectors for easy and quick transient expression of heterologous 
proteins in plants. Plant Biotechnology Journal. 7 (7), 682–93. 
Saxena, P., Hsieh, Y.-C., Alvarado, V.Y., Sainsbury, F., Saunders, K., Lomonossoff, 
G.P. & Scholthof, H.B. (2011). Improved foreign gene expression in plants using 
a virus-encoded suppressor of RNA silencing modified to be developmentally 
harmless. Plant Biotechnology Journal. 9 (6), 703–712. 
Scheller, J., Leps, M. & Conrad, U. (2006). Forcing single-chain variable fragment 
production in tobacco seeds by fusion to elastin-like polypeptides. Plant 
Biotechnology Journal. 4 (2), 243–249. 
Schoemaker, N.J., Dorrestein, G.M., Latimer, K.S., Lumeij, J.T., Kik, M.J., Van der 
Hage, M.H. & Campagnoli, R.P. (2000). Severe leukopenia and liver necrosis in 
young African grey parrots (Psittacus erithacus erithacus) infected with 













Schokker, E.., Wagenberg, A.C.. van & Boekel, M.A.J.. van (1998). A note on the 
use of urea in studying the mechanism of thermal inactivation of extracellular 
proteinase from pseudomonas fluorescens 22F. Enzyme and Microbial 
Technology. 42 (8), 628–698. 
Scholthof, H.B. (2007). Heterologous expression of viral RNA interference 
suppressors: RISC management. Plant Physiology. 145 (4), 1110–1117. 
Sharma, A.K. & Sharma, M.K. (2009). Plants as bioreactors: Recent developments 
and emerging opportunities. Biotechnology Advances. 27 (6), 811–832. 
Shearer, P.L., Bonne, N., Clark, P., Sharp, M. & Raidal, S.R. (2008). Beak and 
feather disease virus infection in cockatiels (Nymphicus hollandicus). Avian 
Pathology. 37 (1), 75–81. 
Shearer, P.L., Sharp, M., Bonne, N., Clark, P. & Raidal, S.R. (2009a). A blocking 
ELISA for the detection of antibodies to psittacine beak and feather disease 
virus (BFDV). Journal of Virological Methods. 158 (1-2), 136–140. 
Shearer, P.L., Sharp, M., Bonne, N., Clark, P. & Raidal, S.R. (2009b). A quantitative, 
real-time polymerase chain reaction assay for beak and feather disease virus. 
Journal of Virological Methods. 159 (1), 98–104. 
Shen, H.-G., Zhou, J.-Y., Huang, Z.-Y., Guo, J.-Q., Xing, G., He, J.-L., Yan, Y. & 
Gong, L.-Y. (2008). Protective immunity against porcine circovirus 2 by 
vaccination with ORF2-based DNA and subunit vaccines in mice. The Journal of 
General Virology. 89 (8), 1857–1865. 
Shen, W.J. & Forde, B.G. (1989). Efficient transformation of Agrobacterium spp. by 
high voltage electroporation. Nucleic Acids Research. 17 (20), 8385. 
Shih, S.M.-H. & Doran, P.M. (2009). Foreign protein production using plant cell and 
organ cultures: Advantages and limitations. Biotechnology Advances. 27 (6), 
1036–1042. 
Siddiqui, S.A., Sarmiento, C., Truve, E., Lehto, H. & Lehto, K. (2008). Phenotypes 
and functional effects caused by various viral RNA silencing suppressors in 
transgenic Nicotiana benthamiana and N. tabacum. Molecular Plant-Microbe 
Interactions. 21 (2), 178–187. 
Solomon, J.S., Nixon, C.P., McGarvey, S.T., Acosta, L.P., Manalo, D. & Kurtis, J.D. 
(2004). Expression, purification, and human antibody response to a 67 kDa 
vaccine candidate for schistosomiasis japonica. Protein Expression and 
Purification. 36 (2), 226–231. 
Stewart, M.E., Bonne, N., Shearer, P., Khalesi, B., Sharp, M. & Raidal, S. (2007). 
Baculovirus expression of beak and feather disease virus (BFDV) capsid protein 
capable of self-assembly and haemagglutination. Journal of Virological 













Stoger, E., Ma, J.K.-C., Fischer, R. & Christou, P. (2005). Sowing the seeds of 
success: pharmaceutical proteins from plants. Current Opinion in Biotechnology. 
16 (2), 167–173. 
Sørensen, H.P. & Mortensen, K.K. (2005). Advanced genetic strategies for 
recombinant protein expression in Escherichia coli. Journal of Biotechnology. 
115 (2), 113–128. 
Tegel, H., Ottosson, J. & Hober, S. (2011). Enhancing the protein production levels 
in Escherichia coli with a strong promoter. The FEBS Journal. 278 (5), 729–739. 
Tegel, H., Tourle, S., Ottosson, J. & Persson, A. (2010). Increased levels of 
recombinant human proteins with the Escherichia coli strain Rosetta(DE3). 
Protein Expression and Purification. 69 (2), 159–167. 
Terpe, K. (2006). Overview of bacterial expression systems for heterologous protein 
production: from molecular and biochemical fundamentals to commercial 
systems. Applied Microbiology and Biotechnology. 72 (2), 211–222. 
Thanavala, Y., Huang, Z. & Mason, H.S. (2006). Plant-derived vaccines: a look back 
at the highlights and a view to the challenges on the road ahead. Expert Review 
of Vaccines. 5 (2), 249–260. 
Tian, L. & Sun, S.S.M. (2011). A cost-effective ELP-intein coupling system for 
recombinant protein purification from plant production platform. PloS ONE. 6 (8), 
e24183. 
Todd, D. (2000). Circoviruses: immunosuppressive threats to avian species: a 
review. Avian Pathology. 29 (5), 373–394. 
Todd, D., Niagro, F.D., Ritchie, B.W., Curran, W., Allan, G.M., Lukert, P.D., Latimer, 
K.S., Steffens, W.L. & McNulty, M.S. (1991). Comparison of three animal 
viruses with circular single-stranded DNA genomes. Archives of Virology. 117 
(1-2), 129–135. 
Torrent, M., Llompart, B., Lasserre-Ramassamy, S., Llop-Tous, I., Bastida, M., 
Marzabal, P., Westerholm-Parvinen, A., Saloheimo, M., Heifetz, P.B. & Ludevid, 
M.D. (2009). Eukaryotic protein production in designed storage organelles. BMC 
Biology. 7 (5), doi: 10.1186/1741–7007–7–5. 
Toussaint, N.C., Maman, Y., Kohlbacher, O. & Louzoun, Y. (2011). Universal peptide 
vaccines - Optimal peptide vaccine design based on viral sequence 
conservation. Vaccine. 29 (47), 8745–8753. 
Trabbic-Carlson, K., Liu, L.L., Kim, B. & Chilkoti, A. (2004a). Expression and 
purification of recombinant proteins from Escherichia coli: Comparison of an 














Trabbic-Carlson, K., Meyer, D.E., Liu, L., Piervincenzi, R., Nath, N., LaBean, T. & 
Chilkoti, A. (2004b). Effect of protein fusion on the transition temperature of an 
environmentally responsive elastin-like polypeptide: a role for surface 
hydrophobicity? Protein Engineering, Design & Selection. 17 (1), 57–66. 
Tremblay, R., Wang, D., Jevnikar, A.M. & Ma, S. (2010). Tobacco, a highly efficient 
green bioreactor for production of therapeutic proteins. Biotechnology 
Advances. 28 (2), 214–221. 
Urry, D.W. (1997). Physical Chemistry of Biological Free Energy Transduction As 
Demonstrated by Elastic Protein-Based Polymers. The Journal of Physical 
Chemistry B. 101 (51), 11007–11028. 
Urry, D.W., Luan, C.H., Parker, T.M., Gowda, D.C., Prasad, K.U., Reid, M.C. & 
Safavy, A. (1991). Temperature of polypeptide inverse temperature transition 
depends on mean residue hydrophobicity. Journal of the American Chemical 
Society. 113 (11), 4346–4348. 
Vardakou, M., Sainsbury, F., Rigby, N., Mulholland, F. & Lomonossoff, G.P. (2012). 
Expression of active recombinant human gastric lipase in Nicotiana 
benthamiana using the CPMV-HT transient expression system. Protein 
Expression and Purification. 81 (1), 69–74. 
Varsani, A., De Villiers, G.K., Regnard, G.L., Bragg, R.R., Kondiah, K., Hitzeroth, I.I. 
& Rybicki, E.P. (2010). A unique isolate of beak and feather disease virus 
isolated from budgerigars (Melopsittacus undulatus) in South Africa. Archives of 
Virology. 155 (3), 435–439. 
Varsani, A., Williamson, A.-L., Stewart, D. & Rybicki, E.P. (2006). Transient 
expression of Human papillomavirus type 16 L1 protein in Nicotiana 
benthamiana using an infectious tobamovirus vector. Virus Research. 120 (1-2), 
91–96. 
Ventura, S. & Villaverde, A. (2006). Protein quality in bacterial inclusion bodies. 
Trends in Biotechnology. 24 (4), 179–185. 
Verver, J., Wellink, J., Van Lent, J., Gopinath, K. & Van Kammen, A. (1998). Studies 
on the movement of cowpea mosaic virus using the jellyfish green fluorescent 
protein. Virology. 242 (1), 22–27. 
Vidi, P.-A., Kessler, F. & Bréhélin, C. (2007). Plastoglobules: a new address for 
targeting recombinant proteins in the chloroplast. BMC Biotechnology. 7 (4). 
Voinnet, O., Rivas, S., Mestre, P. & Baulcombe, D. (2003). An enhanced transient 
expression system in plants based on suppression of gene silencing by the p19 
protein of tomato bushy stunt virus. The Plant Journal. 33 (5), 949–956. 
Wang, X., Shi, F., Wösten, H. a B., Hektor, H., Poolman, B. & Robillard, G.T. (2005). 
The SC3 hydrophobin self-assembles into a membrane with distinct mass 













Woodhouse, K. a, Klement, P., Chen, V., Gorbet, M.B., Keeley, F.W., Stahl, R., 
Fromstein, J.D. & Bellingham, C.M. (2004). Investigation of recombinant human 
elastin polypeptides as non-thrombogenic coatings. Biomaterials. 25 (19), 4543–
4553. 
Wu, W.-Y., Mee, C., Califano, F., Banki, R. & Wood, D.W. (2006). Recombinant 
protein purification by self-cleaving aggregation tag. Nature Protocols. 1 (5), 
2257–2262. 
Yin, S., Sun, S., Yang, S., Shang, Y., Cai, X. & Liu, X. (2010). Self-assembly of virus-
like particles of porcine circovirus type 2 capsid protein expressed from 
Escherichia coli. Virology Journal. 7 (166), doi: 10.1186/1743–422X–7–166. 
Ytterberg, A.J., Peltier, J.-B. & Van Wijk, K.J. (2006). Protein profiling of 
plastoglobules in chloroplasts and chromoplasts. A surprising site for differential 
accumulation of metabolic enzymes. Plant Physiology. 140 (3), 984–997. 
Yusibov, V., Streatfield, S.J. & Kushnir, N. (2011). Clinical development of plant-
produced recombinant pharmaceuticals: Vaccines, antibodies, and beyond. 

















GoTaq  DNA Polymerase (Promega, USA) or Accuzyme™ DNA Polymerase 
(Bioline, USA) were used as per the manufacturer’s recommendations. All PCR was 
performed with a Bio-Rad MyCycler™ (Bio-Rad Laboratories, USA) thermal cycler. 
The concentration of Mg2+ was 2.0 mM for all reactions. All PCR products were 
resolved by electrophoresis on 0.8% agarose gels. Colony PCR was often used to 
screen transformants. A single colony was inoculated into the reaction mixture in 
each individual 0.2 ml PCR tube, using a sterile toothpick. 
 
Cloning 
The relevant bands in agarose gels were excised under long wavelength UV 
illumination and DNA was extracted using a Qiagen Gel Extraction Kit (Qiagen, 
USA). Restriction enzymes used were: AflIII, MluI, NcoI, NotI, XhoI (Roche, USA), 
AgeI, EcoRI, EcoRV and XhoI (Fermentas, Canada). All restriction enzyme digests 
were carried out at 37°C for 2 hours. Clean-up of restriction enzyme digests was 
performed with a Qiagen PCR Purification Kit. Ligation of the insert into the vector 
(similarly digested at compatible enzyme sites) was performed using Rapid DNA 
Ligation Kit (Fermentas, Canada) as per the manufacturer’s recommendations. All 
digested vector DNA was dephosphorylated with Rapid Alkaline Phosphatase Kit 
(Roche, USA) prior to ligation. The ligation products were then transformed into E. 
coli DH5α chemically competent cells (E. cloni® (Lucigen, USA)) as per the 
manufacturer’s instructions and were incubated overnight at 37°C on LB agar 
supplemented with the relevant antibiotics.  
 
Plasmid preparation 
A single colony on a LB agar plate was used to inoculate 10 mL of liquid LB media, 













in an orbital shaker. The cell pellet from 4 mL of culture was collected by 
centrifugation. Plasmid DNA was prepared using a Qiagen Spin Miniprep Kit as per 
the manufacturer’s protocol. Plasmid DNA was sequenced by Macrogen Inc. 
(Netherlands). 




Figure 43: pTRAkc-ERH binary expression vector features:  
“CaMV 35S promoter with duplicated transcriptional enhancer; CHS, chalcone synthase 5’ 
untranslated region; pA35S, CaMV 35S polyadenylation signal; SAR, scaffold attachment region of 
the tobacco Rb7 gene; LB and RB, the left and right borders for T-DNA integration; ColE1ori, origin of 
replication for E. coli; RK2ori, origin of replication for Agrobacterium; bla, ampicillin/carbenicillin-
resistance bla gene; LPH, signal-peptide sequence from the murine mAb24 heavy chain; his6, 6X His 
tag sequence; SEKDEL, ER-retention signal sequence; npt II, kanamycin-resistance npt II gene; Pnos 
and pAnos, promoter and polyadenylation signal of the nopaline synthase gene” (adapted  from 














Figure 44: pPROEX-HTb features (Life Technologies, USA)  
Schematic of pPROEX-HTb vector. Included here are the trc promoter, lacI gene induced by IPTG, 
ampicillin resistance gene (Apr), origin of replication (ori) and the multiple cloning site (Invitrogen-Life 


















Figure 45: Features of pEAQ-HT 
“Light grey arrows, regions non-essential for plasmid growth or transient transformation; dark grey 
arrows, regions essential for plasmid growth and replication; black boxes, T-DNA left (LB) and right 
(RB) borders; white arrows, promoter sequences (CaMV, Cauliflower mosaic virus); solid black lines, 
CPMV RNA-2 UTRs; bordered grey arrows, GFP coding sequences; and black arrows, terminator 
sequences (nos, nopaline synthase). OriV, pRK2 replication origin; ColEI, pBR322 replication origin; 
NPT, neomycin phosphotransferase; TrfA, replication-essential locus”, insert: position of cloned 
gene(s). Adapted from Sainsbury et al. (2009) 
 
 
Figure 46: Features of the pTH expression vector 
“CMVe/p/i: human cytomegalovirus enhancer/promoter/intron region; BGHpA: bovine growth hormone 
polyadenylation signal; Amp: β-lactamase gene; ColE1: origin of plasmid replication; Unique 















Appendix C: ELP28 gene sequence in pMK-TEV-ELP 
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Appendix D: Sequence of multiple cloning site and promer binding reqions  for 
pPROEX-HTb (Invitrogen™, Life Technologies) 
 
 
 
 
 
 
